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Abstract
Epstein  Barr Virus  driven  post  transplant lymphoproliferative disease  (PTLD)  is  a 
serious complication following either stem cell or solid organ transplantation (SOT), 
occurring  as  a  result  of  suppressed  cellular  immunity.  Adoptive  transfer  of  EBV 
specific cytotoxic T cells (EBV-CTLs) is effective as both prophylaxis and treatment 
for PTLD following stem cell transplantation, but is less effective when applied to 
PTLD after SOT. It is likely that the continued pharmacologic immunosuppression 
designed to prevent graft rejection compromises the function of infused EBV-CTLs. 
To address this issue, we have generated calcineurin (CN) mutants that do not bind the 
immunosuppressants  Tacrolimus  (FK506)  and  Cyclosporin  A  (CsA),  therefore 
conferring resistance to these CN inhibitors. A panel of 54 such mutants was designed, 
generated and screened in a Luciferase expression assay, with identification of those 
capable of resisting suppression with FK506, CsA or both. Subsequently, in assays 
utilising both the Jurkat T cell line and primary human EBV-CTL lines, mutant CNa12 
conferred resistance to CsA, mutant CNa22 conferred resistance to FK506 and mutant 
CNb30  rendered  cells  resistant  to  both  calcineurin  inhibitors.  EBV-CTL  lines 
transduced with a retroviral vector encoding these mutants retained the ability to both 
proliferate and secrete normal levels of interferon- in the presence of therapeutic and 
supratherapeutic  levels  of  FK506  (CNa12),  CsA  (CNa22),  or  both  (CNb30).  The 
cytotoxicity, phenotype and antigen dependence of EBV-CTL lines were unaffected 
by expression of mutant CN. A xenogenic murine model of PTLD was established in 
the RAG2
-/-/c
-/-/C5
-/- triple knockout SCID mouse strain and the ability of EBV-CTL 
lines to induce tumour regression was examined. Administration of EBV-CTLs caused
regression of subcutaneous LCL tumours in vivo in some donors. This model will be 
utilised in further investigations of transduced EBV-CTLs in vivo. The generation of 
EBV-CTLs that are resistant to CN inhibitors should allow effective immunotherapy 
in  the  SOT  setting  without  risking  rejection  of  the  graft  by  reducing
immunosuppression.  Additionally  this  represents  a  generic  approach  to  improving 
immunotherapy in the face of immunosuppression in other settings.4
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1.1 Epstein Barr Virus
Following the description of Burkitt Lymphoma in 1958, Epstein, Barr and Achong 
identified the Epstein Barr Virus (EBV) from tumour samples (Epstein, et al 1964). 
This virus has since been identified as a gamma herpesvirus infecting over 90% of 
adults  worldwide  and  classified  as  Human  Herpesvirus  4,  a  member  of  the 
lymphocryptovirus genus (Kieff and Rickinson 2007). After primary exposure, EBV 
establishes  a  latent  infection  of  resting  memory  B  cells,  with  occasional  sporadic 
production of lytic virus from the oropharyngeal cavity but no clinical symptoms in 
most individuals. However, despite the usual subclinical course, EBV contributes a 
significant burden to human health worldwide, being responsible for the development 
of infectious mononucleosis, found in association with several human tumours, and 
possibly contributing to the development of autoimmunity.
1.1.1 Characteristics of EBV
Infectious  EBV  particles  consist  of  a  toroid  DNA  core  within  a  nuclear  capsid, 
enclosed  within  the  viral  envelope  which  contains  many  protruding  glycoproteins. 
These glycoproteins are involved in initiation of infection, with the most abundant, 
gp350/220,  binding  to  the  CD21  molecule  on  B  lymphocytes.  Binding  of  several 
gp350/220 molecules results in both aggregation and probable activation of the CD21 
complex, and uptake of the viral particles via the endocytosis pathway. Glycoproteins
gp42 in association with gH and gL also contribute to B cell adhesion through MHC 
class  II  binding,  an  interaction  that  is  thought  to  be  important  in  fusion  to  the 
endosomal membrane, resulting in entry of the viral capsid to the cytoplasm. Although 
B cell tropic in vitro, EBV is also capable of infecting epithelial cells in vivo, however 
the receptor for entry in  CD21 negative epithelial cells is thus far uncharacterised
(Cohen 2000, Kieff and Rickinson 2007). 
EBV has a linear DNA genome of approximately 180kb, which circularises upon entry 
into the target cell nucleus to form an extrachromosomal DNA episome. The genome Chapter one
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contains 2-5 0.5kb  tandem  terminal repeats and  6-12 3kb tandem internal  repeats, 
along with a short and long coding sequence containing almost one hundred genes 
expressed at different times during infection. Gene expression is controlled through 
expression of viral transcriptional transactivators and inhibitors, along with the use of 
several  different  promoters:  W,  C  and  Q  are  utilised  during  latent  infection,  and 
distinct promoters including F and Z are used during lytic infection (Chatila, et al
1997, Kieff and Rickinson 2007).
1.1.2 Infection with EBV
EBV is transmitted via salivary secretions from seropositive individuals, which infect 
the epithelial cells of the oropharyngeal cavity in a virus naïve target, possibly through
initial adhesion onto the surface of resident B cells. Lytic infection of epithelial cells 
amplifies the number of infectious virions present, which subsequently infect naïve 
resting B cells residing in Waldeyer’s ring (Cohen 2000, Thorley-Lawson and Allday 
2008). 
Following  infection,  transient  expression  of  all  latency  proteins  is  observed  (see 
section  1.1.3  below),  resulting  in  activation  and  proliferation  of  the  naïve  B 
lymphocyte  and  migration  to  lymphoid  follicles.  Once  the  infected  cell  enters  the 
germinal centre (GC), the pattern of gene expression switches to latency II, the default 
programme. Expression of this limited array of EBV genes provides the B cell with 
the survival signals necessary to undergo GC maturation, class switching and somatic 
hypermutation, thus mirroring the process driven by antigen exposure. The infected B 
cell  enters  the  memory  B  cell  compartment  and  EBV  once  again  alters  its  gene 
expression profile to latency 0, whereby it evades the host immune response and can 
reside in the resting memory cell for the life of the individual (see Figure 1). Some 
controversy  exists  regarding  EBV  infection,  for  example  whether  EBV  infects 
exclusively naïve or also mature B cells remains unclear, as does the location of EBV 
infected cells in either the GC or extrafollicular regions of tonsillar tissue (Kuppers 
2003). However,  the  process  described  above  is  currently  the  generally  accepted Chapter one
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model  of  EBV infection  (Snow  and  Martinez  2007,  Thorley-Lawson  and  Allday 
2008).
Sporadic conversion to lytic infection can occur in a small proportion of infected B 
cells upon return to the oropharyngeal lymphoid tissue, or upon differentiation into a 
plasma  cell.  This  results  in  re-infection  of  epithelial  cells  and  release  of  virus  in 
salivary  secretions  but  is  not  normally  associated  with  clinical  symptoms  and  is 
controlled by the host immune response (Cohen 2000).
Figure 1: Illustration of EBV infection and persistence in the immune competent 
host. From Thorley-Lawson and Allday, 2008
Primary  EBV  infection  generally  occurs  during  childhood,  often  without  clinical 
symptoms.  However,  in  western  society  there  is  an  increasing  delay  in  primary 
exposure sometimes into the second or third decade of life. Primary infection during Chapter one
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adolescence  or  adulthood  is  associated  with  the  development  of  infectious 
mononucleosis (I.M.) in an estimated 25% of cases. Symptoms of I.M. include the 
triad of pharyngitis, fever and lympadenopathy, which are though to be caused by the 
magnitude of the immune response to EBV rather than directly by the virus itself. 
These symptoms remain for a period of several weeks, with subsequent malaise that 
may persist for some months (Hislop, et al 2007).
1.1.3 EBV latency
EBV is capable of either lytic infection, resulting in production of infectious virus 
particles  and  death  of  the  host  cell,  or  latent  infection  where  viral  genes  may  be 
expressed but the virus  is not propagated. Lytic infection is  generally observed in 
epithelial  cells  or  terminally  differentiated  plasma  cells,  whereas  latent  infection 
occurs  in  B  lymphocytes.  Four  distinct  programmes  of  viral  latency  have  been 
identified under different circumstances in B lymphocytes in vivo, each expressing a 
selection of the 9 latency genes, but all expressing the non-coding RNAs (EBERs and 
BARTs) (see Table 1). 
Latency 0, otherwise termed the “latency programme” is observed in resting memory 
B  cells  from  healthy  seropositive  individuals,  where  no  viral  gene  products  are 
expressed when the  cell  is  quiescent. Upon  cell  division  as part of  routine  B cell 
homeostasis,  EBNA-1  is  transiently  expressed  to  ensure  replication  of  the  EBV 
genome and distribution to daughter cells. Latency I is observed in Burkitt lymphoma 
cells, which express only EBNA-1. Latency II, the “default programme”, has been 
identified in cells derived from patients with Nasopharyngeal Carcinoma or Hodgkin 
lymphoma, where EBNA-1, LMP-1 and LMP-2 are expressed. Finally, latency III, 
termed the “growth programme”, is observed in vivo in most patients suffering from 
post transplant lymphoproliferative disease (PTLD). Latency III is also expressed in 
vitro by EBV-transformed B cell Lymphoblastoid Cell Lines (LCLs), and entails the 
expression of all 9 latency genes: EBNA-1, EBNA-2, EBNA-3a, 3b and 3c, EBNA-
LP, LMP-1, LMP-2a and LMP-2b (see Table 1). Unless these cells are eliminated by 
the  host  immune  response,  expression  of  the  full  complement  of  latency  proteins Chapter one
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results in B cell transformation and continued proliferation both in vitro and in vivo
(Thorley-Lawson and Allday 2008).
Table 1: Patterns of latency in EBV infection. Detail of when each transcription 
program is observed both in health and disease is shown. EBNA: Epstein Barr Virus 
Nuclear Antigen. LMP: Latent Membrane Protein. EBER: Epstein Barr virus Encoded 
RNA. BART: BamA Rightward Transcripts. From Thorley-Lawson and Allday, 2008.
Transcription program Cell type where found Latent genes expressed
Growth (Latency 3)
Newly infected B cells
Immunoblastic 
lymphoma
EBNA1 (Cp/Wp), 
EBNA2, 
EBNA3A, B, C, 
EBNALP, 
LMP1, 
LMP2A, B,
EBER1, 2, 
BART
Default (Latency 2)
Germinal centre B cells
Hodgkin lymphoma
EBNA1 (Qp), 
LMP1, 
LMP2A, B, 
EBER1, 2, 
BART 
EBNA-1 only (Latency 1)
Dividing memory cells
Burkitt Lymphoma
EBNA1 (Qp), 
EBER1 (?), 2 (?), 
BART(?)
Latency program (Latency 0) Resting memory cells EBER1, 2, 
BART (?)
The  majority  of  PTLD  tumours  express  the  latency  III  EBV  transcription  profile, 
including all 9 latency proteins along with the EBERs and BARTs. The role of these 
genes has been the focus of extensive research to determine how EBV influences the 
growth  of  B  and  epithelial  cells,  the  current  understanding  of  which  will  be 
summarised below.
EBNA-1  is  characterised  by  ubiquitous  expression  throughout  all  EBV  latency 
profiles.  It  is  essential  for  maintenance  of  the  EBV  episome  during  cell  division, 
binding to the origin of replication OriP and associating with host cell chromosomes to 
ensure duplication of viral DNA, and equal distribution of episomes to daughter cells. 
EBNA-1 also has a role as a transcriptional transactivator, up-regulating viral protein Chapter one
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expression from the C promoter (Kieff and Rickinson 2007, Tanner and Alfieri 2001, 
Young and Murray 2003). 
EBNA-2 has been described as a “master transactivator” and is absolutely required for 
transformation of B  cells  (Kieff and Rickinson  2007). An EBV strain  deficient in 
EBNA-2  is  unable  to  immortalise  primary  B  cells  in  culture,  however  this  ability 
returns with the restoration of EBNA-2 (Hammerschmidt and Sugden 1989, Rabson, 
et al 1982). EBNA-2 acts as a transcriptional activator for viral genes, including LMP-
1,  LMP-2 and  also for  the cellular activation  markers CD21  and  CD23,  and anti-
apoptotic genes including c-myc and c-fgr. The activity of EBNA-2 is potentiated 10-
100  fold  by  the  presence  of  EBNA-LP,  which  although  not  essential  for 
transformation itself acts in parallel with EBNA-2.
EBNA-3 A, B and C have considerable sequence similarities, being produced from a 
single  alternatively  spliced  primary  transcript.  EBNA-3A  and  C  have  been 
demonstrated  as  essential  for  transforming  activity  but  EBNA-3B  appears  to  be 
dispensable.  These  are  also  transcriptional  regulators,  being  involved  in  both  the 
down-regulation of EBNA-2 and the up-regulation of LMP-1 and cellular CD21.
LMP-1  is  considered  the  major  transforming  protein  of  EBV  and  is  a  classical 
oncogene, the expression of which consistently induces tumour formation in mice. It 
resembles  the  surface  molecule  CD40,  and  acts  as  a  constitutively  active  TNF 
receptor,  signalling  through  both  the  MAP  kinase  and  JAK/STAT  pathways.  This 
leads to stimulation of NFB and cellular activation, resulting in the expression of 
cellular  activation  markers,  cell  surface  adhesion  molecules  and  cytokines.  Anti-
apoptotic molecules such as Bcl-2 and A20 are also upregulated by LMP-1 (Wang, et 
al 1990).
LMP-2A and B differ only in the absence of the intracellular domain from LMP-2B 
compared to LMP-2A, the most studied of the two to date. LMP-2A may substitute for 
BCR signalling in cells that have undergone crippling Ig gene mutations. Literature 
regarding the activity of LMP-2A suggests that it may have a dual role, being able to 
both block activation signals from the natural BCR, thus preventing activation-induced 
entry into the lytic cycle, and also mimic BCR signals in the absence of antigen. This Chapter one
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provides  survival  signals  to  cells  which  either  cannot  signal  due  to  the  lack  of  a 
functional BCR, or in the absence of antigen in the germinal centre, to drive passage 
into the memory B cell compartment. Some debate remains regarding the detection of 
LMP-2A, with some studies suggesting its expression in memory B cells from healthy 
individuals (Kuppers 2003). LMP-2B is thought to negatively regulate the activity of 
LMP-2A,  therefore  increasing  the  likelihood  of  a  switch  to  lytic  infection 
(Rechsteiner, et al 2008).
The EBERs and BARTs, despite ubiquitous expression in EBV infected cells, do not 
appear to be essential for transformation and their role remains to be elucidated. There 
is some evidence to suggest that the EBERs may mediate cellular responses to IFN-
signalling, however more work is required to establish the function of these RNAs.
The complement of latent EBV genes are therefore capable of providing the B cell 
with  cellular  activation  signals,  increased  resistance  to  apoptosis,  induction  of 
autocrine cytokine secretion and prevention of entry into the lytic cycle. These signals 
appear to be sufficient to mimic B cell activation and therefore drive virus-initiated 
proliferation  in  the  absence  of  normal  cellular  stimuli,  which  contributes  to  the 
development of neoplasia.
1.1.4 The immune response to EBV
Studies of the immune response to primary EBV infection have focussed on patients 
presenting  with  infectious  mononucleosis,  as  these  individuals  are  identifiably 
mounting such an immune response. The progression of this response has been studied 
in  some  detail,  as  has  the  memory  response  in  healthy  carriers.  However, 
investigations of primary asymptomatic infection are not possible as these patients are 
unaware  of  seroconversion.  It  is  therefore  assumed  that  I.M.  is  an  amplified 
representation  of  asymptomatic  primary  EBV  infection.  Although  the  immune 
response mounted towards EBV consists of both humoural and cellular components, 
the cellular arm predominantly controls viral infection.Chapter one
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In the acute phase of I.M., several anti-EBV antibodies are produced including IgM 
and IgG towards the Viral Capsid Antigen (VCA) and IgG antibodies towards the 
Early Antigen (EA).    In addition  to these, neutralising IgM and subsequently IgG 
antibodies  appear  that  recognise  the  major  glycoprotein  gp350  and  are  capable  of 
inducing antibody mediated cellular cytotoxicity. This complement of antibodies is
unlikely to control established EBV infection, but may confer some protection against 
EBV re-activation, or re-infection with additional strains of EBV (Rickinson and Kieff 
2007).
Aside from the magnitude of the CD8 response in I.M., the first and most compelling 
evidence that cellular immunity is critical in EBV control comes from the observation 
that  T  cell  compromised  patients  are  at  increased  risk  of  developing  EBV-driven 
malignancies or viral lesions. In combination with the evidence that disease regression 
can be induced by infusion of EBV-specific T cells (Rooney, et al 1995), this indicates
that CD8 positive EBV-CTLs are central for virus control (Rickinson, et al 1996).
During the acute phase of I.M., a five to 20 fold increase in the number of circulating 
CD8 T cells is induced. The CD8 cell count remains elevated throughout the acute 
phase and subsequently falls during convalescence (Rickinson and Kieff 2007). It has 
been  demonstrated  using  tetramer  analysis  that  during  acute  I.M.  up  to  50%  of 
circulating CD8 T cells can be specific for a single EBV-derived epitope (Callan, et al
1998). Increased levels of CD4 T cells are also observed during I.M., of which up to 
5% are EBV-specific, but this response is less marked than the observed CD8 cell 
expansion (see Figure 2). In addition, NK cell expansion has been identified in the 
peripheral blood of I.M. patients. This, along with the observation that NK cells are 
capable of  inhibiting  outgrowth of  EBV-LCL  in  vitro  by secretion  of  IFN-,  may 
suggest a role for the innate immune system in delaying early progression whilst the 
adaptive response is mounted (Hislop, et al 2007).Chapter one
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Figure 2: Illustration of the course of EBV infection. Representation of changes in 
EBV replication, number of circulating EBV infected cells and anti-EBV CD4 and 
CD8 cells. From Hislop, et al 2007.
It has been demonstrated that the CD8+ T cell response elicited during I.M. primarily 
recognises lytic EBV antigens, for which there is a strict hierarchy of immunological 
dominance. Most EBV-specific CD8 T cells recognise the immediate early proteins 
BZLF1 and BRLF1, with an additional subset directed towards early antigen proteins;
but  CD8  CTL responses  rarely recognise the later  expressed matrix  proteins. This 
hierarchy  closely  reflects  the  efficiency  of  antigen  processing  and  presentation  by 
MHC class I molecules (Pudney, et al 2005). EBV-CTLs recognising latent proteins 
are also detected during acute I.M., but at a comparatively low frequency. However, 
during recovery from acute infection the number EBV-specific CTLs falls to represent 
2-5% of total CD8 T cells, with a disproportionately greater reduction in lytic antigen 
specific  cells  such  that  the  majority  of  remaining  EBV-CTLs in  healthy  carriers 
recognise latent rather than lytic proteins. Chapter one
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The composition of this CD8 response towards latent antigens conforms to a different 
hierarchy of EBV proteins, being comprised mainly of EBNA-3 (A, B or C) specific 
cells, with a small proportion of anti-LMP-2 cells detected. This protein hierarchy is 
conserved across many HLA types, with differences in the epitope specificity between 
alleles (Rickinson, et al 1996). The mechanisms for immunodominance of the EBNA-
3s  and  LMP-2  have  not  been  elucidated,  although  the  EBNA-3s  comprise 
approximately  60%  of  the  unique  sequences  present  in  EBV  latent  proteins  and 
therefore could be expected to represent many of the recognised epitopes (Hislop, et al
2007). Early work identified the presence of a Glycine-Alanine repeat (GAr) within 
the  EBNA-1  protein,  which  was  suggested  to  inhibit  proteosome  processing  and
therefore preclude presentation to CD8+ T cells in MHC class I (Levitskaya, et al
1995). However, EBNA-1 reactive CD8 clones have since been identified (Voo, et al
2004),  and  it  is  possible  that  the  GAr  merely  prevents  translation  from  EBNA-1 
mRNA,  rather  than  actively  interrupting  proteosomal  processing  (Lee,  et  al  2004, 
Tellam, et al 2004, Yin, et al 2003).
In contrast, CD4 responses elicited by EBV infection adhere to a different profile of 
immunodominance. During IM, responses to the lytic proteins BZLF1 and BHLF1 as 
well as the late glycoproteins gp350 and gp110 have been documented. Although CD4 
memory cells following recovery are present at a ten-fold lower frequency than CD8
memory cells, CD4 responses can be reactivated in vitro. Unlike CD8 cells, which are 
mainly EBNA-3 specific, CD4 cells are commonly directed against EBNA-1, EBNA-2 
and EBNA-3C with much lower frequencies detected against EBNA-3A or the LMPs. 
These CD4 responses tend to have a Th1 phenotype, with the ability to secrete IFN-
and are often cytotoxic. Therefore it is possible that these EBV-specific CD4+ cells in 
fact also play the role of cytotoxic effectors rather than fit the traditional profile of 
helper cells (Rickinson and Kieff 2007).
Generation of an effective immune response to EBV infection is critical in control of 
the  virus.  This is  illustrated  by  the  clinical  course  observed  in  X-linked
lymphoproliferative disease (XLP) patients. These patients have a defect in cellular 
immunity caused by the absence or non-functionality of the signalling protein SAP 
(SLAM-associated protein), resulting in reduced cytotoxic responses and inability to Chapter one
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control EBV infection. As a result, XLP patients can develop fulminant I.M. and EBV 
driven lymphoma (Nagy, et al 2009). This illustrates the potential for EBV to cause 
disease if an ineffective immune response is generated.
1.1.5 Association of EBV with malignancy
Along with its ability to transform primary B cells into continuously proliferating LCL 
lines in culture, EBV’s status as an oncovirus is confirmed by its association with 
several human malignancies. These tumours reflect the natural tropism of EBV for B 
lymphocytes  and  epithelial  cells,  and  include  Burkitt  Lymphoma,  Post  Transplant 
Lymphoma,  Hodgkin  lymphoma,  Nasopharyngeal  carcinoma,  a  subset  of  gastric 
carcinomas and some rare T/NK cell lymphomas. The role of EBV in the development
of  some  of  these  tumours  is  not  clearly  defined  despite  a  large  body  of  work 
examining its contribution as an associated, predisposing or causative factor.
EBV  was  first  identified  from  African  Burkitt  lymphoma  (BL)  cell  lines,  initially 
seeming to play a causal role following identification in almost all samples tested
expressing the latency I programme. However, it has since become clear that EBV is 
merely one of many factors contributing to the development of this disease which 
include  both  immune  exhaustion  as  a  result  of  malaria  infection  as  well  as  the 
diagnostic  characteristic  of  BL,  the  c-myc  translocation.  It  is  thought  that  the 
translocation of c-myc to place it under the influence of the constitutively active Ig 
promoters  drives  growth,  and  that  the  presence  of  EBV  may  allow  escape  from 
apoptosis (Thorley-Lawson and Allday 2008).
EBV is detected in up to 50% of Hodgkin Lymphoma (HL) samples, with abundant 
LMP-1 expression in Reed-Sternberg cells (Young and Murray 2003). Furthermore, 
EBV-positive HL patients have higher titres of anti-EBV antibodies compared to other 
lymphoma patients (Levine, et al 1971). There appears to be underlying differences in
the aetiology and behaviour of EBV positive/EBV negative HL however the exact 
mechanism by which EBV contributes to lymphomagenesis remains to be elucidated. 
Work by Mancao et al identified a critical role for LMP-2A signalling in promoting Chapter one
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the  survival  of  B  cells  carrying a  crippled  Ig  gene  rearrangement.  This  finding  is 
significant  as  approximately  25%  of  HD  Reed-Sternberg  cells  do  not  express  a 
functional B cell receptor due to Ig mutations, and would be expected to undergo 
apoptosis.  Therefore  the  action  of  LMP-2A  provides  a  role  for  EBV  in  the 
development of HD (Mancao, et al 2005, Mancao and Hammerschmidt 2007).
Undifferentiated nasopharyngeal carcinoma (NPC) is uniformly associated with EBV, 
with EBERs and EBNA-1 expressed in most tumour samples. In addition, LMP-1 is 
expressed in a large proportion of tumours (Young and Murray 2003). EBV is found 
in epithelial cells comprising the lesions, but not the associated lymphocytes. Patients 
with undifferentiated NPC often have raised titres of IgA antibodies that recognise 
EBV structural proteins, which can be associated with poorer prognosis (Cohen 2000). 
Once again, the contribution of EBV to disease development is unclear, and other 
factors, eg. diet, may also be important.
It can be concluded that EBV is likely to play a role in the development of several 
tumours worldwide, however the mechanism of this contribution is elusive, and is 
likely  to  differ  for  each  circumstance.  One  possibility  is  that  EBV  contributes 
according  to  a  “first  hit”  model,  whereby  the  presence  of  virus  predisposes  to
tumorigenesis but EBV is not involved in maintenance or progression of the disease. 
The role of EBV in the development of post transplant lymphoma is more clearly 
defined, and will be discussed below.
1.2 Post Transplant Lymphoproliferative disease
PTLD is a significant complication of both stem cell and solid organ transplantation, 
and  is  associated  with  considerable  morbidity  and  mortality.  As  transplantation 
medicine progresses, transplantation has become an increasingly possible therapeutic 
option and patients survive longer following the procedure, therefore the impact of 
PTLD has increased (Everly, et al 2007). Currently, PTLD is the most common post 
transplant malignancy in paediatric patients, and is second only to skin cancers in adult 
patients, affecting between 1 and 35% of transplanted individuals (Abu-Elmagd, et alChapter one
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1998, Opelz and Dohler 2004, Taylor, et al 2005, Webber, et al 2006). Five  year 
mortality  associated  with  the  disease  can  reach  50%  despite  current  treatment 
regimens (Caillard,  et  al  2005,  Leblond  and  Choquet  2004).  PTLD  remains  a
considerable problem following transplantation and more effective treatment options 
are required.
1.2.1 Clinical presentation and classification of PTLD
Presentation of PTLD can be variable, therefore a high index of suspicion is required 
in  all  patients  post  transplant,  however  up  to  80%  present  with  fever,  50%  with 
lymphadenopathy, and non-specific symptoms including malaise and weight loss are 
also  commonly  seen.  Tonsillar  involvement  or  symptoms  reflective  of  I.M.  are 
frequent (Everly, et al 2007, Taylor, et al 2005), and extranodal presentation such as
small bowel bleeding or CNS involvement may also be seen, particularly in T cell
PTLD. A minority of patients (approximately 10%) have bone marrow involvement, 
and occasional patients may be asymptomatic.
The term PTLD encompasses a heterogeneous group of B cell proliferative disorders 
that range from polymorphic B cell hyperplasia to aggressive, high grade, monoclonal 
B  cell  lymphoma.  The  WHO  classification  of  PTLD  recognises  three  distinct 
categories (Harris, et al 2000). Early lesions or hyperplastic PTLD are characterised 
by non-invasiveness, with preservation of local tissue structure and often affect tonsils 
or lymph nodes. Early PTLD is associated with a good prognosis  and is likely to 
respond to a reduction of immunosuppressive therapy. Polymorphic PTLD begins to 
invade local tissue architecture and can involve nodal and extranodal sites. Areas of 
necrosis are often observed along with atypical nuclear structure of involved B cells. 
Polymorphic  PTLD  is  the  most  common  stage,  and  is  less  likely to  respond  to  a 
reduction  of  immunosuppression  alone,  requiring  further  interventions.  Finally, 
Monomorphic  PTLD  often  resembles  Non-Hodgkin  Lymphoma,  is  high-grade  and 
invasive with destruction of local tissue architecture and involvement of extra-nodal 
sites (Lim, et al 2006, Taylor, et al 2005). Both polymorphic and monomorphic PTLD 
are  generally  of  B  cell  lineage  but  approximately  5-10%  of  patients  show  T  cell Chapter one
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lymphoproliferation.  Rare  “other  types”  of  post  transplant  lymphoma  represent  a 
fourth  category,  see Table 2.  It  should  be  noted  however  that  data  regarding  the 
clinical significance of histological presentation are conflicting (Hayashi, et al 2001, 
Pinkerton, et al 2002).
Table 2: WHO classification of PTLD. Three main categories are recognised based 
mainly on morphological features. From Harris et al, report from the WHO meeting, 
2000.
1.2.3 PTLD risk factors
A multitude of analyses assessing PTLD have confirmed that it arises in between 1 
and 35% of solid organ transplant recipients (Abu-Elmagd, et al 1998, Abu-Elmagd, et 
al 2009, Caillard, et al 2005, Cockfield 2001, Issa, et al 2009, Knight, et al 2009, 
Opelz  and  Dohler  2004,  Shiba,  et  al  2004,  Webber,  et  al  2006).  This  range  of 
incidences can be further subdivided into risk based on whether the patient is adult or
paediatric, the nature and intensity of immunosuppression used, and the type of organ 
transplanted (Knight, et al 2009, Opelz and Dohler 2004).
The  increased  risk  identified  for  paediatric  compared  to  adult  patients  has  been 
attributed not to difference in recipient age per se, but to the fact that the majority of Chapter one
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adults are seropositive at the time of transplant, whereas a large proportion of children 
are  EBV  naïve  and  experiencing  primary  infection  in  an  immunosuppressed  state 
(Caillard, et al 2005). Primary EBV infection occurring in an individual unable to 
mount a cellular immune response results in very high rates of PTLD development, 
with  risk  increased  by  10-76  fold  (Preiksaitis  2004).  EBV  seronegativity  prior  to 
transplantation followed by subsequent EBV infection is well established as a major 
risk factor for PTLD development (Ho, et al 1985, Shahinian, et al 2003, Walker, et al
1995), see Figure 3.
Figure 3: Increased risk of PTLD in patients under 20 years of age and EBV 
negative recipients. The proportion of patients aged <20 years developing PTLD is 
increased compared to all other age groups. EBV seronegative recipients also have 
increased risk of PTLD. From Caillard et al, 2005.Chapter one
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In addition, PTLD risk is strongly associated with the type of organ grafted. It is likely 
that this is reflective of the differing immunosuppression  requirement for different 
organs. Immunostimulatory grafts, such as intestinal or heart-lung transplants require 
stronger immunosuppression to prevent rejection compared to those that provoke less 
intense allogeneic responses and therefore require lower immunosuppressive doses eg 
kidney transplants (see Table 3). 
Table 3: Incidence of PTLD by transplant type. Adapted from (Cockfield 2001).
Transplant type Incidence of PTLD
Kidney 1%
Liver 2.2%
Heart 3.4%
Lung 1.8-7.9%
Heart-Lung 9.4%
Intestinal 7-11%
Multivisceral 13-33%
Bone Marrow <1%
Some studies have found that certain immunosuppressive agents are associated with 
higher risk of PTLD development (Opelz and Dohler 2004, Penn 1987), however this 
has  not  been  observed  in  other  studies  (Birkeland  and  Hamilton-Dutoit  2003, 
Landewe,  et  al  1999).  It  seems  likely  that  PTLD  risk  is  increased  by  a  higher 
cumulative dose of immunosuppression, rather than by a particular agent (Brumbaugh, 
et al 1985, Sokal, et al 1997). However, one US study of over 25000 renal transplant 
recipients suggested an increased risk of PTLD in patients receiving FK506 compared 
to CsA, a finding supported by the study of Opelz in 2004. In addition, patients treated 
with  Mycophenolate  Mofetil  (MMF)  may  have  a  reduced  risk  of  PTLD,  possibly 
because MMF also has a suppressive effect on B cells (Caillard, et al 2005). The role 
of  individual  IS  agents  is  therefore  not  entirely  clear,  however  in  general  highly 
immunosuppressive regimens are associated with increased PTLD compared with less Chapter one
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immunosuppressive regimens (Caillard, et al 2005, Gutierrez-Dalmau and Campistol 
2007).
Despite the conclusion that PTLD is the result of immunosuppression generally rather 
than a specific agent, it should be noted that the use of T cell depletion (TCD) in both 
stem cell and solid organ transplantation is associated with increased risk of PTLD 
development. T cell depletion is an effective strategy for graft versus host disease 
(GVHD) prophylaxis either in vivo using anti-thymocyte globulin (ATG) or of the 
graft itself pre-infusion, however these are also major PTLD risk factors in the SCT 
setting. Indeed, PTLD is rarely observed in SCT in the absence of in vitro or in vivo T 
cell depleting antibodies  (Caillard, et al  2005,  Landgren,  et al 2009,  Lynch,  et al
2003). This risk can be reduced by depleting both T and B cells from the stem cell 
graft rather than T cells alone (Liu, et al 2004). Various T cell depleting strategies are 
also used as both induction therapy and for treatment of rejection episodes in SOT, 
however many studies have found that TCD is a risk factor for PTLD development in 
this setting also (Issa and Fishman 2009).
It has been suggested that the grafted organ itself contributes to the pathogenesis of 
PTLD via chronic low-level antigen stimulation, a hypothesis that is supported by the 
relatively high incidence of PTLD involving the transplant (Birkeland 1983, Lim, et al
2002).  However,  it  is  difficult  to  separate  the  relative  contributions  of  increased 
immunostimulation by a particular type of graft from the heavier immunosuppression 
required to protect it from rejection. Increased lymphoma risk is also seen in patients 
with inherited or acquired immunodeficiencies (eg. Wiskott-Aldrich Syndrome, HIV 
infection),  or  following  immunosuppressive  treatment  for  autoimmune  conditions, 
suggesting that immune compromise itself is the main risk factor rather than organ 
grafting (Birkeland and Hamilton-Dutoit 2003).
1.2.4 The role of EBV in PTLD development
The relationship between iatrogenic immunosuppression in organ transplant recipients 
and an increased risk of lymphoma has long been recognised, and the association with Chapter one
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EBV infection is now well established (Buell, et al 2005, Caillard, et al 2005, Ho, et al
1985, Rickinson, et al 1996, Shahinian, et al 2003, Swerdlow, et al 2000, Walker, et al
1995). Over 90% of PTLD lesions are EBV positive, including over 90% of B-lineage 
and approximately 50% of the much rarer T-lineage tumours. There are several lines 
of evidence suggesting that EBV plays a role in the development of these tumours. 
First, EBV can be detected in over 90% of tumour tissue, and EBV associated RNAs 
(EBERs) frequently co-localise to the malignant cells histologically. Furthermore, in 
these tumour samples EBV genomes are often clonal, indicating that the virus was 
present at the time of transformation. The EBV viral load in peripheral blood samples 
often rises prior to development of PTLD, particularly in SCT patients. In addition, the 
well  characterised  oncogenic  potential  of  the  expressed  EBV  genes  in  vitro
demonstrates that EBV has the capacity to drive the development of PTLD. The role 
of EBV  is  further highlighted  by  tumour  regression  which can  be  induced  by  the 
infusion  of  EBV-specific  T  cells (Rooney,  et  al  1998).  Therefore,  the  weight  of 
evidence  strongly  suggests  that  EBV  is  centrally  involved  in  the  pathogenesis  of 
PTLD (Nalesnik 1998, Tsao and Hsi 2007).
As discussed above, in the immune competent host EBV infection is controlled by the 
cellular immune response. Infected cells normally express the latency 0 programme,
with efficient recognition and removal of any that express immunogenic EBV derived 
proteins. However, upon compromise of cellular immunity, the immune environment 
becomes  permissive  for  EBV  infected  cells  to  establish  other  latency  phenotypes, 
escape  recognition  or  elimination  by  CTLs  and  drive  B  cell  proliferation.  This  is 
observed in several groups of immunocompromised patients: in stem cell transplant 
patients  prior  to  reconstitution  of  T  cell  responses  from  the  graft,  during 
pharmacological immunosuppression to prevent graft rejection following solid organ 
transplant,  in  immunodeficient  HIV  patients,  or  in  patients  with  primary 
immunodeficiencies  such  as  Wiskott-Aldrich  syndrome  and  XLP (Hopwood  and 
Crawford 2000, Young and Murray 2003). Therefore the critical factor in control of 
EBV infection is intact EBV-specific cellular immunity, which maintains the virus is 
its quiescent state without clinical symptoms.Chapter one
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However, despite these observations regarding the role of EBV in the development of 
PTLD, it is clear that the combination of immunosuppression and EBV infection alone 
is not sufficient for tumour formation. The majority of transplanted patients receive
immunosuppressive  therapy  for  many  years  without  development  of  PTLD.  It  is 
thought  that  several  other  factors  may  allow  EBV  to  drive  outgrowth  of  B  cells, 
including the cytokine environment (eg. TNF mutations,  IFN levels) (Lee, et al
2006b, McAulay, et al 2009) and the accumulation of additional genetic changes in 
proliferating B cells (eg. bcl-6 and c-myc mutations) (Lim, et al 2006). 
It should also be noted that a subset of PTLD consisting of up to 10% of cases is EBV-
negative (Leblond, et al 1998). This well recognised but poorly understood group of 
malignancies  are  more  aggressive, tend  to  occur  late  after  transplantation  and  can 
include either B or T cell lymphomas (Ghobrial, et al 2005, Nelson, et al 2000, van 
Gorp, et al 1994). It has been suggested that they should be considered as a separate 
entity from early, EBV positive PTLD as their clinical behaviour more closely reflects 
spontaneous  lymphoma  in  the  immunocompetent  population  and  a  distinct  gene 
expression profile has been identified in these tumours (Craig, et al 2007).
1.2.5 Prediction of PTLD
Despite the recognition of several factors that increase PTLD incidence in various 
cohorts of patients, identification of the individual patient likely to develop the disease 
remains a challenge. 
PTLD prediction differs considerably between stem cell and solid organ transplant 
patients. In patients undergoing T cell depleted SCT, EBV viraemia in the first few 
months  post  transplant  appears  predictive  of  PTLD,  which  enables  pre-emptive 
intervention allowing good results in several studies (Ahmad, et al 2009, Gustafsson, 
et al 2000, Omar, et al 2009, Wagner, et al 2004). However, while PTLD very rarely 
occurs in the absence of EBV viraemia, the positive predictive value of viraemia is 
variable,  the  optimal  threshold  for  intervention  in  these  patients  has  yet  to  be 
determined, therefore  patients  in  some  of  these  trials  were  probably  over-treated Chapter one
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(Greenfield, et al 2006). Meij et al have demonstrated that combining measurement of 
EBV viral load with the presence or absence of EBV-specific CD8 T cells as assessed 
by HLA-peptide tetramers increased the positive predictive value of EBV viraemia 
from 30% to 100% in patients undergoing T cell depleted SCT (Meij, et al 2003), but 
these assays are not yet in routine clinical use. Current practice generally includes 
close monitoring of viral load in such patients, with pre-emptive treatment in patients 
at highest risk.
In SOT  patients  the  association  between  increased  EBV  load  and  development  of 
PTLD  is  less  clear,  as  many  patients  with  high  viral  loads  do  not  progress  to 
development of PTLD (Benden, et al 2005, Doesch, et al 2008). Attempts to predict 
those patients most likely to develop PTLD have utilised several assays examining 
cytokine polymorphisms (Lee, et al 2006b), general measures of cellular immunity 
(Lee, et al 2006a) or CD4/CD8 counts (Sebelin-Wulf, et al 2007) in combination with 
EBV viraemia. The most successful of these combined the two contributing factors in 
PTLD development: EBV load and anti-EBV immunity. Smets et al measured EBV 
copy  number  per  g  DNA  in  conjunction  with  EBV  specific  immunity  using 
ELISPOT, resulting in the PTLD index (IPTLD) with 86% sensitivity, 100% specificity 
and positive predictive value, and 92% negative predictive value (Smets, et al 2002). 
This  represents  a  significant  improvement  on  previous  attempts  to  predict  PTLD 
which often had poor positive predictive value; however the use of IPTLD is limited by 
the requirement to establish an LCL line from each patient to measure EBV specific 
immunity. Should a more rapid and reliable method for measurement of functional 
EBV-immunity become available, the IPTLD index promises to be useful in predicting 
the highest risk patients. Alternatively, combination of EBV load with more general 
measures of immune capability in immunosuppressed patients may prove to be an 
adequate  predictive  measure.  The  ability  to  identify  those  patients  at  highest  risk 
would be beneficial for pre-emptive treatment of PTLD, allowing earlier intervention 
and the initiation of patient-specific therapies. Early application of these approaches 
could reduce PTLD related mortality.Chapter one
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1.3 Current treatment strategies for PTLD
Strategies to treat PTLD are currently based on three main approaches: restoration of 
anti-EBV immunity,  reduction  of tumour  burden, or the elimination of EBV itself 
(Svoboda, et al 2006) (see Figure 4). 
1.2.1 Reduction of immunosuppression
First  line  treatment  generally  addresses  the  former  issue,  with  reduction  of 
immunosuppressive  therapy  aiming  to  allow  reconstitution  of  the  cellular  immune 
response  to  EBV  and  subsequent  control  of  proliferating,  EBV  infected  B  cells.
Reducing the level of immunosuppression alone provokes a clinical response in up to 
60% of patients, especially in those who are diagnosed early and are suffering from 
early lesions or polymorphic PTLD (Tsai, et al 2001). The efficacy of this approach 
was  illustrated  by  Guppy  et  al,  with  demonstration  of  increased  EBV-specific 
immunity concurrent with reduced IS in nine patients (Guppy, et al 2007). However, 
this  approach  carries  a  considerable  risk  of  either  transplant  rejection  in  the  SOT 
patient, or development of GVHD in the SCT patient. In fact, in one major series 
examining outcome following heart transplantation, death from graft loss following 
reduction in immunosuppression was as common as death from PTLD (Webber, et al
2006).Chapter one
_____________________________________________________________________
38
Figure 4: Illustration of balance between EBV infected B cells and EBV-specific 
T cells. Top panel: Maintenance of balance in healthy individuals ensures control of 
EBV infection. Middle panel: EBV-infected B cells proliferate in immunosuppressed 
patients, leading to PTLD. Lower panel: Restoration of balance by reduction of B cells 
or augmentation of T cell responses. (Hsieh, et al 1999)
1.2.2 Monoclonal antibodies
In  order  to  reduce  tumour  bulk,  B  cell  specific  monoclonal  antibodies  were  first 
employed  against  PTLD  in  1991,  with  the  use  of  anti-CD21  and  CD24  inducing 
complete remission in 16 of 26 treated patients (Fischer, et al 1991). These antibodies 
were  subsequently  replaced  by  the  chimaeric  anti-CD20  monoclonal  antibody 
Rituximab, which was introduced in 1998 and has since become widely used. The Chapter one
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target  molecule  CD20  is  expressed  in  approximately  90%  of  PTLD  tumours,  and 
binding of Rituximab to this surface marker results elimination of the cell. Several 
mechanism are thought to be involved in this process, including complement mediated 
cytotoxicity (CDC), antibody dependent cellular cytotoxicity (ADCC) and apoptosis 
(Zhou, et al 2008). In addition, the presence of NK cells has been demonstrated to be 
important in Rituximab action in one study (Markasz, et al 2009).
As outlined above, Rituximab appears effective as pre-emptive treatment in patients 
undergoing  T  cell  depleted  SCT  who  develop  EBV  viraemia.  Several  trials  have 
addressed the efficacy of this drug when used as treatment for established PTLD, with 
response  rates  of  44-75%  when  Rituximab  is  used  as  single  agent  therapy,  with 
complete remission achieved in 28-75% (Choquet, et al 2006, Svoboda, et al 2006). 
However, more recent data have suggested that Rituximab therapy is associated with 
significant rates of partial response and relapse, likely due to the transient depletion of 
B cells achieved (Choquet, et al 2007, Messahel, et al 2006). In addition, it has been 
suggested that the pan-B cell depletion resulting from treatment with Rituximab could 
compound  the  already  profound  immunodeficiency  experienced  by  patients  post-
transplant (Verschuuren, et al 2002), although the impact of this on antibody levels 
and infections has been disputed by other authors (Davis, et al 1999).
1.2.3 Chemotherapy
Chemotherapy is a widely used and effective treatment for non-PTLD malignancies in 
the  general  population,  and  is  also  used  as  therapy  for  EBV-driven  lymphoma  in 
transplant patients. Low dose chemotherapy with cyclophosphamide and prednisolone
appears to be an effective therapy for PTLD in the SOT setting (Gross, et al 2005). 
Despite response rates of up to 70%, toxicity is a serious consideration, with treatment 
related mortality of 25% (Elstrom, et al 2005, Svoboda, et al 2006). Furthermore, in 
SCT  patients,  prolonged  courses  of  even  low  dose  chemotherapy  may  have  a 
deleterious effect on the stem cell graft. Currently, a prospective, randomised study is 
underway  in  paediatric  PTLD  comparing  cyclophosphamide/prednisolone
chemotherapy alone or in combination with Rituximab.Chapter one
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1.2.4 Other approaches
For  patients  with  localised,  accessible  disease,  surgical  resection  combined  with 
reduction  of  immunosuppression  may  be  highly  effective (Green  2001).
Administration of anti-viral agents such as ganciclovir to combat EBV proliferation 
remains  controversial  for  PTLD treatment.  While  two  studies  suggested that 
ganciclovir  treatment  in  the  immediate  post  transplant  period  can  reduce  the 
development of PTLD in kidney, liver and pancreas transplant recipients (Darenkov, 
et al 1997, McDiarmid, et al 1998), other studies show no effect of anti-viral therapy
(Davis  1998).  Due  to  their  mode  of  action  targeting  the  lytic  cycle  of  EBV, it  is 
unlikely that these drugs would have an impact on latently infected proliferating B 
cells (Crumpacker 1996). However it remains possible that release of infectious virus 
from  lytically  infected  cells  compounds  the  situation  in  PTLD  patients  and 
interruption of this pathway could be beneficial. As with the other therapies above, 
anti-viral  drugs  have  their  own  toxicity  profile,  including  myelosuppression  by 
ganciclovir and nephrotoxicity with cidofovir.
In conclusion, all treatment options that are routinely available for PTLD at present are 
associated with negative effects: reduced IS increases the risk of rejection, Rituximab 
may compound immunosuppression and has significant relapse rates, chemotherapy 
carries considerable treatment  related toxicity and the efficacy of anti-virals is not 
established. The drawbacks of these currently available therapeutic options has led to 
the development of new approaches to PTLD treatment. Intuitively, the most logical 
approach to this is to correct the underlying deficit in EBV-specific immunity. 
1.4 Adoptive immunotherapy
The term immunotherapy refers to the use of immunological agents to treat disease. In 
the case of PTLD, there is an underlying deficiency in the cellular immune response, 
which allows EBV to drive inappropriate B cell growth. PTLD is an ideal candidate 
for the application of immunotherapy due to expression of EBV latent proteins on 
tumour  cells,  which  therefore  constitute  an  immunogenic  target.  One  approach  to Chapter one
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immunotherapy for EBV-PTLD is to correct the underlying deficit in cell mediated 
immunity  by  administration  of  EBV-specific  cytotoxic  T  cells,  generated  ex  vivo, 
which home to the tumour and lyse EBV-expressing cells.
As immunotherapy in this setting targets the cause of the disease rather than treating 
the  resulting  tumour,  it  has  several  advantages  over  conventional  therapies;  it  is 
specific to the tumour cells therefore causing fewer side-effects, and is long-lasting as 
the EBV-CTLs establish immunological memory and persist to control disease long 
term.  However,  a  major  drawback  of  immunotherapy  currently  limiting  its  more 
widespread use  is  the requirement for  generating a new  cell line for  each patient, 
requiring considerable time, resources and technical expertise.
1.4.1 Immunotherapy in stem cell transplantation
The potential for immunotherapy to reconstitute anti-viral immunity post stem cell 
transplantation was first established in 1992 with infusion of T cell clones to three 
patients which successfully controlled CMV  disease following  stem  cell  transplant
(Riddell, et al 1992). This preliminary study was followed by a larger series in which 
CMV  specific  CTLs  were  infused  pre-emptively  into  patients  developing  CMV 
viraemia post SCT. CTLs were well tolerated and no CMV viraemia or disease were 
observed  in  14  patients  (Walter,  et  al  1995).  Since  these  initial  studies,  adoptive 
immunotherapy for CMV has been used successfully in over 50 patients (Einsele, et al
2002, Peggs, et al 2003).
Immunotherapy for EBV-PTLD arising after stem cell transplantation was also mush 
studied  during  this  period.  Initially,  infusion  of  unmanipulated  donor  lymphocytes 
(DLI) was explored as a means to boost T cell responses prior to reconstitution of 
cellular immunity from the stem cell graft. Despite inducing regression of established 
PTLD in  6 patients, the presence of alloreactive T cells within the DLI led to  an 
unacceptably high incidence of GVHD as a result of this therapy (Heslop, et al 1994b, 
Papadopoulos, et al 1994).Chapter one
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Therefore, although total lymphocyte preparations from the stem cell donor can be 
effective  against  PTLD,  removal  of  the  alloreactive  cells  and  concomitant 
enhancement of the EBV compartment was desirable to circumvent the initiation of 
GVHD.  This  was  achieved  by  multiple  stimulations  of  donor  peripheral  blood 
mononuclear cells (PBMCs) with autologous EBV-transformed B cell lines in vitro. 
This technique results in expansion and activation of EBV-specific cells and loss of 
alloreactivity,  generating  EBV-specific,  MHC-restricted  cytotoxic  T  cell  lines. 
Infusion  of  donor-derived  EBV-specific  CTL  lines  into  10  patients  post  stem  cell 
transplant was well tolerated, with no de novo EBV disease developing, control of 
active  EBV  replication  in  two  patients  and  resolution  of  frank  lymphoma  in  one 
(Heslop, et al 1994a, Rooney, et al 1995). This study confirmed that EBV-CTLs can 
prevent and control EBV-driven disease, do not cause GVHD, and importantly that the 
infused  cells  can  persist  for  some  time  after  administration.  This  was  the  first 
successful trial of adoptive immunotherapy for PTLD and paved the way for further 
studies.
In subsequent studies, it was established that adoptively transferred CTLs persist long-
term in vivo through retroviral gene marking of infused CTLs with the Neomycin 
resistance gene (Heslop, et al 2009). In addition, infusion of EBV-specific CTLs to 
patients at high risk of PTLD after T cell depleted SCT effectively prevented PTLD 
when compared to a historical control cohort (Rooney, et al 1998). To date, EBV-
CTLs have been administered to over 200 patients at multiple different institutions 
(Gustafsson,  et al  2000,  Hale,  et al 2008,  Merlo, et al  2008).  These  studies  have 
established adoptive immunotherapy with EBV-specific CTLs to be safe and effective 
in both preventing and treating EBV-PTLD after T cell depleted stem cell transplant. 
Therefore  in  this  setting,  reconstitution  of  the  EBV  compartment  of  the  immune 
system can be achieved using adoptive transfer of ex-vivo expanded donor EBV-CTLs, 
which effectively controls PTLD.Chapter one
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1.4.2 Immunotherapy in solid organ transplantation
Following  the  success  of  adoptive  immunotherapy  in  the  setting  of  stem  cell 
transplantation, this approach has also been applied to PTLD arising after solid organ 
transplant. In contrast to SCT patients, PTLD arising after SOT is almost exclusively 
of recipient origin and therefore recipient EBV-CTLs, or EBV-CTLs which are HLA-
matched to the recipient are required. Immunotherapy trials post SOT can be divided 
into  those  utilising  patient  derived  (autologous)  CTLs  and  those  using  third  party 
derived, HLA-matched donor CTLs (allogeneic). 
1.4.2.1 Autologous EBV-CTLs
Immunologically, autologous  EBV-CTLs are the  ideal product to  combat  recipient 
derived EBV reactivation in the SOT patient. Expression of EBV latent antigens in 
LCLs,  which  are  used  as  APCs  for  CTL  generation  in  vitro,  is  identical  to  that 
observed in  most  PTLD  tumours.  Therefore,  EBV-CTLs  produced  by  exposure  to 
these LCLs are a polyclonal cell line targeting the tumour’s immunogenic antigens in 
the context of the correct HLA alleles.
Adoptive immunotherapy with autologous EBV-CTLs generated from patient blood 
taken pre-transplant was first administered to three SOT patients in 1998, resulting in 
transient increases in CTLp frequency and reductions in EBV viraemia. This study 
established the feasibility and safety of CTL infusion in the SOT setting (Haque, et al
1998). It was subsequently established that EBV-CTL lines can be reactivated from 
patients receiving immunosuppressive therapy with identical growth kinetics to those 
derived from healthy donors (Khanna, et al 1999, Savoldo, et al 2001). In addition, 
one autologous CTL line generated by Khanna et al was administered to a patient with 
progressive PTLD. Complete remission was induced, thus demonstrating the potential 
for clinical efficacy in SOT patients. However, secondary lesions developed in this 
patient, raising questions regarding the persistence of EBV-CTLs in the presence of 
immunosuppression  and  their  ability  to  control  disease  long-term  (Khanna,  et  al
1999).Chapter one
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Subsequently, the effect of autologous EBV-CTLs in SOT patients has been assessed 
in four main studies performed between 2002 and 2006, treating 25 patients either 
prophylactically  or  for  established  disease.  Immunological  parameters  and  clinical 
responses in these patients consistently suggest that, while adoptive immunotherapy 
can induce responses, these can be partial or temporary (Comoli, et al 2002, Comoli, 
et al 2005, Savoldo, et al 2006, Sherritt, et al 2003). Categorisation of patients treated 
in all studies thus far according to prophylaxis or treatment shows that, of 39 evaluable 
patients  treated  for  established  PTLD,  19  achieved  complete  remission,  3  partial 
remissions were observed and 16 did not respond. One patient has stable disease. Of 
21 patients at risk of PTLD treated prophylactically, no PTLD was observed (Merlo, et 
al 2008). 
Expansion  and  persistence  of  the  infused  CTLs post  SOT  is  generally  modest 
compared to that observed following HSCT, however some responses are achieved. 
Several trials have shown an increase in EBV-CTLp frequency following infusion of 
autologous  EBV-CTLs,  for  example  in  one  study  increases  of  1.5-4.8  fold  were 
documented  (Savoldo,  et  al  2006).  However,  it  was  generally  noted  that  these 
increases were transient, often dropping again between cell infusions, sometimes to 
pre-treatment levels (Comoli, et al 2002, Haque, et al 1998, Savoldo, et al 2006). It is 
possible that in the presence of immunosuppressive therapy, the proliferative potential 
of infused EBV-CTLs is curbed resulting in limited in vivo expansion and persistence 
following administration. However, infusion of EBV-CTLs has been shown to have an 
impact on EBV viraemia in some patients, with reductions in EBV-load documented. 
Although  these  are  also  sometimes  transient  decreases,  some  patients  experience 
sustained lowering of EBV genomes and therefore reduced risk of PTLD development 
(Comoli,  et  al  2002,  Haque,  et  al  1998).  In  contrast,  one  study  demonstrated  an 
increase in plasma EBV-DNA consistent with lysis of infected cells approximately 2 
weeks  following  EBV-CTL  infusion;  however  this  was  not  accompanied  by  a 
subsequent reduction in EBV-DNA detected in PBMC samples (Savoldo, et al 2006).
The  body  of  evidence  thus  far  illustrates  that  EBV-CTL  therapy  has  considerable 
promise in the setting of post-SOT PTLD, with clinical responses induced in some 
patients.  However,  for  many  patients  the  infusion  of  EBV-CTLs  is  an  adjunctive Chapter one
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therapy alongside or following several conventional approaches, therefore attributing 
these  responses  to  immunotherapy  alone  can  be  difficult.  In  conclusion,  whilst 
promising, the use of EBV-CTLs in the setting of SOT remains to be fulfilled to its 
potential.
1.4.2.3 Generation of EBV-CTLs from seronegative recipients
As discussed above, EBV negativity at the time of transplant is a major risk factor for 
PTLD  in  SOT  recipients,  and  many  paediatric  patients  fall  into  this  category. 
However, current protocols that are routinely used for generation of EBV-CTLs from 
PBMCs are based on re-activation of memory CTLs within the T cell compartment. 
EBV negative recipients do not have memory EBV-CTLs, therefore cell lines from 
these patients must be generated from naïve T cells as in a primary response.
Generation  of  EBV-CTL  lines  from  EBV  negative  patients  using  the  standard 
protocols  for  EBV  positive  donors  has  generally  been  unsuccessful,  therefore 
alternative methods have been developed. Two approaches have been shown to result 
in successful establishment of EBV cell lines. Stimulation of PBMC with autologous 
LCL followed by selection and restimulation of activated CD25 positive cells can be 
used to enrich for EBV-specific cells and to generate EBV-specific, CD4+, MHC class 
II restricted, cytotoxic cell lines (Savoldo, et al 2002). Alternatively, stimulation of 
PBMC by autologous LCL in the presence of the cytokines IL-12 and IL-7, rather than 
standard supplementation with IL-2, resulted in CD8+, class I restricted cytotoxic T 
cell lines (Comoli, et al 2006). As a result of these studies, adoptive immunotherapy 
with autologous EBV-CTLs can be available to a wider patient cohort including those 
EBV-negative individuals who are at highest risk.
One major drawback with the generation of autologous CTLs on a patient-by-patient 
basis  is  the  considerable  time  required  for  in  vitro  expansion  of  these  cells. 
Establishment  of  an  LCL  line  occurs  in  approximately 4-6  weeks,  after  which  an 
additional 4-5 weeks is required for EBV-CTL generation and testing. While this 10 
week period may not be a consideration if CTLs are used prophylactically, it would Chapter one
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significantly limit the applicability of this approach for pre-emptive use or therapy of 
established PTLD. It has been proposed that this delay could be covered by reducing 
immunosuppression  and  administering Rituximab therapy  to  allow  generation  of  a 
patient-specific  therapeutic  product (Savoldo,  et  al  2006).  Alternatively,  another
approach developed to circumvent this delay is the use of pre-generated, allogeneic 
CTL lines from partially HLA matched third party donors.
1.4.2.3 Third party EBV-CTLs
In order to overcome the practical issues associated with generation of autologous cell 
lines on a patient-by-patient basis, Haque et al have established a well characterised 
bank of 100 EBV-CTL lines that are immediately available (Wilkie, et al 2004). Cells 
from this facility can be selected based on the closest HLA match between the patient 
and the cell product and shipped to the patient’s treating hospital, obviating the need 
for  specialist  facilities  and  removing  the  lag  time  required  for  LCL  and  CTL 
generation. Despite the inevitable HLA mismatches, a phase II trial of this approach 
recently demonstrated  complete  responses  in  12  of 33  treated patients,  and partial 
responses in a further 9 patients all of whom were refractory to conventional treatment 
options. These responses were well maintained, with one complete and four partial 
responders relapsing but two partial responders converting to complete response. No 
patient  experienced  graft  rejection  or  toxicity  as  a  result  of  CTL  treatment.  It  is 
important to note that immunosuppression was reduced in all patients in this trial and 
was stopped entirely in 26, although in some patients this was re-introduced prior to 
EBV-CTL infusion. The impact of these changes are difficult to assess but may have 
had  the  dual  effect  of  both  allowing  the  transferred  EBV-CTLs  to  function 
unimpaired, whilst allowing the recipient’s EBV-immunity to recover. However, along 
with recovery of EBV-specific immunity, it is possible that an allo-reactive response 
directed towards the therapeutic cells could be generated by the recipient, resulting in 
clearance  of  the  infused  CTLs. While  persistence  of  the  transferred  cells  was  not 
systematically  studied,  the  data  available  suggest  that  third  party  CTLs  are 
undetectable  within  4-6  weeks  of  the  first  infusion,  possibly  suggestive  of Chapter one
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immunological clearance. This possibility is highlighted by the development of allo-
antibodies directed towards the mismatched HLA antigens in one patient.
Overall,  52%  of  patients  maintained  a  response  six  months  post  infusion, 
demonstrating a considerable benefit of EBV-CTL therapy in a patient group with 
advanced  disease  and  otherwise  poor  prognosis  (Haque,  et  al  1998,  Haque,  et  al
2007). This approach is a promising alternative for patients who have failed reduction 
of immunosuppression or Rituximab therapy for whom autologous EBV-CTLs are not 
available, and is associated with significant response rates.
1.4.2.4 Effect of pharmacological immunosuppression on cell therapy
Although  EBV-CTLs  can  be  generated  from  immunosuppressed  patients  and 
expanded ex vivo, it can be concluded from the above studies that the remarkable 
success of immunotherapy for both CMV and EBV post stem cell transplantation has 
not been replicated following SOT. Two explanations are generally offered for the 
disappointing results achieved thus  far.  The first  of these is  that, unlike post-SCT 
where  conditioning  has  “emptied”  the  immune  compartment,  leaving  an 
immunological niche into which the cells can expand, EBV-CTLs administered post 
SOT enter a lymphocyte replete patient and must therefore compete to expand and 
establish  a  memory  population.  Another  possibility  is  that  the  function  of  the 
adoptively transferred CTLs is compromised by ongoing immunosuppressive therapy
in  the  SOT  setting,  whereas  the  majority  of  SCT  patients  received  EBV-CTLs
following cessation of immunosuppression. Indeed, Savoldo et al studied the effect of 
the two main immunosuppressants used to prevent graft rejection following SOT. The 
calcineurin inhibitors Tacrolimus (FK506) and Cyclosporin A (CsA) both inhibited 
proliferation, and profoundly reduced cytokine secretion from ex vivo expanded EBV-
CTL lines (Savoldo, et al 2001). In addition, it has been shown that although CMV-
specific CD8+  T  cells are  present  at  normal  levels  in  patients  receiving 
immunosuppressive therapy, these cells display impaired functionality as shown by 
reduced IFN- secretion (Engstrand, et al 2003). Chapter one
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As  a  result  of  the  above  evidence,  we  propose  that  the  efficacy  of  adoptive 
immunotherapy for PTLD  following SOT  could be enhanced by the  generation of 
EBV-CTL lines that are resistant to the suppressive effects of calcineurin inhibitors. 
This approach would remove the need for tapering immunosuppressive therapy and 
therefore the attendant risk of graft rejection, while allowing the infused cell product
to function uninhibited. To this end, we have investigated the possibility of rendering 
EBV-CTLs resistant to calcineurin inhibitors by transduction with calcineurin mutants.
1.5 Generation of immunosuppression resistant CTLs
for immunotherapy
1.5.1 Mechanism of action of CN inhibitors
Activation of T cells is critical in the induction of an immune response, inducing a 
complex interplay between helper and cytotoxic T cells, B cells and the innate immune 
system that is critical in generating efficient and appropriate responses. Therefore the 
interruption of cellular immunity by disrupting T cell activation is the focus of many 
immunosuppressive agents.
T cell activation is initiated by binding of cognate antigen, presented in the appropriate 
MHC  molecule,  to  the  T  cell  receptor  (TCR).  Adhesion  molecules  stabilise  this 
immunological synapse, and costimulatory pathways must also be triggered to deliver 
co-ordinated signals to the nucleus of the T cell, resulting in effective activation. The 
most important of these being binding of CD28 on the T cell by CD80/86 on the target 
antigen presenting cell, although several other possible costimulatory pathways that 
can  substitute  for  CD28.  Following ligation  of  the  TCR,  several phosphatases  are 
activated  and  initiate  signalling  through  four  main  pathways.  With  help  from  the 
CD45 molecule, the Src family kinases Lck and Fyn dephosphorylate ZAP-70 and 
Syk, leading to activation of phospholipase C 1 (PLC1). This results in hydrolysis of 
Phosphatidylinositol-5,4-bisphosphate  (PIP2)  to  diacyl glycerol  (DAG)  and  inositol
phosphate3 (IP3), simultaneously activating three pathways: the Ras pathway, resulting Chapter one
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in Erk translocation to the nucleus, protein kinase C  (PKC) activation initiates the 
NFB pathway (nuclear factor kappa light chain enhancer of activated B cells), and 
the Calmodulin/Calcineurin pathway activating the nuclear factor of activated T cells
(NFAT). TCR ligation also triggers mitogen activated protein kinase kinase kinase 
(MEKK) signalling, which activates p38 and Jnk, allowing entry to the nucleus and 
the presence of activated Fos and Jun. Binding of CD28 leads to activation of PIP3, 
which  in  conjunction  with  PKC  (activated  by  DAG),  leads  to  activation  and 
translocation  of  NFB  (Aringer  2002).  As  communication  between  pathways  and 
cross-regulation  is  increasingly  understood,  it  is  becoming  clear  that  the  defined 
signalling  “pathways”  involved  in  T  cell  activation  are  in  fact  complex  networks 
(Smith-Garvin, et al 2009). T cell activation remains under continued investigation, 
however a simplified illustration of the understanding of these pathways to date in 
shown in Figure 5.Chapter one
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Figure 5: Illustration of T cell activation signal pathways. From Cell Signalling 
Technologies  (http://www.cellsignal.com/reference/pathway/T_Cell_Receptor.html)
Calcineurin is highlighted with red box.
As  shown  above,  calcineurin  (CN)  is  a  key  component  of  the  calcium-regulated 
activation  pathway  in  T  cells.  Calcineurin  is  a  heterodimeric  serine-threonine 
phosphatase, comprised of a catalytic subunit (CNa) and a regulatory subunit (CNb) 
whose primary substrate is the transcription factor Nuclear Factor of Activated T cells 
(NFAT). Dephosphorylation of NFAT exposes its nuclear localisation signal resulting 
in translocation to the nucleus, where it is involved in regulating the expression of 
multiple genes involved in cellular activation, the classical example of which is IL-2 
but also including IL-3-5, IL-8, IL-13, IFN-, CD40L and others (Im and Rao 2004, Chapter one
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Kiani, et al 2000). In addition, CN is thought to have effects on other transcription 
factors  including  activation  of  JNK,  activation  of  IB  kinase  resulting  in  NFB
activation, dephosphorylation of Elk-1 and indirect modulation of CREB. It can be 
concluded that CN is a pivotal molecule in activation of T cells, critical in activation 
of genes controlled by NFAT and also involved to a lesser extent in augmenting other 
activation pathways (Kiani, et al 2000). 
The discovery of CN inhibitors in the 1980s revolutionised the field of transplantation 
medicine, allowing more effective suppression of the allo-specific immune response 
than was previously achievable, thus reducing rejection rates and improving survival 
post transplantation. Inhibition of CN activity results in profound suppression of T cell 
responses as normal activation signals are interrupted and T cells cannot respond to 
antigen  binding.  The  CN  inhibitors  FK506  and  CsA  sterically  prevent 
dephosphorylation  of  NFAT  by  binding  to  the  composite  face  of  CNa  and  CNb, 
inhibiting access to the active site by NFAT (Ho, et al 1996). Calcineurin inhibitors 
are currently the most commonly used class of immunosuppressive agents, which form 
the  cornerstone  of  many  SOT  anti-rejection  regimens.  Although  often  used  in 
conjunction with  agents such as prednisolone,  Mycophenolate Mofetil  (MMF) and 
with  additional  treatment  during  rejection  episodes,  CN  inhibitors  are  the  key 
immunosuppressive  agents  used  in  transplantation  medicine.  In  SOT  patients  who 
develop PTLD, other immunosuppressive agents such as MMF can often be safely 
discontinued  but  withdrawal  of  CN  inhibitors  frequently  results  in  graft  rejection 
(Webber,  et  al  2006).  Therefore  we  have  focussed  on  generating  T  cells  that  are 
resistant to suppression by FK506 and CsA.
FK506 and CsA are naturally occurring fungal metabolites which, despite their very 
similar effects and mode of action, are structurally distinct (see Figure 6). Both are 
bound by a cellular chaperone protein upon cell entry, the prolyl isomerases FK506 
binding protein 12  (FKBP12)  and Cyclophilin  A (CyPA) respectively. Calcineurin 
was established as the intracellular target of FK506 and CsA, and a pivotal molecule 
in T cell activation in 1991 (Liu, et al 1991). The role of CN had been previously 
unknown and its importance in cell signalling became clear as a result of the effects of 
its  inhibition.  Neither  the  drugs  or  their  chaperones  are  immunosuppressive Chapter one
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independently, but once bound the complex interacts with CN with extremely high 
specificity and sterically inhibits NFAT dephosphorylation, thus reducing this function 
of CN by several hundred to 1000 fold (see Figure 7) (Kiani, et al 2000).  
Figure 6: Structure of FK506 (a) and CsA (b). Similarities in mechanism of action 
and effects are not reflected structurally. Pubchem (http://pubchem.ncbi.nlm.nih.gov)
b aChapter one
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Figure  7:  Schematic  representation  of  CN  inhibitor  mechanism  of  action. (a) 
Normal cellular activation. (b) Binding of CN by FK506/CsA sterically inhibits NFAT 
dephosphorylation therefore preventing T cell activation.
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1.5.2 Previously identified resistance to CN inhibitors
Calcineurin mutants with the ability to confer resistance to CN inhibitors have been 
reported  previously  in  the  literature.  These  studies  focussed  on  the  effect  of  CN 
mutants in yeast, with the aim of identifying the role of various residues of the CN 
molecule,  rather  than  the  potential  utility  of  the  CN  mutation  itself.  Nevertheless, 
several CN mutants capable of conferring resistance to FK506, CsA or both have been 
identified.
In 1994, Milan et al identified two CNb mutants that conferred some resistance to both 
CN inhibitors in a yeast system, however these were also associated with reduced 
phosphatase  activity.  This  study  established  the  importance  of  CNb  in  both  CN 
phosphatase  activity  and  immunosuppressant  binding,  particularly  highlighting  the 
role of the C terminal latch region (Milan, et al 1994). Several studies followed to 
dissect the role of CNa and CNb regions in binding, activity and suppression of CN, 
with Kawamura identifying three CNa mutants that increased resistance to FK506 but 
not CsA, and Cardenas characterising three CsA and one FK506 resistant CNa mutant. 
(Cardenas, et al 1995, Kawamura and Su 1995). Although some of these studies were 
conducted in a yeast system, the results were reproduced showing resistance to FK506 
or CsA in the human Jurkat cell line (Zhu, et al 1996). Finally, during investigation of 
a naturally occurring FK506 resistant strain of C. neoformans, a striking mutation was 
identified by Fox et al consisting of a six base pair duplication in the CNb gene. This 
results in a two amino acid insertion in the latch region whose importance had been 
previously established, and confers FK506 resistance while retaining CN activity (Fox, 
et al 2001).
This body of work provides insight into the mechanism of action of the both the CN 
molecule and CN inhibitors, and a basis for investigation of further FK506 or CsA 
resistant CN mutants. In addition to testing these published mutants for resistance to 
CN  inhibitors  in  human  cell  lines,  we  have designed  further  mutations  using  the 
information gained from these studies regarding the importance of specific areas of the 
protein, together  with  predictions  based  on  the  crystal  structure  of  the 
FKBP12/FK506/CN and CsA/CyPA/CN complexes (Griffith, et al 1995, Huai, et alChapter one
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2002, Jin and Harrison 2002, Ke and Huai 2003, Kissinger, et al 1995). We have
introduced these CN mutants into human T cells using retroviruses to confer resistance 
to  CN  inhibitors with  the  aim  of generating  cells  that  retain  functionality  in  the 
presence of these immunosuppressive drugs.
1.5.3 Retroviral transduction of T cells
Gene transfer to human cells can be achieved using a variety of methods. However, as 
ex vivo expanded T lymphocytes proliferate rapidly, transduction with viral vectors 
remains the method of choice, ensuring integration into the genome and subsequent 
stable transgene expression. Several studies have been performed in which transduced 
T  cells  were  administered  to  patients,  the  majority of  which  to  date  have  utilised 
Moloney murine leukaemia virus (MLV) derived gamma retroviral vectors. Efficient 
gene transfer to human T cell lines can be achieved using MLV based vectors, with 
transduction efficiencies of up to 80-90% (Quintas-Cardama, et al 2007).
Due to serious adverse events observed in two clinical trials for X-SCID following 
transduction  of  haematopoietic  stem  cell  (HSC)  with  retroviral  vectors,  research 
efforts  have  focussed  on  improving  the  safety  of  viral  vectors.  Development  of 
leukaemia in these patients is attributed to activation of the proto-oncogene LMO2 by 
nearby retroviral integration, followed by selective pressure favouring cells expressing 
the transgene and accumulation of further genetic abnormalities (Hacein-Bey-Abina, 
et  al  2008,  Hacein-Bey-Abina,  et  al  2003,  Howe  2008).  Integration  of  the  viral 
genome  has  been  shown  to  favour  sites  of  active  transcription,  with  integration 
“hotspots”  near  LMO2  in  stem  cells,  and  read-through  from  the  strong  viral  LTR 
promoter up-regulating expression of cellular genes. Thus, efforts to produce safer, 
self-inactivating  (SIN)  vectors  with  different  integration  profiles  and  weaker, 
endogenous  promoters  to  reduce  read-through  have  resulted  in  the  SIN  retro  and 
lentiviral vectors (Schambach, et al 2007, Thornhill, et al 2008).
In contrast, retrovirally transduced mature T cells have been administered to over 100
patients with no adverse events recorded thus far, including 33 patients who received Chapter one
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neo
R marked EBV-CTLs post HSCT or Hodgkin’s lymphoma. These patients have 
been followed up for over ten years, with persistence of infused cells demonstrated 
and no adverse events associated (Rooney, et al 1998, Roskrow, et al 1998). Several 
factors may explain this difference in safety profile of retrovirally transduced stem 
cells compared to T cells. First and most importantly T cells, in contrast to stem cells, 
are differentiated, thus limiting their potential for malignant transformation (Rossig 
and Brenner 2004). Furthermore, the pre-activation of HSCs that is necessary to allow 
retroviral  transduction  may  force  rapid  cell  division  and  hence  predispose  to  the 
acquisition  of  genetic  mutations,  whereas  transduction  of  EBV-CTLs  can  be 
performed  using  LCL  stimulation  which  mimics  physiological  stimulation.  In 
addition,  transduced  HSCs  are  introduced  into  the  myelosuppressed  patient, 
undergoing  multiple  rounds  of  proliferation  and  differentiation  to  reconstitute  the 
immune  system.  This  “empty”  niche  in  which  transduced  cells  have  a  selective
advantage may be permissive environment for malignant transformation. Importantly, 
integration site analysis from neo
R marked EBV-CTLs demonstrates multiple different 
integration sites, mainly in non-coding regions, with no preference for proximity to 
oncogenes (Pule, et al 2004). Furthermore, retroviral transduction of T cells has been 
shown not to affect the V usage of the T cell repertoire, the phenotype or the function 
of the treated cells (Coito, et al 2004, Ferrand, et al 2000, Recchia, et al 2006).
This evidence suggests that the use of retroviral vectors for transduction of mature T 
cells is a safe approach to gene transfer to facilitate adoptive immunotherapy. Our 
laboratory has considerable experience in the use of the MLV derived SFG retroviral 
vector (Riviere, et al 1995), which in addition has been utilised in several clinical 
trials. We have therefore used this vector to achieve gene transfer of CN mutants to 
EBV-CTL lines.Chapter one
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1.6 In vivo modelling of PTLD
Following the development of CN inhibitor resistant EBV-CTLs in vitro, the function 
of these cells was examined in vivo prior to the initiation of a clinical trial. The use of 
animal  models  in  research  is  generally  considered  acceptable  when  the  in  vitro
situation does not adequately reflect the wider biological environment, and where a 
suitable animal model exists. As the in vivo development and treatment of PTLD can 
not be modelled fully in vitro, we believe it is justified to use animal models to study 
this disease and evaluate new therapies.
1.6.1 Large animal models for PTLD
Previously, EBV infection was studied using primate models. Both new and old world 
primate  systems  are  available  and  reflect both  human  EBV  infection  and  PTLD 
development. Because of ubiquitous infection with simian herpesviruses, resulting in 
the production of cross-reactive antibodies, old world species are resistant to EBV 
infection.  However,  Rhesus  monkeys  are  susceptible  to  rhesus  gammaherpesvirus 
infection which produces an IM like illness, and these have been used to study primary 
infection (Johannessen 2002).
New  world  monkeys  are  not  immune  to  EBV,  and  have  been  used  to  study  both 
infection and PTLD. The common marmoset experiences an IM-like illness at primary 
infection  with  EBV  without  subsequent  development  of  lymphoma,  whereas  the 
cotton  top  tamarind  consistently  develops  PTLD-like  large  B  cell  lymphoma 
(Johannessen 2002).
Although  these  models  provided  useful  early  insights  into  EBV  infection  and 
immunity, the use of  non-human  primates poses  considerable ethical and  practical 
problems.  In  addition  to  the  endangered  status  of  new  world  monkeys,  all  these 
species are rare, costly, and require specialist facilities and expertise. The advent of 
appropriate  mouse  models  enabled  the  study  of  EBV  whilst  circumventing  these 
issues.Chapter one
_____________________________________________________________________
58
1.6.2 Mouse models of PTLD
Balb/C mice can be experimentally infected with murine herpesvirus 68 (MHV68), 
leading  to  an  IM-like  illness  after  approximately  3  weeks  (Nash,  et  al  2001).  In 
addition, MHV68 leads to spontaneous murine LPD development in 9% of animals, 
which can be increased to 60% by immunosuppression with CsA, mirroring the effect 
of EBV infection in humans (Sunil-Chandra, et al 1994).
The  description  in  1983  of  the  prkdc  mutation  producing  the  SCID  CB17  mouse 
represented  a  considerable  advance  for  the  study  of  human  tumorigenesis  and 
treatment. SCID CB17 mice have a defect in DNA repair which prevents effective 
VDJ recombination, leading to a lack of functional T and B cells (Bosma, et al 1983). 
Since the first demonstration of human tumour cell engraftment into SCID mice by 
Reddy in 1987, this model has been widely used for studying cancer development and 
treatment in vivo (Reddy, et al 1987). Following depletion of NK cells, SCID mice 
readily  accept  engraftment  of  xenogenic  PBMC  or  LCL  tumours,  either 
intraperitoneally (i.p.) or subcutaneously (s.c.), and represent an appropriate model for 
PTLD  immunotherapy  (Johannessen  2002,  Wagar,  et  al  2000).  Regression  of 
established LCL tumours by autologous EBV-CTL lines was demonstrated by Lacerda 
et al, and this model has subsequently been utilised by several groups (Foster, et al
2008, Lacerda, et al 1996, Quintarelli, et al 2007).
Despite the presence of the prkdc mutation and reduced T/B cells, the defect in DNA 
repair in SCID CB17 mice is not complete, with up to one quarter of animals retaining 
some residual T or B cells. In addition, SCID CB17 animals have functional NK cells 
which must be depleted prior to human cell engraftment. In order to design improved 
models,  the  NOD-SCID  and  2-microglobulin  knockout  NOD-SCID  strains  were 
utilised. These mice allow more efficient engraftment of human cells, likely because 
of  absent  NK  activity  (Wagar,  et  al  2000).  An  additional  SCID  mouse  strain 
developed  in  our  laboratory  is  the  triple  knockout  model  (3KO),  generated  by  a 
genetic back-cross of the RAG2
-/-/-chain
-/- mouse (Goldman, et al 1998) with the 
naturally C5 deficient AJ mouse strain (M. Blundell, Personal Communication). The Chapter one
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resulting RAG2
-/-/-chain
-/-/C5
-/- strain is devoid of T cells, B cells and NK cells and 
provides the ideal background for study of xenografted human tumour cell lines.
Triple  knockout  SCID  mice  were  used  to  establish  the  LCL  model  of  PTLD 
development  at  our  institute.  This  model  has  been  used  to  assess  the  efficacy  of 
immunotherapy during administration of CN inhibitors with untransduced EBV-CTLs
in comparison to those rendered resistant to CN inhibitors by transduction with CN 
mutants. Demonstration of improved CTL activity in the presence of CN inhibitors by 
transduced  compared  to  untransduced  CTLs without  toxicity  will  provide  the 
necessary scientific background required before proceeding to a clinical trial of CN 
transduced CTLs in the prophylaxis and treatment of PTLD in humans.
1.6.3 Measurement of tumours in vivo
Early studies of tumour development models in vivo assessed tumour progression by 
palpation  of  s.c.  tumours,  in  conjunction  with  calliper  measurement  of  accessible 
lesions. Measurement of i.p. tumours posed more of a challenge, with alterations in 
animal  behaviour  and  death,  followed  by  histological  examination  of  tumour 
progression, often used as end points (Lacerda, et al 1996). These methods have been 
superseded in recent years by the growing use of bioluminescent imaging technology, 
which allows precise tracking and quantification of xenografted tumour cells. Serial 
measurement of bioluminescent signal represents a sensitive, non-invasive technique 
for monitoring tumour progression or regression (Foster, et al 2008).
Bioluminescence refers  to the production of light  by naturally occurring luciferase 
enzymes, released upon oxidation of luciferin substrates to non-reactive oxyluciferins 
(Berger,  et  al  2008b).  Approximately  30  luciferase-luciferin  systems  have  been 
identified  from  many  animal  species,  the  most  widely  used  of  which  is  from  the 
common firefly Photinus pyralis (Chandran, et al 2009). Isolation of Firefly luciferase 
and purification of the D-luciferin substrate allowed application of this technology to 
scientific  research.  Luminescence  has  been  utilised  for  many  years  as  an  in  vitro
reporter  gene,  easily  detectable  in  luminometers  due  to  its  low  background  in Chapter one
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biological systems and concurrent low signal-to-noise ratio (Nguyen, et al 1988). The 
development of sensitive charged coupled device (CCD) cameras and subsequently the 
Xenogen IVIS imaging system has allowed application of bioluminescent imaging to 
in vivo systems (Contag, et al 1997, Contag, et al 1998).
Bioluminescent imaging has become widely used for in vivo monitoring, including 
application to the EBV-PTLD model by previous groups. These studies have shown 
serial tumour monitoring using Luciferase transduced LCL, demonstrating progression 
and  regression  upon  treatment  (Foster,  et  al  2008),  as  well  as  tracking  of  Luc 
transduced EBV-CTLs demonstrating homing to the tumour (Quintarelli, et al 2007). 
These studies establish that bioluminescent imaging does not interfere with the utility 
of the SCID mouse EBV-PTLD model.
Nevertheless, variation due to factors other than tumour growth is possible when using 
bioluminescent  imaging,  including  luciferase  transgene  silencing,  inadequate 
vascularisation of the region of interest, and methodological differences. Therefore, 
we have assessed these issues and established bioluminescent imaging as a technique 
to monitor both xenografted tumour and T cells in our triple knockout mouse model.
1.7 Alternative applications of CN inhibitor resistance
1.7.1 Immunotherapy post stem cell transplantation
The  ability  to  render  cells  resistant  to  suppression  by  CN  inhibitors  could  have 
benefits extending further than treatment of PTLD developing post SOT. The main 
alternative  application  of  immunotherapy  in  the  face  of  immunosuppression  arises 
following SCT. T cell depletion associated with conditioning therapy together with 
post-transplant  immunosuppression  used  to  prevent  GVHD  render  SCT  patients  at 
increased risk of infections for a window of several months post transplant. Hence 
during this period, viral infections, particularly with EBV, CMV and adenovirus are a 
major cause of morbidity and mortality. Adoptive immunotherapy represents a rational 
approach to prevention or treatment of these complications.Chapter one
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For  EBV-associated  PTLD,  the  majority  of  patients  receiving  EBV-CTLs  as
prophylaxis or treatment to date have had their immunosuppression tapered prior to 
infusion, to allow optimal function of the infused CTLs. However, some patients have 
previous or active GVHD at the time of development of PTLD, particularly when T 
cell specific agents such as ATG are used as therapy, thus precluding withdrawal of 
immunosuppression. In such circumstances, CN inhibitor resistant EBV-CTLs could 
confer  protective  immunity  against  EBV  without  the  need  to  reduce 
immunosuppression and the attendant risk of increased GVHD.
Conversely,  in  some  clinical  trials  of  immunotherapy  with  CMV-specific  CTLs
following SCT, immunosuppressive therapy with CN inhibitors has been continued 
after infusion of the therapeutic product to control GVHD (Mackinnon, et al 2008). 
Whilst these studies have shown that the infused CTLs expand in vivo and may have 
some efficacy including viraemia and preventing CMV disease, it remains likely that 
ongoing immunosuppression curtails the function of the infused cell product to some 
extent.  Furthermore,  CTL  cytotoxicity  is  thought  to  remain  unaffected  by  CN 
inhibitors, therefore this may contribute to short-term disease control (Savoldo, et al
2001). Suppression with  CN inhibitors in vitro prevents proliferation  and cytokine 
secretion after 1-2 weeks culture; therefore cells may retain functionality in the short 
term  following  infusion. However,  proliferation  and  establishment  of  memory 
responses  in  the  longer  term  is  likely  to  be  compromised  by  ongoing 
immunosuppression,  a  problem  which  would  be  circumvented  by  rendering  cells 
resistant to CN inhibitors prior to administration.
In  addition  to  virus-related  disease,  T  cell  therapy  may  also  be  used  to  target 
leukaemia  and  other  tumours,  through  conventional  or  chimaeric  T  cell  receptor 
transfer (Morgan, et al 2006, Pule, et al 2008, Stauss, et al 2008). Immunotherapy 
directed towards tumour antigens to enhance the GVL effect following SCT, target 
residual disease and maintain long term remission is likely to be most effective if 
administered early post transplantation when the immune compartment is empty and 
the tumour burden is low. However, administration of GVHD prophylaxis is also most 
important in the immediate post transplant period. Therefore, the ability to render cells Chapter one
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resistant to CN inhibitors may allow continued protection from GVHD in parallel with 
efficient anti-tumour function by the infused CTLs.
The generation of CN inhibitor resistant CTLs may therefore represent a considerable 
advance in the treatment of EBV-PTLD after SOT, as well as for viral infections and a 
broader range of malignancies post SCT.Chapter one
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1.8 Project aims
 To design and generate a panel of CN mutants conferring resistance to FK506, 
CsA or both.
 To screen this panel of mutants in cell line assays to identify those retaining 
activity in the presence of CN inhibitors.
 To assess the selected mutants in retrovirally transduced normal donor EBV-
CTL lines for the ability to confer resistance to CN inhibitors.
 To  determine  if  transduction  of  EBV-CTLs  with  CN  mutants  alters  their 
phenotype, antigen dependence or growth kinetics.
 To  establish  a  xenogenic  murine  model  of  EBV-PTLD  and  optimise 
bioluminescent imaging.
 To test the efficacy of immunotherapy with transduced EBV-CTL lines in the 
face of immunosuppression in vivo.Chapter two
Materials and MethodsChapter two
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2.1 Materials
2.1.1 Reagents
Unless  otherwise  stated,  all  tissue  culture  reagents  were  supplied  by  Gibco  BRL 
(Invitrogen) and all general chemicals were supplied by Sigma.
General reagents and enzymes:
(methyl-
3H) Thymidine TRK758 Perkin Elmer
1kb Plus DNA Ladder 10787-018 Invitrogen
51Chromium labelled sodium chromate  NEZ030002MC Perkin Elmer
Agar 1.10283.0500 MERCK
Agarose  AM-9042 Invitrogen
Cyclosporin A (Sandimmune) 478941 Sandoz Pharmaceuticals
D-Luciferin 360221 Regis Technologies
ELISA substrate reagent pack DY999 R&D Systems
Ficoll-Paque PLUS 17-1440-02 Amersham Biosciences
GeneJuice 70967-3 Novagen
Lipofectamine2000 11668-019 Invitrogen
Matrigel 354234 Beckton Dickinson
MeltiLex wax scintillation 1205-441 Perkin Elmer
Primocin ant-pm-1 Invivogen
Recombinant human IL-2 Z00368 GenScriptChapter two
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Red Cell Lysis Buffer 00-4333 EBioscience
Restriction Endonucleases + buffers New England Biosciences
Retronectin T100B TaKara
Sucrose BDH8029 BDH
Tacrolimus (Prograf) 119488 Astellas pharmaceuticals
Polybrene AL-118 Sigma
Tissue culture media and supplements:
Medium Supplements
Foetal Bovine Serum. 
(Sigma F7524)
Complete DMEM
(Invitrogen 61965-026)
10% FBS, 100U/ml penicillin, 100µg/ml streptomycin 
(Invitrogen 15140-122)
Complete RPMI 
(Invitrogen 61870-010)
10% FBS, 100U/ml penicillin, 100µg/ml streptomycin
Optimem 
(Invitrogen 31985-047)
No additions.
CTL media 45% hyclone RPMI (Hyclone SH30096.02), 45% Click’s 
media (Irvine Scientific 9195), 20mM L-glutamine, 10% 
hyclone FBS (Hyclone SH30070.03), 100U/ml penicillin, 
100g/mlstreptomycin
Trypsin/EDTA
(Invitrogen 25300-062)
2x freezing medium 60% FBS, 20% DMSO (Sigma D2650), 20% complete 
RPMI.
IMDM (Sigma 13390) 10% FBS, 100U/ml penicillin, 100µg/ml streptomycin 
(Invitrogen 15140-122), 20mM L-glutamine.
AIM V (Invitrogen 12055-
091)
No additionsChapter two
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2.1.2 Buffers and solutions
All  buffers  and  solutions  were  prepared  in  double  distilled  water  (ddH20),  sterile 
solutions  were  prepared  in  ddH20,  autoclaved  for  15  minutes  at  121
OC  or  sterile 
filtered through a 0.22m filter. Composition of buffers and solutions is listed below.
Buffer Ingredients
Orange G loading buffer (6x) 10mM Tris Ph 7.5, 50Mm EDTA, 10% Ficol 400, 
0.4% Orange G (Sigma 861286))
Flow Cytometry staining buffer 
(FACS buffer)
PBS, 0.5% FBS
Flow cytometry fixing buffer 
(FACS fixing buffer) 
FACS buffer + 0.5% Paraformaldehyde (Sigma 
441244)
Luria-Bertani Broth (LB) 25g Luria Broth base powder (Invitrogen 12795-
027) per litre dH20. Ampicillin (Sigma A9393) was 
added at 10mg/ml where indicated (LB-Amp). 
Supplemented with 1.5% (w/v) Bacto-Agar for 
solid medium.
TAE (x50) 0.2M Tris, 1M acetic acid (BDH) 50mM EDTA, 
pH8.0
ELISPOT Acetate Buffer 4.6ml 0.1M acetic acid, 11ml 0.1M sodium acetate, 
46.9ml ddH20
APC Complex solution PBS/ 0.1% Tween 20
ELISPOT Coating buffer 1.59g Na2CO3, 2.93g NaHCO3, 200mg NaN3, made 
up to 1L with sterile water pH 9.6, Sterile filtered
0.22µm
ELISA stop solution 2N H2SO4. 54ml concentrated H2SO4 in 1L dH2O.Chapter two
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2.1.3 Kits
Purelink Miniprep K2-10010 Invitrogen
Maxiprep 12165 Qiagen
QIAquick gel extraction kit 28704 Qiagen
QIAquick PCR purification kit 28104 Qiagen
DualGlo Luciferase assay E2920 Promega
Duoset ELISA kits IL-2 and IFN DY202 and DY285 R&D systems
2.1.4 Cell lines
293T  Human embryonic kidney cell line 
B95-8 Marmoset  cell  line  that  releases  high  titres  of  transforming  EBV
(DSMZ cell bank ACC 100). 
Jurkat T cell line derived from non-hodgkin lymphoma patient. Kind gift from 
Dr  Clio  Rooney,  Center  for  Cell  and  Gene  Therapy,  Houston,  TX, 
USA.
HSB-2 LAK sensitive cell line derived from acute lymphoblastic leukaemia 
patient (DSMZ cell bank ACC 435). 
LCL Derived from normal donor B cells transformed with supernatant from 
B95-8 cells
CTL Generated from normal donor PBMC stimulated with autologous LCL
FLYRD18 HT1080 derived cell line stably expressing moloney MLV GagPol and 
RD114 Env genes. (ECACC cell bank 95091902)Chapter two
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2.1.5 Antibodies
The following monoclonal antibodies were used in this study:
Flow cytometry: 
Becton Dickinson: CD3-APC (555355), CD4-FitC (555346), CD19-PerCP (SJ25C1), 
CD25-APC (555434).
eBioscience: CD3-Pacific Blue (57-0037-73), CD4-Pacific Blue (57-0048-73), CD8-
Pacific Blue (57-0086-73), CD16-PE (12-0168-73), CD56-PE (12-0569-71), CD62L-
APC (17-0629-73), .
Serotec:  CD45RO-PE (MCA461PET).
Western blotting: 
Becton Dickinson: CNa (556350).
AbCam: CNb (ab49658), -actin (ab49846).
ELISPOT: 
MabTech: IFN- capture Ab (mAB 1-DIK), IFN- detection Ab (mAb 7-B6-1).
Multiscreen ELISPOT plates MAHAS4510 Millipore 
APC reagent kit PK6100 Vector laboratories 
AEC tablets A6926 Sigma
Cytotoxicity assay:
Isoplate 1400-515 Perkin Elmer
OptiPhase ‘Supermix’ scintillation fluid 1200-439 Perkin Elmer
Plate sealer 0580 ABgeneChapter two
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2.1.6 Western Blotting
CelLytic Lysis buffer C3228 Sigma
Protease inhibitor cocktail P8340 Sigma
Sample buffer NP0008 Invitrogen
Reducing agent NP0009 Invitrogen
Anti-oxidant NP0005 Invitrogen
SeeBlue Plus2 pre-stained standard LC5925 Invitrogen
NuPAGE 4-12% novex Bis-Tris gels NP0321 Invitrogen
MOPS Buffer NP0001 Invitrogen
Transfer buffer NP0006 Invitrogen
SuperSignal West Pico Chemiluminescent Substrate 34080 Pierce
2.1.7 PCR
Primers IDT DNA
Phusion DNA Polymerase F-530 Finnzyme, supplied by NEB
Phusion PCR buffer F-519 Finnzyme, supplied by NEB
dNTPs U1515 Promega
Quick Ligase M2200 NEB
Quick Ligase Buffer B2200 NEB
2.1.8 Bacteria
DH5heat-shock competent bacteria C2987H NEB Chapter two
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2.2 Methods
2.2.1 DNA manipulation
2.2.1.1 Small scale DNA preparation
Single colonies were picked from an agar plate and grown overnight in 5ml LB-Amp. 
The Invitrogen purelink miniprep kit was used to isolate plasmid DNA according to 
the manufacturer’s instructions.
2.2.1.2 Large scale DNA preparation
500ml  LB-Amp  cultures  were  inoculated  with  a  5ml  bacterial  culture  and  grown 
overnight  with  shaking.  Qiagen  maxiprep  kit  was  used  as  per  the  manufacturer’s 
instructions to extract plasmid DNA from the resulting bacterial prep.
2.2.1.3 Measurement of DNA concentration
DNA  concentration  was  calculated  by  measuring  the  absorbance  of  light  with  a 
wavelength of 260 nm (A260) using a NanoDrop ND-1000 spectrophotometer with a 
0.2  mm  pathlength;  at  this  wavelength  50  µg/ml  of  double-stranded  DNA  has  an 
absorbance of 1.
2.2.1.4 Design and generation of mutants
Crystallographic data were used to identify critical residues involved in the interaction 
between  Calcineurin  and  the  FK506/FKBP12  or  CsA/Cyclophilin  A  heterodimers. 
These were substituted with alternatives predicted to interrupt binding based on their 
charge or side chain characteristics. Chapter two
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Mutations were generated using overlap extension PCR. Two fragments of the CN 
gene adjacent to the target site were amplified in initial mutagenesis PCRs utilising 
one complimentary  external primer  and one  internal primer  containing  the desired 
sequence change. 35 cycles of amplification were performed (40s 98
o, 30s 64
o, 90s 
72
o) using Phusion polymerase. Products were purified using Qiaquick PCR clean-up 
columns and joined in a fusion PCR using the two external primers and amplification 
conditions above. External primers included AgeI and NotI restriction enzyme sites to 
facilitate subsequent subcloning. Following generation of mutants and subcloning into 
the SFG vector, CNa/b mutants were confirmed by capillary sequencing (Lark).
2.2.1.5 PCR purification
The product of the above PCR reactions was purified with the Qiagen QIAquick PCR 
clean-up  column  according  to  the  manufacturer’s  instructions.  A  portion  of  the 
resultant product was examined by gel electrophoresis to confirm size and purity.
2.2.1.6 Restriction endonuclease digestion
A 20-fold over-digestion was performed to produce fragments for subsequent ligation 
or for confirmation of successful cloning. 0.5-5g of plasmid DNA was digested in a 
final  volume  of  20-200l.  The  recommended  buffer  was  used,  diluted  to  1x  with 
ddH20 and 0.1mg/ml BSA was added where required. The volume of enzyme varied 
according to concentration but never exceeded 10% (v/v) of the final reaction volume. 
CNa and CNb mutants generated as above were subcloned as AgeI-NotI fragments 
into the SFG_eGFP retroviral vector. Digestion was performed for 3 hours at 37
oC and 
verified by agarose gel electrophoresis. Double digestions were performed in parallel 
where  buffers  were  compatible  or  sequentially  following  clean-up  of  DNA  where 
buffers were incompatible using the Qiagen QIAquick clean-up kit.Chapter two
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2.2.1.7 Gel electrophoresis
The size of PCR products and digested plasmids was confirmed by gel electrophoresis. 
1% agarose gels were prepared in 1x TAE buffer by boiling in a microwave. Once 
melted and cooled, 0.5g/ml ethidium bromide was added to allow DNA visualisation. 
DNA samples were mixed with Orange G loading buffer at a ratio of 6:1 prior to 
addition to agarose gels. 1kb plus DNA ladder was included to allow determination of 
DNA fragment size. Gels were electrophoresed at 50-100V and up to 150mA in 1x 
TAE  buffer  until  adequate  separation  of  bands  was  observed.  Fragments  were 
visualised by exposure to UV light using the UVIdoc gel documentation system.
2.2.1.8 Gel extraction
Following identification of the correct bands by gel electrophoresis, the desired band 
was visualised using a UV transillumintor and excised from the gel using a clean 
scalpel blade. Gel extraction was then performed using the QIAquick gel extraction kit 
according to manufacturer’s instructions.
2.2.1.9 Ligation
Following restriction enzyme digestion of vector and insert, ligations were performed 
using 100ng of vector DNA at a Vector:Insert molar ratio of 1:3 and 1:6. Ligations 
were performed at room temperature for 5-10 minutes using Quick Ligase (NEB), 
according to the manufacturer’s instructions. 2l of the ligated DNA was transformed 
into E.coli as described above for miniprep and confirmation of successful cloning.
2.2.1.10 Plasmids
The SFG plasmid was used for expression of wild type and mutant CN genes. SFG is 
based on the Murine Moloney Leukaemia Virus, with the transgene start codon at the Chapter two
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start site of the deleted viral env gene. This is followed by an internal ribosomal entry 
site (IRES), allowing expression of the downstream reporter gene eGFP. Fragments 
were cloned in using the unique AgeI site upstream of the transgene start site, and the 
NotI site immediately following the transgene termination codon. The SFG plasmid 
was  also  utilised  to  express  FLuc_eBFP  for  transduction  of  LCLs  used  during 
subsequent in vivo experiments, where FLuc is followed by the foot and mouth disease 
2A expression sequence instead of an IRES for expression of the reporter gene blue 
fluorescent protein.
2.2.1.11 Codon optimisation
An optimal sequence was designed using pMol software, based on optimisation of 
human codon usage, raising GC content to 70%, reduction of local hairpins and literal 
repeats to a minimum and avoidance of splice signals. The sequence was assembled 
with ligation-by-PCR using Phusion polymerase from overlapping oligonucleotides.
The synthetic DNA was confirmed to be correct by capillary sequencing (Lark). This 
work was performed by Dr Martin Pule.
2.2.2 Bacterial manipulation
2.2.2.1 Growth and maintenance of E.coli
Escherichia coli (E.coli) were grown in liquid LB media with 10mg/ml ampicillin 
(LB-Amp) at 37
oC with agitation at 200rpm, or streaked out on solid LB-Amp agar 
plates supplemented with 1.5% Bacto Agar. For long term storage, bacterial cultures 
grown from a single colony were stored in 20% volume for volume (v/v) glycerol and
stored at -80
oC.Chapter two
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2.2.2.2 Bacterial transformation
Competent DH5 E.coli were transformed by heat shock. 25l competent bacteria 
were thawed on ice, 1-10ng DNA was added and incubated on ice for 30 minutes. 
Bacteria were transferred to a 42
o water bath for 35 seconds then placed on ice for 2 
minutes. 250l warm LB media was added and the cells were incubated at 37
oC with 
shaking for 1 hour. The resulting culture was streaked onto an LB-Amp agar plate and 
incubated at 37
o overnight.
2.2.3 Cell culture
2.2.3.1 Propagation of adherent cell lines
The adherent cell lines 293T and FLYRD18 were cultured in complete DMEM in 80 
or  175cm
2  tissue  culture  coated  flasks  at  37
oC  with  a  5%  CO2  atmosphere  and 
passaged when 80-90% confluency was reached, approximately biweekly. Cells were 
washed with 1x PBS, incubated for 5 minutes at 37
oC with trypsin/EDTA, diluted 1:8-
1:12 in fresh complete DMEM and transferred to new flasks.
2.2.3.2 Propagation of non-adherent cell lines
Non-adherent cell lines including Jurkat, LCL, B95-8 and HSB-2 were cultured in 
complete  RPMI  in  upright  80cm
2  tissue  culture  flasks  at  37
oC  with  a  5%  CO2
atmosphere. Cells were maintained at a density  of between approximately 0.2  and 
1x10
6/ml, and passaged by 1:8-1:20 dilution with fresh medium when semi-confluent 
as determined by changing media colour.Chapter two
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2.2.3.3 Isolation of peripheral blood mononuclear cells (PBMC)
Whole  blood  obtained  by  venesection  and  anti-coagulated  with  preservative  free 
heparin was diluted 1:1 with 1xPBS and 35ml layered onto 15ml Ficoll-Paque in 50ml 
centrifuge tubes. Tubes were centrifuged at 700g for 30 minutes at room temperature
without brake, whereupon the white blood cell layer at the ficoll:plasma interface was 
removed. PBMC were washed x2 with PBS and resuspended in complete RPMI or 
CTL medium.
2.2.3.4 Generation of EBV supernatant from B95-8 cell line
The B95-8 cell line is derived from marmosets and continuously releases high titres of 
EBV. EBV preparations for transforming human PBMCs are prepared from this cell 
line in a CELLine flask, resulting in concentration of the produced virus. 2.5x10
7 B95-
8  cells  are  prepared  in  15ml  warm  complete  RPMI  and  inoculated  into  the  cell 
compartment of the CELLine flask. One litre of warm RPMI containing 5% FCS is 
added to the nutrient compartment, separated from the cells by a nutrient permeable 
membrane. Cells  are incubated  for  7  days;  whereupon  they  are  harvested  and  old 
medium is replaced with 15ml fresh complete RPMI. The litre of RPMI with 5% FCS 
is replaced with 1L warm plain RPMI and the cells incubated for a further 7 days. 
Following this culture period, cells and media are collected from the cell compartment 
and centrifuged at 450g for 20 minutes; the supernatant containing the EBV virus is 
collected and centrifuged again under these conditions. The resulting supernatant is 
passed through a 0.45m filter and frozen in 200l aliquots at -80
oC for later use.
2.2.3.5 Generation of B-LCL lines
5x10
6 freshly isolated PBMC from healthy donors were centrifuged and resuspended 
in 200l EBV supernatant produced from the B95-8 cell line. 1.8ml complete RPMI 
containing 1g/ml Cyclosporin A (CsA) to inhibit EBV-specific T cell responses and Chapter two
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hence facilitate LCL growth was added and 200l cells aliquoted into five wells of a 
flat-bottom 96 well tissue culture plate (96wp) (5x10
5/well). 1ml complete RPMI with 
CsA was added to the remaining 1ml cells and 200l aliquotted to 10 further wells 
(2.5x10
5/well). The outer wells were filled with sterile distilled water and the cells 
were incubated at 37
oC in 5% CO2. The cells were incubated for one week, at which 
time half media changes were performed as necessary, determined by media colour, 
until cells were beginning to expand and clumps appeared. Subsequently, one well 
seeded with 5x10
5 cells was combined with two seeded with 2.5x10
5 cells in a 24wp 
and cells expanded for a further week, whereupon the LCL line was transferred to a 
vented 25cm
2 tissue culture flask.
2.2.3.6 Generation of EBV-CTL lines
EBV-CTLs were  cultured  in  45%  Click’s  medium,  45%  Hyclone RPMI  and  10% 
Hyclone  FBS  supplemented  with  20mM  L-Glutamine,  100U/ml  Penicillin  and 
100g/ml Streptomycin (CTL medium).  2x10
6 freshly isolated PBMCs were plated 
per well of a 24wp and stimulated with 5x10
4 irradiated (40Gy) autologous LCL (ratio
40:1) in 2ml CTL medium. After 9-11 days, 10
6 viable cells per well were replated 
into 24wp and stimulated with 2.5x10
5 autologous irradiated LCL (ratio 4:1). CTL 
were restimulated in this way weekly thereafter. 100U/ml IL-2 was added on day 13-
14, replenished by resuspension in fresh IL-2 containing CTL medium at every weekly
stimulation and by half-volume media changes containing 200U/ml IL-2 3-4 days after 
each stimulation. If CTLs became over-confluent, each well was divided into two and 
1ml CTL media with IL-2 was added to each.
2.2.3.7 Cryopreservation of cell lines
Cells  were  cryopreserved  for  long  term  storage.  Cells  were  centrifuged  and 
resuspended  in  0.5ml  cold  complete  RPMI  per  5-10x10
6  cells.  Cells  and 
cryopreservation  tubes  were  cooled  on  ice.  An  equal  volume  of  cold  2x  freezing Chapter two
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medium  was  added  to  the  cells  dropwise  on  ice  with  gentle  agitation.  1ml  was 
aliquoted to each cryopreservation tube and cells were transferred to -80
oC in a cooled 
isopropanol freezing container. This results in a controlled temperature decrease of -
1
oC per minute. The following day, cells were transferred to the vapour phase of liquid 
nitrogen for long term storage. When required, cells were rapidly warmed to 37
oC and 
washed twice in warm complete RPMI.
2.2.4 Dual Luciferase Assay
293T cells were plated at 7x10
4 per well in 24 well tissue culture plates in complete
DMEM  without  antibiotics.  The  following  day,  cells  were  triple  transfected  with 
400ng NFAT-RE_FLuc NFAT responsive Firefly Luciferase plasmid (Clontech), 8ng 
phRG-TK constitutively expressed Renilla luciferase control plasmid (Promega) and 
600ng SFG-CN plasmid. The plasmids were combined and transfected into 293T cells
using  Lipofectamine2000  according  to  the  manufacturer’s  instructions.  Two  days 
later, cultures were stimulated with 20ng/ml phorbol 12-myristate 13-acetate (PMA)
and 1g/ml ionomycin with or without 10ng/ml FK506 or 200ng/ml CsA. The next 
day, a Dual Luciferase Assay was performed in triplicate according to manufacturer’s 
instructions and analysed using a FLUOstar Optima Luminometer (BMG Labtech).
Transfected unstimulated and stimulated cells in the absence of CN inhibitors were 
used  as  negative  and  positive  controls  respectively.  Firefly  luciferase  activity  was 
normalised to Renilla luciferase activity to control for transfection efficiency. Results 
were expressed as percent activity of the stimulated sample for each construct without 
FK506/CsA (% resistance).Chapter two
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2.2.5 Production and titration of retrovirus
2.2.5.1 Production of transient retroviral supernatant
For Jurkat transductions, RD114 pseudotyped transient retroviral supernatants were 
generated  by  triple  transfection  of  4.69g  Peq-Pam  plasmid  (moloney  GagPol), 
3.125g RDF plasmid (RD114 envelope), and 4.69g SFG-CN plasmids into 293T 
cells using GeneJuice (Novagen). 1.5-1x10
6 293T were plated per 10cm tissue culture
dish the day prior to transfection in 10ml complete IMDM. DNA was combined in 
470l plain DMEM and 30l genejuice was added. Transfection mix was incubated 
for 15 minutes at room temperature, before dropwise addition to cells.  Supernatant 
was harvested after 48 and 72 hours, combined and snap frozen in a bath of dry ice 
and ethanol for storage at -80
oC.
2.2.5.2 Production of stable retrovirus producer lines
High titre producer lines were generated by multiple transduction of FLY-RD18 cells 
with GALV pseudotyped SFG retrovirus containing CN mutants, produced as above. 
FLY-RD18  cells  were  transduced  daily  for  2  weeks,  bulk  FACS  sorted  for  high 
expression  of  eGFP  and  single  cell  cloned  by  limiting  dilution.  This  work  was 
performed by Dr Martin Pule. Supernatant from the expanded clones was titred on 
293T cells to identify the highest titre producers. These stable producer lines were 
used to generate high titre retroviral supernatants for transduction of EBV-CTLs.
2.2.5.3 Titration of retroviral supernatant
Retroviral supernatants were titrated on 293T cells. 2x10
4 cells were plated per well of 
a 24wp the day prior to titration. Six doubling dilutions of viral supernatant from 100 
to 3l were prepared in 200l media and added to cells. Polybrene was included to a 
final concentration of 5g/ml. Cells were incubated for 3 days when the cells were Chapter two
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harvested and analysed by flow cytometry for expression of the GFP reporter gene. 
Viral titre (infectious particles per ml) was calculated by multiplication of the number 
of transduced cells by the dilution. 
2.2.6 Retroviral transduction
2.2.6.1 Retroviral transduction of cell lines and CTLs
Non-tissue  culture  treated  24wp  were  coated  for  2  hours  at  37
oC  with  7g/ml 
Retronectin in PBS and washed once with PBS. In some experiments, RN was pre-
loaded with 0.2-0.5ml retroviral supernatant for 30 minutes at room temperature prior 
to addition of cells. 0.5x10
6 Jurkat cells or CTLs were added per well in 0.5ml media, 
along with 2ml retroviral supernatant. Plates were spun for 40 minutes at 1000g and 
incubated at 37
o. 100U/ml IL-2 was added to EBV-CTLs, which were transduced 3 
days after their second stimulation. 
2.2.6.2 Assessment of transduction efficiency
Transduction efficiency was assessed by flow cytometry. Jurkat cells or EBV-CTLs
(three  or  seven  days  after  transduction  respectively)  were  harvested  with  cell 
dissociation buffer, washed with PBS and 2x10
5 cells resuspended in 300l FACS 
buffer. Cells were analysed for expression of the GFP reporter gene using the FitC 
channel of a CyAn flow cytometer (Dako). Untransduced Jurkat cells or CTLs were 
used as negative controls and SFG_eGFP alone transduced cells as positive controls.
2.2.6.3 FACS sorting of transduced cells
Transduced  Jurkat  cells  were  sorted  to  ensure  expression  of  the  same  mean 
fluorescence index (MFI) of GFP. 10x10
6 cells were prepared in 1ml PBS with 1% 
FBS.  FACS  sorting  was  performed  by  flow  cytometry  operator  Ajad  Eddaoudi. Chapter two
_____________________________________________________________________
81
Expression  of  GFP  was  standardised,  cells  expressing  GFP  within  a  window 
containing the highest MFI represented in all cultures were selected. After sorting, 
Jurkats were cultured in complete RPMI containing 20% FCS and 1% Primocin for 
one week to encourage growth and prevent contamination.
2.2.6.4 Western blot analysis of CN expression
5x10
6 Jurkat cells or 2x10
6 EBV-CTLs were harvested and washed twice in PBS. Cell 
pellets were resuspended in 125l CelLytic lysis buffer containing 10% v/v Protease 
Inhibitor Cocktail and agitated at room temperature for 15 minutes. Samples were 
spun at 100g for one minute in a microcentrifuge and clear supernatant was removed 
to  a  chilled  1.5ml  microcentrifuge  tube.  Samples  were  frozen  at  -20
oC  or  run 
immediately.  10l  sample  lysate  was  combined  with  4l  sample  buffer  and  1.5l 
reducing agent, boiled for 15 minutes at 70
oC and centrifuged at 100g for 1 minute.
Samples were kept on ice until loading. Sample were loaded onto pre-cast 4-12% Bis-
tris polyacrylamide Novex gels and run in XCell Sure-Lock Mini-Cell (Invitrogen) 
with  1x  NuPage  MOPS  SDS  running  buffer  at  200V  for  1-1½  hours  with  500l 
antioxidant  (Invitrogen)  in  the  central  chamber.  SeeBlue  Plus2  pre-stained  protein 
ladder was included in the outermost wells. The separated proteins were transferred 
onto Polyvinylidene Difluoride (PVDF) membrane using the XCell II blot module and 
1x transfer buffer at 25V for 1 hour. Prior to protein transfer, the PVDF membrane 
was immersed in methanol for 30 seconds, and soaked in 1x transfer buffer for 5 
minutes.
After transfer, the PVDF membrane was blocked with 5% BSA in PBS with agitation 
for at least one hour at room temperature, or overnight at 4
oC to prevent non-specific 
antibody staining.  The  membrane was  washed  for 10  minutes  with  agitation  three 
times at room temperature and subsequently incubated with primary antibody in 5ml 
2.5% BSA in PBS for 2 hours with agitation at room temperature, or overnight at 4
oC. 
Primary antibodies were used at the following dilutions: CNa=1/1000, CNb=1/2000, 
-actin=1/4000. Membrane was washed again and incubated with secondary rat anti-
mouse  antibody,  1/2500  dilution  in  5ml  1%  BSA  in  PBS  for  45minutes  at  room Chapter two
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temperature with  agitation.  1ml  ECL  Western  Blotting substrate  was  added  to  the 
membrane  and  incubated  for  2  minutes  at  room  temperature.  Protein  bands  were 
visualised  and  quantitated  using  UVIchemi  (UVItech)  chemiluminescence 
documentation  system  and  UVIsoft  (UVItech)  software.  Membranes  were  cut  into 
sections according to protein size, and the appropriate section was stained for -actin 
was used to ensure comparable protein loading between samples.
2.2.7 Assessment of IL-2 secretion from Jurkat cells
Jurkat cells cultured in RPMI were split 1/10 the day prior to stimulation. The next 
day, 5x10
5 Jurkat cells were plated per well of a 48wp and stimulated with 20ng/ml 
PMA and 1g/ml Ionomycin. FK506/CsA was added at varying concentrations (0.5-
40ng/ml and 50-800ng/ml respectively). Cells were incubated for 24h, when samples 
of  supernatant  were  harvested  and  frozen  at  -20
oC  for  ELISA.  To  measure  IL-2 
secretion, the IL-2 DuoSet ELISA was used according to manufacturer’s instructions 
and read using a FLUOstar Optima. To enable quantitation of IL-2 concentration, a 
standard curve was included using concentrations of IL-2 between 15 and 1000pg/ml. 
In most experiments the assay was linear between 60 and 1000 pg/ml.
2.2.8 Testing of EBV-CTL lines
2.2.8.1 ELISPOT assessment of IFN- secretion
To assess IFN- release from EBV-CTLs in response to stimulation with autologous 
LCL, a multiscreen ELISPOT plate (Millipore, MAHAS4510) was coated overnight 
with 100l per well 10g/ml capture antibody in coating buffer. Wells were washed 
x3 with 150l PBS for five minutes and blocked with 150l complete RPMI for at 
least one hour. CTLs (resuspended at 5x10
5/ml in AIM V) or PBMC (resuspended at 
2x10
6/ml) from the same donor were used as responders. Four doubling dilutions of 
responder cells were prepared and 100l CTLs (5x10
4, 2.5x10
4, 1.25x10
4, 6.25x10
3) Chapter two
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or PBMC (2x10
5, 1x10
5, 5x10
4, 2.5x10
4) were added per well in triplicate along with 
10
5  autologous  or  allogeneic  irradiated  (40Gy)  LCL.  The  plate  was  incubated 
undisturbed  at  37
oC/5%  CO2  for  18-20  hours.  Triplicate  controls  consisting  of 
responders or stimulators alone were included. After overnight incubation, cells were 
removed and the plate washed six times with PBS/0.05% Tween. Biotin conjugated 
detection antibody was prepared at 1g/ml in PBS/0.5% Tween, 100l was added per 
well  and  incubated  at  37
oC  for  two  hours.  The  plate  was  washed  and  Avidin-
peroxidase  complex  was  added  for  one  hour  at  room  temperature.  Spots  were 
developed with 3-amino-9-ethylcarbazolesubstrate mix (AEC, Sigma). The number of 
spots  was  counted  using  an  ELISPOT  plate  reader  (Bioreader  3000).  The  mean 
number of spots in triplicate wells was calculated, with subtraction of the mean from 
control wells, and results expressed as specific spot forming cells per 10
5 effectors.
2.2.8.2 ELISA assessment of IFN- secretion 
24 hours after the 6
th stimulation, samples of supernatant were taken from EBV-CTL 
cultures  and  frozen  at  -20
oC.  IFN-  concentration  was  measured  using  the  IFN-
DuoSet ELISA kit according to the manufacturer’s instructions. A standard curve was 
included with samples from 15pg/ml to 1000pg/ml, the linear range of the assay was 
60-1000pg/ml in most experiments.
2.2.8.3 
3H-thymidine uptake proliferation assay
On the day of stimulation 6, 10
5 CTLs were plated in triplicate in U bottomed 96wp, 
with  or  without  stimulation  by  2.5x10
4  autologous  irradiated  LCL 
(responder:stimulator  ratio  4:1),  in  the  presence  or  absence  of  10ng/ml  FK506  or 
200ng/ml CsA. After 4 days, wells were pulsed with 1l (37Bq) 
3H-thymidine and 
incubated for a further 19-20 hours, when cells were harvested to a filter mat using a 
Tomtec  MachIIIM  Harvester  96.  MeltiLex  wax  scintillation  was  applied,  and 
thymidine incorporation measured using a Wallac 1450 MicroBeta trilux beta-counter Chapter two
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(Perkin Elmer). Specific proliferation was calculated by subtracting mean counts per 
minute  (cpm)  of  CTL  and  LCL  alone  control  wells  from  those  containing  CTLs
stimulated with LCL.
2.2.8.4 
51Cr-release cytotoxicity assay
Cytotoxicity  of  EBV-CTL  lines  was  determined  using  a  chromium  release  assay. 
2x10
6 HSB-2 cells or autologous/allogeneic LCL targets were incubated at 37
o with 
1mCi 
51Cr labelled sodium chromate for 1 hour, washed three times with RPMI, and 
counted.  5x10
3  target  cells  were  co-cultured  with  EBV-CTLs  in  triplicate  in  V-
bottomed  96wp  at  effector:target  ratios  of  30:1,  15:1  and  7.5:1  with  or  without 
10ng/ml FK506 or 200ng/ml CsA. Target cells alone in complete media or lysed with 
1%  TritonX-100  were  used  to  determine  spontaneous  and  maximum  release 
respectively. Plates were centrifuged at 180g for three minutes before and after 4-6
hours  incubation  at  37
oC.  50l  supernatant  was  harvested,  mixed  with  150l
scintillation  fluid  in  isoplates  (Perkin  Elmer),  which  were  sealed  and  -irradiation 
(counts per minute) read using a Wallac 1450 MicroBeta trilux. Percent specific lysis 
was calculated as follows: (specific release – spontaneous release)/(maximum release 
– spontaneous release).
2.2.8.5 Flow cytometric analysis of EBV-CTL phenotype
Four days after the 5
th stimulation with autologous LCL, 2x10
5 CTLs per tube were 
washed in PBS and incubated in 100l FACS buffer with monoclonal antibodies for 
20 minutes at 4
oC in the dark. Cells were washed twice with 3ml cold FACS buffer 
and  resuspended in  400l  FACS  buffer for  analysis. CTL  lines  were assessed  for 
expression of surface markers using the following monoclonal antibodies: CD3, CD4, 
CD19, CD25 (Becton Dickinson), CD45RO (Serotec), CD8, CD16, CD56, CD62L 
(eBioscience).  Appropriately  matched  isotype  controls  were  included.  Cells  were 
analysed on an LSRII flow cytometer (Becton Dickinson).Chapter two
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2.2.8.6 Antigen dependence
To  confirm  that  transduced  EBV-CTLs  remained  dependent on  stimulation  with 
specific antigen, following 4 stimulations with autologous LCLs, CTLs were cultured 
without further stimulation with LCL and cell growth was monitored thereafter. In 
some cultures, addition  of 100U/ml  IL-2 twice  weekly was continued. CTLs were 
counted weekly and re-plated at 10
6 viable cells per well of a 24wp.
2.2.9 In vivo investigations
2.2.9.1 Mouse strains
RAG2
-/-/-chain
-/-/C5
-/-  triple  knockout  mice  as  described  in  section  1.6.2  were 
obtained from a breeding colony maintained in our institute and housed in individually 
ventilated cages. Autoclaved food, water and bedding were utilised for these animals 
and  mice  were  handled  under  aseptic  conditions  at  all  times.  Ethical  approval  for 
murine work was obtained as per project licence number PPL70_5249.
2.2.9.2 Subcutaneous injection of LCL
10
7 LCL transduced with the FLuc_eBFP firefly luciferase retroviral vector per animal 
were washed three times with PBS and resuspended in 50l cold plain RPMI. This 
was mixed with 50l cold Matrigel and loaded into a 0.5ml 27 gauge (G) tuberculin 
syringe. Animals were restrained by scruffing and cells were injected subcutaneously 
on the right flank.
2.2.9.3 Monitoring of LCL tumours
The size of LCL tumours was assessed with callipers bi-weekly, in addition to weekly 
monitoring with bioluminescent imaging. For imaging, anaesthesia was induced by 
inhalation of isofluorane with oxygen. 2mg D-Luciferin was injected intraperitoneally 
in 200l volume and animals were placed in the imaging chamber. Anaesthesia was 
maintained by delivery of isofluorane and oxygen to individual animals within the Chapter two
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imaging chamber. A region of interest (ROI) was delineated around the tumour site 
and images were captured  at two minute  intervals until the signal from  each ROI 
plateaued. Animals recovered individually in warmed chambers. Total light counts 
within  each ROI  is  measured  and  used  along  with  exposure  time  to  calculate  the 
counts per second emitted by each tumour area.
2.2.9.4 Administration of EBV-CTLs
10
7 cryopreserved EBV-CTLs from the same donor as the LCL were thawed the day 
prior to injection, washed and rested overnight in 5ml CTL medium with 20U/ml IL-2 
at 37
oC/5% CO2. The following day, CTLs were spun and resuspended in 100l plain 
RPMI  and  transferred  to  a  0.5ml  syringe.  Animals  were  warmed  at  37
oC  for  10 
minutes and CTLs were injected into the tail vein using a 27G needle. Pressure was 
applied to the injection site following administration to reduce bleeding.
2.2.9.5 Administration of IL-2
2500U  recombinant  human  IL-2  was  administered  intraperitoneally  in  200l  PBS 
three  times  per  week  using  a  0.5ml,  27G  tuberculin  syringe.  This  was  performed 
concurrently  with  D-luciferin  administration  where  appropriate  to  minimise  the 
number of injections given.
2.2.10 Statistical analysis
Proliferation,  IFN-  secretion  and  phenotype  of  transduced  and  UT  CTLs  in  the 
absence  of  CN  inhibitors  were  compared  using  a  one-way  analysis  of  variance 
(ANOVA). Proliferation and IFN- secretion of transduced CTLs in the presence of 
CN inhibitors was compared to that of UT CTLs in the absence of CN inhibitors using 
a one-way ANOVA with the Dunnett’s post-hoc test. Enrichment of GFP +ve CTLs
was assessed using the paired t-test. Cytotoxicity was compared between transduced 
and UT CTLs in the presence or absence of CN inhibitors using a two-way ANOVA. 
Analysis was performed using SPSS statistical package (v16).Chapter three
Design of CN mutants, evaluation in cell 
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3.0 Aims
 To design and generate a panel of CNa and CNb mutants to confer resistance 
to FK506 or CsA.
 To assess resistance from these mutants in cell line screening assays.
 To  determine  mutants  conferring  optimal  resistance  for  further  study  in
primary T cells.
3.1 Introduction
Calcineurin  inhibitors  specifically  disrupt  CN  activity  in  T  cells,  preventing 
transduction of the activation signal from the engaged T cell receptor to the nucleus 
thereby  preventing  T  cell  activation.  Suppression  of  T  cells  by  the  CN  inhibitors 
FK506  and  CsA  is  mediated  through  binding  to  a  common  surface  on  the  CN 
heterodimer, the location of which results in blocking of the active site. The composite 
face of CNa and CNb  provides the docking site  for both the FK506:FKBP12 and 
CsA:CyPA complexes as they sterically inhibit access to the active site for NFAT. 
Therefore, this region provides an attractive target for mutagenesis, with the potential
to disrupt the binding of either or both of these drugs. While other possibilities have 
been suggested (Matsuda, et al 2000), binding of these drugs to CN is widely thought 
to  be their predominant  mechanism of action, therefore  prevention  of this  binding 
should confer complete resistance to suppression by FK506 or CsA (Ho, et al 1996).
As  discussed  in  section  1.5.2,  previous  studies  have  identified  naturally  occurring 
mutations in CN that can confer a degree of resistance to either FK506 or CsA in 
yeast. The information gleaned from these investigations provides a useful base for
design of additional and combination mutants. Following the generation of a panel of 
CN mutants, a screening assay was utilised to identify those to pursue in primary cell Chapter three
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work.  We  have  established  and  optimised this  assay  and  utilised  it  to  select  CN 
mutants that may confer resistance to therapeutic levels of FK506 or CsA in the Jurkat 
T cell line.
3.2 Design and generation of CN mutant panel
3.2.1 Design of CN mutants
In order to generate CN mutants able to resist binding by CN inhibitors, we combined 
previously published information regarding resistance in yeast with detailed structural 
data. These structural data provided information regarding both the conformation of 
CN and those residues that are likely to be critical in the interaction between CN and 
the IS:immunophilin complexes (Griffith, et al 1995, Ke and Huai 2003). We were 
able to identify several regions likely to be involved in this interaction and focussed on 
these  when  designing  mutants.  Published  mutations  shown  to  confer  resistance  to 
either  FK506  or  CsA  were  generated,  along  with  combination  mutants  and  also 
variations  of  these  mutants  with  substitution  for  a  different  amino  acid  (AA).  In 
addition, we generated several novel mutants based on the crystal structure of CNa/b 
in complex with either FK506/FKBP12 or CsA/CyPA. 
Each targeted residue was substituted with either a conservative or a radical mutation. 
Conservative  mutations  replaced  the  original  AA  with  another  possessing  similar 
characteristics, for example Serine with Asparagine at CNa 353 (mutant CNa6), or the 
reverse N122S in CNb7, whereas radical mutations replaced the original AA with one
from a different group, or with a contrasting side chain eg Valine at position CNa 314 
is a hydrophobic AA with a moderately sized side chain, this is substituted with either 
an  amphipathic  (Lysine),  a  hydrophilic  (Arginine)  or  another  hydrophobic  residue 
(Phenylalanine) to produce CNa18-20. These alterations insert a residue containing a 
larger  side  group  than  the  original,  in  addition  some  mutations  alter  the  charge 
characteristics which at this critical residue could be expected to affect CN inhibitor 
binding. Data from Ke and Huai suggest that this residue is likely to be of importance 
in the interaction with both W121 of CyPA and K35 of FKBP12, therefore alterations Chapter three
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here have the potential to disrupt interactions with both FK506 and/or CsA (Ke and 
Huai 2003). 
In  addition  to  various  single  AA  substitutions,  and  based  on  the  identification  of 
naturally  occurring  yeast  mutants  that  are  resistant  to  FK506,  we  investigated  the 
generation of CNb mutants containing a two AA insertion following residue K125. As 
shown by Fox et al, insertion of VQ at this location confers 50% resistance to FK506, 
therefore we generated mutants containing either these residues or insertion of IE or 
LA at this site. This insertion was also combined with substitution mutants to create a 
second generation of constructs. When examining the crystal structure of CNb in this 
region,  it  seems  likely  that  insertion  of  amino  acids  following  K125  may  disrupt 
secondary structure of the C terminal loop of CNb latch region, which is important in 
FK506 binding. The insertion of these two residues appears to distort this loop which 
links  two  -helices,  such  that  it  protrudes  outwards  into  the  region  where  FK506 
binds. We therefore incorporated insertions at this site into several of our panel of 
mutants. In contrast, CsA does not contact the latch region in such close proximity 
therefore CsA resistance is not anticipated from insertions at this location (Fox, et al
2001). 
Generation  of  the  panel  of  mutants  was  an  ongoing  process,  whereby  knowledge 
gained  from  testing  earlier  batches  guided  engineering  of  subsequently  designed
mutants.  Several  combination  mutants  were  generated  incorporating  changes  that 
conferred some effect in earlier builds, therefore resistant mutants evolved throughout 
the  design  phase.  In  total  22  CNa  mutants  and  32  CNb  mutants  were  designed 
covering various regions of the components of the CN heterodimer. The distribution of 
these mutants is shown in Figure 8. Location of CNa and CNb mutants are shown 
separately in panels (a) and (b), followed by the assembled heterodimer in (c). Panels 
(d) and (e) show binding of CN by FKBP12:FK506 and CsA:CyPA respectively. It 
can be seen that the mutants generated are located on the composite binding face of 
CN,  making  it  likely  that  docking  of  the  immunosuppressive  complexes  may  be 
disrupted. Details of the AA changes made for all mutants are shown in Table 4.Chapter three
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Figure 8: Location of CN mutations. a) CNa and b) CNb chains projected separately 
with location of mutations highlighted. c) CNa/CNb heterodimer showing binding face 
for  FKBP12/FK506  or  CyPA/CsA  with  location  of  mutations  highlighted.  d)  CN 
heterodimer bound by FKBP12. e) CN heterodimer bound by CyPA. CNa shown in 
blue, CNb in red and FKBP12/CyPA in grey. Mutated residues in CNa are highlighted 
in white, in CNb are highlighted in silver.
a b
c d
eChapter three
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Table  4:  Mutations  in  CNa  and  CNb. Amino  acid  changes  were  introduced  to 
generate a panel of 54 CN mutants designed to confer resistance to CN inhibitors.
Construct Mutations Construct Mutations
CNa1 L354A; K360A CNb1 K125A
CNa2 L354A; K360F CNb2 K125E
CNa3 T351E; K360F CNb3 K125W
CNa4 W352A CNb4 N122A
CNa5 S353H CNb5 N122H
CNa6 S353N CNb6 N122F
CNa7 F356A CNb7 N123S
CNa8 W352A; S353H CNb8 N123H
CNa9 W352C CNb9 N123R
CNa10 W352E CNb10 N123F
CNa11 K360F CNb11 N123K
CNa12 T351E; L354A CNb12 N123W
CNa13 W352C; K360F CNb13 Q51S
CNa14 W352C; L354A; K360F CNb14 K165Q
CNa15 M347W CNb15 M119A
CNa16 M347R CNb16 M119W
CNa17 M347E CNb17 L116R
CNa18 V314K CNb18 L116Y
CNa19 V314R CNb19 V120L
CNa20 Y341F CNb20 V120F
CNa21 V314K; Y341F CNb21 K125-VQ-Ins
CNa22 V314R; Y341F CNb22 K125-IE-Ins
CNb23 K125-LA-Ins
CNb24 V120S
CNb25 L124T
CNb26 V120S; L124T
CNb27 V120D
CNb28 V120D; L124T
CNb29 N123W; K125-LA-Ins
CNb30 L124T; K125-LA-Ins
CNb31 V120D; K125-LA-Ins
CNb32 M119-F-Ins; G121-LF-InsChapter three
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3.2.2 Generation of CN mutants
Site  directed  mutagenesis  was  performed  using  overlap  extension  PCR,  with  the 
desired sequence change contained within overlapping primers at the target site. Two 
initial  PCRs  were  performed  using  complementary  external  primers,  and  internal 
primers containing these changes. The products of these two reactions were combined 
in a fusion PCR to join and amplify the desired final sequence. Template DNA for 
generation of CN mutants was wild type CNa (obtained from Dr. Pule) or CNb (cDNA 
derived from Jurkat cells and confirmed by sequencing). 
Primers for mutagenesis reactions were designed to contain the specific change, whilst 
considering  several  other  parameters:  length,  GC  content  and  melting  temperature 
(Tm) were standardised, with sufficient overlap to prime the subsequent fusion PCR. 
pMol software written by Dr. Pule was utilised to design many of these primers. An 
example  of this  strategy  is  shown in Figure 9,  using wtCNb  as template  DNA to 
produce  mutant  CNb1.  The  products  of  these  fusion  reactions  were  AgeI-NotI 
subcloned into the SFG-eGFP retroviral vector, followed by sequencing to confirm 
that the desired sequence change was present and that no other alterations had been 
introduced during the amplifications (see Figure 10 for an example of sequencing).Chapter three
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(a)
(b)
Figure 9: Illustration of mutagenesis strategy. (a) Illustration of generation of CN 
mutants. Initial PCRs utilise one external primer (pale blue) and one internal primer 
containing  the  desired  sequence  change  (dark  blue).  Subsequent  fusion  PCR  joins 
product of initial  PCRs  to  generate the final product.  Restriction  enzyme  sites  for
subcloning products into the SFG retroviral vector are indicated in pink. (b) Detail of 
target site and overlapping primer sequences to generate desired change, aaa->gcc for 
CNb1. Mutagenesis primers shown in blue, template DNA in black and target codon 
in red.
External 
primer Age I
site
CNb 
end
CNb 
start
Not I
site
Mutagenesis 
primers
Target 
site
External 
primer
aggtattgaagatgatggtggggaacaatctgaaagatacacagttacagcaaattgtagacaaaaccataataaatg
aggtattgaagatgatggtggggaacaatctggccgataca 
ctggccgatacacagttacagcaaattgtagacaaaaccataataaatgChapter three
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Figure  10:  Example  of  sequencing  confirming  successful  site  directed 
mutagenesis. The altered amino acid is highlighted and produces the residue change 
K125A from wtCNb to give CNb1. 
.
CNa 1 SFG
9249 bp
CNa 1
AmpR
GFP
5' LTR
3' LTR
IRES
AgeI (2072)
NotI (3819)
Figure 11: Diagram of SFG retroviral vector. CNa1 is followed by eGFP. LTRs, 
IRES and ampicillin resistance gene (Amp
R) are also indicated. AgeI/NotI sites shown 
were used to clone CN mutants into the SFG vector.
Mutants were subsequently cloned into the retroviral vector SFG-eGFP, upstream of
an internal ribosomal entry site (IRES) allowing expression of the reporter gene eGFP. 
Transcription of CN in this vector is driven from viral long terminal repeats (LTRs), 
wtCNb sequencing
CNb1 sequencingChapter three
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with the start codon of the transgene at the site of the deleted viral env gene as shown 
in Figure 11 (Riviere, et al 1995). Following successful generation of this panel, the 
54 mutants were screened in cell line screening assays to determine their activity in the 
presence of CN inhibitors. 
3.3 Screening of CN mutants in cell lines assays
3.3.1 Establishing a Luciferase screening assay to identify resistant CN 
mutants
In order to identify CN mutants that retained the ability to dephosphorylate NFAT in 
the  presence  of  CN  inhibitors  and  may  therefore  confer  resistance,  we  utilised  a 
transient assay in 293T cells using the Dual Luciferase System (Promega). This assay 
measures the level of expression of two luciferase genes, Renilla luciferase derived 
from  R.  reniformis  and  Firefly  luciferase  derived  from  Photinus  pyralis.  These 
luciferases utilise distinct substrates for light emission, therefore sequential addition of 
the substrates determines  expression  of the two  enzymes separately. In this  assay, 
firefly luciferase (FLuc) expression was driven by an NFAT responsive promoter and 
Renilla  luciferase  (RLuc)  was  encoded  on  a  constitutively  active  control  plasmid, 
driven by a CMV promoter. Therefore as CN dephosphorylates NFAT and allows 
translocation  to  the  nucleus,  FLuc  is  expressed  as  a  measure  of  CN  activity.  In 
contrast, RLuc expression is constitutive; its expression not affected by CN activity,
and therefore can be used as an internal control for intra-assay variations in parameters 
such as cell density and transfection efficiency. 
3.3.1.1 Optimisation of dual luciferase assay
Considerable optimisation of this assay was required. Firstly, expression of RLuc and 
FLuc  was  assessed  independently  and  together  in  the  absence  of  CN  mutants  to 
determine the limitations of the technique. Luciferase plasmids were co-transfected Chapter three
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into  293T  cells  using  Lipofectamine2000,  which  were  stimulated  with  PMA  and 
ionomycin to induce cellular activation. Expression of both luciferases was assessed 
from  untransfected  or  single  transfected  cells  in  the  presence  or  absence  of 
stimulation. As shown in Figure 12, no FLuc signal was detected in untransfected or 
RLuc transfected cells, and a low level of background signal from FLuc transfected 
cells  (approx  2000  Relative  Light  Units  (RLU)).  This was  increased  15-fold  by 
stimulation  of  cells  with  PMA  and  ionomycin,  expression  which  was  reduced  to 
background levels by addition of FK506. This established that the NFAT responsive 
FLuc plasmid is a reliable indicator of CN activity in 293T cells, and that the two 
substrates for RLuc and FLuc do not cross-react, as no FLuc signal is detected from an
RLuc transfected sample. In addition, transfection with both Luciferases did not alter 
FLuc results.
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Figure 12: Expression of Firefly luciferase from transfected 293T cells. Cells were 
transfected either singly or with both Luciferases, and stimulated in the presence of 
increasing concentrations of FK506. UT: Untransfected, Stim: stimulated overnight 
with PMA+ionomycin, 5ng/ml: concentration of FK506 included at stimulation.Chapter three
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We next examined expression of RLuc in cells transfected with one or both Luciferase 
plasmids.  Once  again,  no  RLuc  signal  was  detected  from  untransfected  or  FLuc 
transfected cells,  confirming substrate specificity.  However,  RLuc expression  from 
transfected cells was considerably increased with cellular stimulation, and was further 
amplified upon co-transfection with FLuc. Indeed, signal from RLuc in co-transfected, 
stimulated samples reached the upper limit of detection of the luminometer at 4x10
5
RLU  (see  Figure 13a).  The role of  RLuc in  this  assay to  provide  a constitutively 
active, consistent internal control cannot be achieved if expression is affected by the 
activation  status  of  the  cell.  We  therefore  substituted  RLuc  driven  by  the  CMV 
promoter for a construct containing codon optimised RLuc under the control of the 
herpes  simplex  virus  thymidine  kinase  (HSV-TK)  promoter.  This  promoter  lacks 
binding sites for many mammalian transcription factors that are present in the original
CMV promoter and we hypothesised that it would therefore be less susceptible to 
activation in 293T cells. This plasmid was tested as previously. As shown in Figure
13b, while RLuc was expressed at much lower levels from the phRG-TK promoter, 
expression was unaffected by stimulation of 293T cells. Although RLuc expression 
was  increased  when  co-transfected  with  FLuc,  the  signal  was  unaffected  by 
stimulation or by the addition of FK506. Therefore, phRG-TK was selected as the 
internal control plasmid for use in the dual luciferase assay screening. FLuc expression 
in  all  subsequent  experiments  was  normalised  to  RLuc  expression  to  control  for 
transfection efficiency, therefore data are presented as fold increase of FLuc signal.Chapter three
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Figure 13: Renilla luciferase expression from CMV-RLuc but not phRG-TK is 
sensitive to cellular activation. (a) Variation in expression of original CMV-Renilla 
control  plasmid  showing  effect  of  stimulation  and  co-transfection  with  FLuc.  (b) 
Expression of RLuc from the indicated concentration of phRG-TK transfected alone or 
with FLuc, stimulated or unstimulated.
Following  the  selection  of  phRG-TK  and  FLuc,  CNa  constructs  were  included  to 
produce  CN  mutant  expressing  internally  controlled  FLuc  reporter  cells  to  detect 
FK506 resistance. Transfection efficiency was assessed by monitoring expression of 
eGFP from the CN_eGFP plasmid. To establish the appropriate concentration of CN 
plasmid  to  confer  resistance,  and  FLuc  plasmid  to  report  resistance,  a  variety  of 
combinations were tested. Figure 14 shows that while limited resistance is seen in this 
experiment, the combination producing greatest FLuc expression in the presence of 
FK506 contains 400ng FLuc and 600ng CNa. After normalisation to RLuc signal, this 
sample retains a 10-fold increase in RLU expression compared to unstimulated 293T 
cells, therefore these concentrations were used for future experiments.
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Figure 14: Determination of optimal CNa and FLuc plasmid concentration. Each 
set of three bars shows 1) FLuc expression in unstimulated cells 2) FLuc expression 
following stimulation and 3) FLuc expression following stimulation in the presence of 
10ng/ml FK506. Varying amounts of CNa (wt or CNa2) and FLuc plasmids  were 
transfected. The increase in FLuc expression compared to untransfected 293T cells is 
shown. The selected combination is illustrated with a star.
These parameters were subsequently used to test CNa mutants 1-8 in the presence of 
FK506 to determine whether this assay is sufficiently sensitive to detect resistance to 
this drug, as determined by continued FLuc expression in the presence of FK506. In 
initial experiments both CNa2 and CNa4 appeared to confer some resistance in this 
assay (data not shown), but the resistance observed was low when cells were assayed 
24 hours after transfection. However, 293T cells transfected in this manner showed 
increased  GFP  expression  at  48  hours  post  transfection  compared  with  24  hours, 
indicating that expression of CN mutants was also likely to be increased at this time 
point.  Therefore,  this  experiment  was  repeated,  assaying  luciferase  expression 
following  stimulation  at  48  hours  post  transfection.  As  shown  in Figure 15,  this 
resulted in improved detection of resistance to FK506 conferred by CNa2 and CNa4.Chapter three
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Figure 15: Luciferase assay screening of CNa mutants 1-8. Resistance to FK506 in 
CNa2 and CNa4 is improved by stimulation 48 hours after transfection.
In  order  to  determine  the  reliability  of  the  screening  assay,  this  experiment  was 
repeated twice. Similar results were obtained in each experiment, confirming that this 
assay is reliable and can be used to screen the panel of mutants, identifying those that 
confer resistance and excluding those that do not (see Figure 16a). To ease comparison 
between  different  mutants,  resistance  was  then  expressed  as  the  percent  activity 
retained in the presence  of FK506, compared to  the activity of that sample in the 
absence of FK506 (see Figure 16b).Chapter three
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Figure 16: Dual luciferase screening is reliable in multiple assays. a) Screening of 
CNa  mutants  1-8.  Resistance  to  FK506  was  detected  in  samples  transfected  with 
mutants 2 and 4 in all assays performed. b) Resistance for each mutant expressed as 
the percent signal in the presence of FK506 compared to the stimulated signal for that 
sample. Mean + SEM of 3 experiments shown.Chapter three
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3.3.2 Screening of CNa and CNb mutants in Luciferase assay
Following  optimization  of  this  screening  assay  so  that  it  performs  adequately  to 
differentiate those mutants that confer some resistance from those that do not, all 54 
CNa and CNb mutants were screened as described above to determine resistance to 
10ng/ml FK506 or 200ng/ml CsA. Figure 17 shows the percent resistance conferred 
by CN mutants to FK506 and CsA, defined as the percent FLuc signal (normalised for 
RLuc) in the presence of CN inhibitor compared to 293T cells transfected with the 
same mutants stimulated in the absence of CN inhibitor. This guided the selection of 6 
CNa mutants that conferred resistance to FK506 (CNa2, 4, 9, 12, 15 and 17) and 5 
resistant to CsA (CNa18, 19, 20, 21 and 22) and 6 CNb mutants, one resistant to 
FK506  only  (CNb12),  one  resistant  to  CsA  only  (CNb26)  and  four  conferring 
resistance  to  both  (CNb21,  22,  23  and  30).  This  threshold  for  selection  (15% 
resistance) was determined by comparison of CNa mutants 1-8 to an initial screen in 
the subsequent assay utilising Jurkat cells as described below. These 17 CN mutants 
were then pursued in further testing.Chapter three
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Figure  17:  Transfection  of  293T  cells  with  CN  mutants  allows  luciferase 
expression in the presence of CN inhibitors. Screening of (a) CNa mutants and (b) 
CNb mutants for resistance to 10ng/ml FK506 (purple bars) and 200ng/ml CsA (blue 
bars). Resistance was determined by comparing luciferase expression upon stimulation 
in  the  presence  of  CN  inhibitors  to  luciferase  expression  upon  stimulation  in  the 
absence of CN inhibitors. Mean and SEM of 3 experiments shown.Chapter three
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3.3.3 Development of Jurkat IL-2 secretion assay
To assess the capability of the selected mutants to confer resistance to CN inhibitors in 
a biologically relevant model, cytokine secretion by the Jurkat cell line was assessed. 
Jurkats are a human T cell line, which secrete IL-2 in response to stimulation with 
mitogens such as PMA and ionomycin. However, IL-2 secretion in response to such 
stimulation is prevented by the addition of FK506 or CsA, thus allowing detection of 
resistance. 
3.3.3.1 Source of Jurkat cells and detection of IL-2 secretion
Although Jurkat cells are reported to be capable of high IL-2 secretion, significant 
batch-to-batch  variation  has  been  observed  in  this  regard.  Therefore,  we  obtained 
Jurkat cells from several sources and stimulated these to determine which would be 
most appropriate for use in further studies. IL-2 secretion from Jurkats was measured 
by ELISA 24 hours after stimulation with 20ng/ml PMA and 1g/ml ionomycin, and it 
was established that of these 5 cultures, batches 2 and 4 secreted no IL-2, batch 1
secreted negligible amounts that increased slightly upon stimulation, batch 5 secreted 
no IL-2 without stimulation and approximately 1000pg/ml with stimulation, however 
batch 3 secreted no IL-2 without stimulation but secreted approximately 5000pg/ml 
following stimulation with mitogens (see Figure 18). Therefore, batch three (obtained 
from Dr Clio Rooney, Baylor College of Medicine, TX, USA) was selected for further 
use.Chapter three
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Figure 18: Variable IL-2 secretion from different batches of Jurkat cells. Jurkat 
cells  from  five  different  sources  were  stimulated  with  PMA  and  ionomycin,  IL-2 
secretion by each batch before and after stimulation were measured by ELISA. Mean 
and SEM of two experiments. Batch 1 was previously used in our laboratory, batch 2 
was a gift from Dr. W. Qasim, ICH, batches 3 and 4 were a kind gift from Dr Clio 
Rooney, Baylor College of Medicine, and batch 5 was purchased from the DSMZ cell 
bank.
As a result of high IL-2 secretion by the selected batch of Jurkats, it was necessary to 
dilute the samples as those tested initially were above the linear range of the assay. 
Therefore, supernatants from two experiments were assayed either neat and diluted 
1/20, or diluted 1/3 and diluted 1/21 respectively. This established that considerable 
dilution of Jurkat supernatants from this batch was necessary to obtain accurate results 
(see Figure 19). Stimulated Jurkat cells from batch 3 secreted up to 15000pg/ml IL-2, 
which  was  accurately  measured  when  tested  at  a  dilution  of  approximately  1/20. 
Results from these samples remained in the upper portion of the linear range therefore 
subsequent ELISAs were performed using samples diluted 1/40, which consistently 
produced  results  within  the  range  of  the  assay  (between  approximately  50  and 
1000pg/ml IL-2). It was also confirmed that this dilution did not increase background 
and that addition of 10ng/ml FK506 to the cells at stimulation abrogated secretion of 
IL-2 (data not shown).Chapter three
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Figure 19: Dilution of Jurkat supernatants allows accurate measurement of IL-2 
concentration. Supernatant harvested from stimulated Jurkats were tested by ELISA 
both neat and in dilutions. Samples from two separate experiments were assayed at 
low or no dilution and at 1/20 or 1/21 dilution. Diluted samples were in the linear 
range of the assay and therefore gave an accurate result.
3.3.3.2 Transduction of Jurkat cells
RD114 pseudotyped retrovirus was generated by triple transfection of 293T cells with 
SFG_CN_eGFP, GagPol (PeqPam) and Env (RDF) plasmids. Transient supernatants 
were harvested at 48 and 72 hours, combined and snap frozen before transduction of
Jurkat  cells  using  Retronectin  and  spinfection.  This  method  achieved  good 
transduction  efficiencies  as  determined  flow  cytometrically  by  eGFP  expression. 
Further, as shown in Figure 20, transgene expression was stable for at least 11 weeks 
in culture. Chapter three
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Figure 20: Expression of CN mutants remains stable long term in vitro. Jurkat 
cells were FACS sorted and maintained in culture for 11 weeks to ensure continuous 
transgene expression. GFP expression as determined by flow cytometry 1 week post 
sort is displayed on the left, along with the corresponding data following 11 weeks in 
continuous culture on the right.
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3.3.3.3 Correlation of Jurkat IL-2 ELISA with 293T luciferase assay
Following  establishment  of  the  Jurkat  model  and  confirmation  that  efficient 
transduction  of  these  cells  can  be  achieved  using  SFG  retrovirus  containing  CN 
mutants, initial testing of resistance was undertaken to compare the performance of 
Luciferase screening with the Jurkat assay. To determine the appropriate cut-off for
the Luciferase assay to select which mutants to pursue, RV was generated from CNa 
mutants 1-8 and transduced Jurkats were assessed for their ability to secrete IL-2 in the 
presence of FK506. Figure 21 shows that in the presence of 10ng/ml FK506, CNa2 
transduced  cells  secreted  IL-2  at  34%  of  the  level  secreted  by  UT  Jurkats  in  the 
absence of IS. In contrast, CNa1 transduction allowed secretion of IL-2 at 9% of the 
level secreted by untransduced Jurkat cells. In corresponding luciferase assays in 293T 
cells, CNa1 gave a mean 7% resistance to FK506, whereas CNa2 gave a mean 19% 
resistance. To rationalise the number of mutants tested in the Jurkat system, a cut-off
of 15% resistance in FLuc expression was set, which would select CNa2 but not CNa1 
for  further  study.  This  threshold  was  applied  to  all  other  CN  mutants  and  led  to 
selection of the 17 mutants described in section 3.3.2.Chapter three
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Figure 21: Transduction with CN mutants allows IL-2 secretion from Jurkat cells 
in the presence of FK506. IL-2 secretion from unstimulated Jurkat cells (unstim), 
cells stimulated for 24 hours with 20ng/ml PMA and 1g/ml ionomycin (stim), or 
cells stimulated in this manner with addition of the indicated concentration of FK506 
(0.5-40ng/ml). Cells transduced with CNa2 (34%) and CNa1 (9%) were able to secrete 
IL-2 despite increasing concentrations of FK506. Dotted line indicated secretion of IL-
2  by  UT  Jurkat  cells  without  CN  inhibitors  (100%).  Mean  and  SEM  of  three 
experiments are shown.
3.3.4. Identification of resistant CN mutants in IL-2 secretion assay
Following optimisation of the assay, Jurkat cells were transduced with all the selected 
mutants  and  transduction  efficiency  was  assessed.  Where  transduction  was  below 
80%, Jurkats were sorted to select GFP expressing cells, however where greater than 
80% GFP expression was achieved cultures were not sorted. These cells were then 
tested as described above, to assess their ability to secrete IL-2 in the presence of 
either  FK506  or  CsA,  based  on  the  resistance  profile  identified  by  Luciferase 
screening. 
Considerable variation in the amount of IL-2 secreted between assays was observed, 
compounding direct comparison. To account for inter-assay variation and facilitate Chapter three
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accurate  interpretation  of  results,  IL-2  secretion  is  calculated  compared  to  the 
stimulated  UT  sample  in  the  absence  of  CN  inhibitors  for  each  experiment.  The 
resulting  percent  IL-2  secretion  was  combined  to  give  a  mean  percent  secretion 
compared to this standard level. 
Figure 22(a) shows IL-2 secretion from CNa transduced Jurkats in the presence of 
FK506. IL-2 secretion by UT and wtCNa transduced Jurkats is abrogated by FK506 at 
levels as low as 0.5ng/ml. In general, there was a reasonable correlation with the 293T 
luciferase assay, with several of the mutants identified also showing resistance in the 
Jurkat  IL-2  secretion  assay.  Mutant  CNa12,  which  gave  the  highest  resistance  to 
FK506 in the Luciferase assay, retains the ability to secrete IL-2 up to the highest 
concentration tested (40ng/ml), which is significantly higher than the therapeutic range 
(7-12ng/ml). Compared to IL-2 secretion by stimulated UT Jurkats with no FK506, 
CNa12  transduced Jurkats  retained a  mean  84%  IL-2  secretion  in  the presence of 
10ng/ml FK506. CNa2 also retains some activity in the presence of 10ng/ml FK506, 
secreting IL-2 at a mean of 35% of the level secreted by untransduced Jurkat cells.
Mutants CNa 15 and 17 continue to secrete IL-2 in the presence of 0.5 or 1ng/ml 
FK506, however this secretion drops at concentrations of 5ng/ml or higher. CNa4, 9 
and 12 did not confer resistance to FK506.
As shown in Figure 22(b), CNa mutants CNa18, 19, 21 and 22 secrete high levels of 
IL-2 throughout the therapeutic range of CsA (100-250ng/ml) and in the presence of 
supratherapeutic concentrations up to 800ng/ml. When compared to secretion by UT 
Jurkats  without  CsA,  these  mutants  secrete  between  171%  (CNa18)  and  259% 
(CNa22) IL-2 at 200ng/ml CsA. CNa20 conferred 40% resistance to CsA. It is notable 
that in this assay, those cells that were transduced with CNa mutants 18, 19, 21 and 22 
secreted an increased level of IL-2 upon stimulation compared to UT Jurkats. This 
effect was not observed with wtCNa or other mutants. This could be a consequence of 
the increased level of CN in the cell activating more NFAT and therefore leading to 
more IL-2 secretion, however this increase was not observed in cells transduced with 
wtCNa. It is possible that alteration of residue V314, which is common to those four 
mutants, affects either the activity or the stability of the CN molecule, allowing hyper-Chapter three
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activity. This was a consideration when selecting the appropriate mutants for further 
study.
Jurkat cells transduced with CNb mutants were also assessed for secretion of IL-2 in 
the presence of CN inhibitors. As shown in Figure 23, mutant CNb30 provided the 
highest resistance to both CN inhibitors, secreting 47% IL-2 in the presence of10ng/ml
FK506 and 26% with 200ng/ml CsA. CNb21 also retained some activity, with 26% 
resistance to FK506 and 8% to CsA and CNb23 retained 24% IL-2 secretion with 
FK506 and 9% with CsA.  In this assay, CNb12  and 22 did not confer significant 
resistance to FK506 and CNb22 and 26 showed no resistance to CsA. Interestingly, all 
CNb mutants that conferred resistance contained a 2AA insertion at position K125, 
despite  some  other  mutants  being  identified  in  the  Luciferase  screening  assay. 
Furthermore, transduction with CNb mutants did not result in increased IL-2 secretion
upon stimulation compared to UT Jurkats.Chapter three
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Figure 22: Transduction of Jurkat cells with CNa mutants allows IL-2 secretion 
in  the presence of  FK506  (a) or  CsA (b). Mean and  SEM  of three  experiments 
shown. Dotted line indicates IL-2 secretion by UT Jurkat cells stimulated without CN 
inhibitors (100%).Chapter three
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Figure  23:  IL-2  secretion  by  CNb  transduced  Jurkat  cells  in  the  presence  of 
increasing  concentrations  of  FK506  (a)  or  CsA  (b). Mean  and  SEM  of  three 
experiments shown. Dotted line indicates IL-2 secretion by UT Jurkat cells stimulated 
without CN inhibitors (100%).Chapter three
_____________________________________________________________________
115
3.3.5. Analysis of CN expression following transduction
Some  variation  was  observed  in  the  mean  fluorescence  intensity  (MFI)  of  GFP 
expression between samples transduced with different mutants, therefore differences 
in CN expression were also likely. To exclude the possibility that differences in the 
resistance profile to FK506/CsA were a result of differences in CN expression, we 
analysed expression of CN directly using Western blotting. Jurkat cells transduced 
with  retroviral  supernatants  generated  during  different  batches  of  production  were 
compared to establish the variation in CNa expression between individual mutants or
RV  batches.  In  particular,  we  looked  at  expression  of  those  mutants  that  gave 
resistance, to determine whether these expressed the highest levels of CNa.
Samples were tested from all cultures transduced with virus made in two different 
batches: Retroviral supernatants for CNa1-8 were generated first, and supernatants for 
CNa9, 12, 15 and 17 were generated later, and had a higher MFI when GFP expression 
was assessed by flow cytometry, therefore these two batches were examined for CNa 
expression. Lysate was generated from 2x10
6 transduced or untransduced Jurkat cells, 
and 40l loaded per sample. Membranes were cut into sections based on the expected 
size of CNa and -actin and each portion probed with the appropriate antibody. Bands 
were  quantified  and  expression  of  CNa  was  normalised  according  to  the  -actin 
expression for each sample. Expression of CNa in transduced cells was compared to 
that in untransduced control samples. As shown in Figure 24, while -actin expression 
was similar between lysates, the expression of CNa mutants, though always higher 
than untransduced samples, varied widely.Chapter three
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Figure  24:  Jurkat  cells  transduced  with  virus  from  different  batches  show 
variation in CNa expression. Expression of -actin is shown to control for protein 
loading. RV containing CNa1-8 was generated together; RV containing CNa9, 12, 15 
and  17  was  generated  at  a  separate  time  point.  Quantification  of  CN  and  -actin
expression is shown in table 5.
Table  5:  Quantification  of  protein  bands  identified  by  Western  blot. CN 
expression  is  adjusted  to  account  for  variation  in  protein  loading  established  by 
quantification of -actin. UT in yellow, RV batch 1 highlighted in blue (average CNa 
increase 2.5), RV batch 2 highlighted in purple (average CNa increase 5.4).
Sample Actin 
expression
Relative 
Actin
CNa 
expression
Adjusted 
CNa 
Relative 
CNa
UT 256573 1.39 37394 26922 1.00
wtCNa 184720 1.00 88932 88932 3.30
CNa1 291505 1.58 140428 88986 3.31
CNa2 364950 1.98 202181 102334 3.80
CNa3 475205 2.57 172876 67200 2.50
CNa4 489258 2.65 115091 43453 1.61
CNa5 400919 2.17 125468 57808 2.15
CNa6 410236 2.22 155501 70019 2.60
CNa7 382215 2.07 107311 51862 1.93
CNa8 299687 1.62 54663 33693 1.25
CNa9 446198 2.42 233043 96477 3.58
CNa12 326098 1.77 310761 176032 6.54
CNa15 358333 1.94 265704 136970 5.09
CNa17 406611 2.20 369523 167871 6.24
38 kDa
-actin
49 kDa
62 kDa
CNa
UT wtA A1 A2 A3 A4 A5 A6 A7 A8 A9 A12 A15 A17Chapter three
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Table 5 shows the relative expression of CNa mutants compared to UT Jurkat cells,
normalised  to  -actin  expression.  These  data  establish  that  there  is  considerable 
variation  in  the  expression  of  CN  both  within  and  between  batches  of  RV.  RV 
containing  CN  mutants  1-8  was  generated  at  the  same  time  point,  however  CN 
expression varies between cells transduced with the different retroviral supernatants. 
For  example,  cells  expressing  mutant  CNa4  show  a  1.6  fold  increase  in  CNa 
expression compared to UT Jurkats, whereas those transduced with CNa2 show a 3.8
fold increase. CNa8 appears to be unstable as there is very little increase in expression 
from  UT,  despite  comparable  levels  of  GFP.  This  variation  is  increased  further 
between batches of virus made at different times, with expression of CN from Jurkats 
transduced with mutants CNa9, 12, 15 or 17 all showing further increased expression 
of  between  5 and  6.5  fold  compared  to  UT  Jurkat  cells.  Overall,  average  CN 
expression from cells transduced with RV batch 1 was 2.5 fold above UT, compared to 
a  5.4  fold  increase  in  cells  transduced  with  RV  from  batch  2.  Therefore,  data 
concerning  relative  resistance  to  CN  inhibitors  generated  from  these  cells  are
questionable  and  might  be  attributed  to  differences  in  CN  expression  rather  than 
mutant activity.
3.3.6. FACS sorting of transduced Jurkat cells and re-analysis
In order to control for the variability in CN mutant expression observed above, all 
cultures  were  sorted  by  fluorescence  activated  cell  sorting  (FACS)  to  comparable
levels of GFP expression to reduce CN variation. Since expression of CN mutants 
occurs from the same RNA transcript as GFP, normalising for GFP expression should 
ensure that differences observed in resistance to CN inhibitors reflect true differences 
in the level of activity retained by CN mutants rather than differences in the amount of 
CN expressed. The mean fluorescence intensity (MFI) of GFP expression following 
FACS sorting of retrovirally transduced Jurkat cells is shown in Table 6. It can be seen 
that CNb mutants were sorted to a higher level of GFP expression (mean MFI 570) 
than CNa mutants (mean MFI 75), reflecting that CNb is a smaller transgene, therefore Chapter three
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expression of GFP from an IRES following CNb is likely to be brighter compared to 
expression following the larger CNa
Table  6:  Mean  fluorescence  intensity  of  GFP  comparable  following  FACS 
sorting.
Construct MFI
UT -
wtCNa 76
CNa2 89
CNa4 78
CNa9 87
CNa12 83
CNa15 88
CNa17 80
CNa18 66
CNa19 60
CNa20 66
CNa21 72
CNa22 59
wtCNb 487
CNb12 556
CNb21 601
CNb22 600
CNb23 574
CNb26 577
CNb30 593
Following FACS sorting, transduced Jurkat cultures were again examined by Western 
blot to confirm comparable expression of CNa/CNb (Figure 25 and Figure 26). These
data establish that variation in CN expression between cultures is reduced following 
sorting of Jurkats to similar GFP level. Quantification of -actin and CNa is presented 
in Table 7, showing increase in CNa expression of between 2.7 and 13.1 fold (CNa4 
and CNa20 respectively) by transduced compared to UT Jurkats. This range of CNa
expression is larger than anticipated after FACS sorting of Jurkat cells, however with 
the exception of CNa4, 9 and CNa20, all other samples show consistent increase in 
CNa expression of 5.2 to 8.6 fold compared to UT cells. It remains possible that the Chapter three
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mutations introduced into the CN molecule affect the stability of these mutants and 
that the observed differences in expression reflect reduced/increased half-life in the 
cells,  rather  than  variable  transduction  or  sorting.  As our  aim  is  to  identify  those 
mutants that are able to confer the highest resistance to FK506/CsA, a mutant with
reduced stability would be undesirable for this purpose although it may render cells 
resistant if expressed at a higher level. Therefore, screening was continued with no 
further attempts to normalise CN expression in outlying cultures. 
Figure  25:  CNa  expression  between  transduced  Jurkat  cells  is  comparable 
following  FACS  sorting. Untransduced  Jurkat  cells  (UT) are  compared  to  cells 
transduced with wild type CNa (WT) or CNa mutants (A2-A22). -actin is shown as 
an internal control. Quantification of CNa bands, normalised for variation in protein 
loading, shows an 8 fold increase of CNa expression when transduced with wild type. 
Cultures transduced with mutant CNas show variable increase of expression, from 2.7 
fold  (A4)  to  13  fold  (A20)  increase  compared  to  untransduced  Jurkats.  For  band 
quantification see Table 7.
UT WT A2 A4 A9 A12 A15 A17 A18 A19 A20 A21 A22
38kDa
49kDa
62kDa
CNa
-actinChapter three
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Table 7: Quantification of CNa expression from sorted Jurkat cells. Expression of 
CNa is adjusted for variation in protein loading as determined by -actin staining. 
Outlying cultures are shaded.
Sample Actin Relative 
actin
CNa Adjusted 
CNa
Relative 
increase
UT 476029 1.00 31869 31869 1.00
wtCNa 566859 1.19 320298 269158 8.44
CNa2 584732 1.23 204542 166294 5.23
CNa4 546819 1.15 98780 858956 2.70
CNa9 584359 1.23 110754 90044 2.83
CNa12 556635 1.17 308563 263729 8.28
CNa15 595646 1.25 219259 175407 5.50
CNa17 684073 1.44 274984 190961 6.00
CNa18 718771 1.51 322832 213796 6.71
CNa19 794290 1.67 374349 224161 7.04
CNa20 537082 1.13 472480 418124 13.14
CNa21 578963 1.22 335523 275019 8.66
CNa22 619985 1.30 257329 197945 6.20
Expression of CNb in transduced Jurkat cells is shown in Figure 26, and quantification 
of these bands in Table 8. Jurkat cells transduced with CNb and sorted to the same
level of GFP expression show a consistent increase in CNb expression of between 1.8 
and  3.8  fold  compared  to  UT  Jurkat  cells (wtCNb  and  CNb21  respectively). 
Interestingly,  while  the  MFI  of  cultures  transduced  with  CNb  mutants  was 
considerably higher than those transduced with CNa mutants, a more modest increase 
in CNb than CNa expression was generally observed. This may reflect the level of 
wtCNa compared CNb expressed in untransduced Jurkats.Chapter three
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Figure  26:  CNb  expression  between  transduced  Jurkat  cells  is  comparable 
following  FACS  sorting. Untransduced  Jurkat  cells  (UT)  are  compared  to  cells 
transduced with wild type CNb (WT) or CNb mutants (CNb12-30). -actin is shown 
as internal control. Quantification of CNb bands, normalized for variation in protein 
loading, shows a 1.8 fold increase of CNb expression when transduced with wild type. 
Cultures transduced with  mutant CNbs show variable increase of expression, from 
1.96 fold (CNb23) to 3.75 fold (CNb21) increase compared to untransduced Jurkats.
Table 8: Quantification of CNb expression from sorted Jurkat cells. Expression of 
CNb is adjusted for variation in protein loading as determined by -actin staining.
Sample Actin Relative 
actin
CNb Adjusted 
CNb
Relative 
increase
UT 96178 1.25 1381600 1105280 1.00
wtCNb 94041 1.22 2403819 1970343 1.78
CNb12 80203 1.04 2708518 2604344 2.35
CNb21 77013 1.00 4147483 4147483 3.75
CNb22 105693 1.37 3818658 2787342 2.52
CNb23 101715 1.32 2857820 2165015 1.96
CNb26 107522 1.40 3025538 2161099 1.96
CNb30 92351 1.20 3414232 2845193 2.57
14kDa
28kDa
38kDa
49kDa
UT WT CNb12 CNb21 CNb22 CNb23 CNb26 CNb30
CNb
-actinChapter three
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After standardization of CN expression between transduced Jurkat cells by sorting to 
consistent GFP levels, the resistance conferred by CN mutants was re-tested. Once 
again  Jurkats  were  stimulated  with  mitogens  in  the  presence  of  increasing 
concentrations of CN inhibitors and their ability to secrete IL-2 was determined.
Figure 27 illustrates  that  CNa12  again  provides  the  highest  resistance  to  10ng/ml
FK506,  with  85%  secretion  of  IL-2  compared  to  UT  cells  in  the  absence  of  CN 
inhibitors. CNa2 also confers resistance, with 68% IL-2 secretion. In the presence of 
CsA, those four mutants that secreted the highest IL-2 before sorting continued to do 
so in this assay, with CNa22 secreting 368% IL-2 compared to UT Jurkats (without 
CN  inhibitors),  CNa19  secreting  288%,  and  CNa18  and  21  secreting  intermediate 
levels. 
In addition, the previously noted increase in secretion of IL-2 from mutants CNa18, 
19,  21 and 22  is  observed  from other  constructs  following  FACS sorting.  Indeed, 
increased IL-2 secretion of varying degrees occurs from all CNa transduced cultures 
including wtCNa in this experiment. It is therefore likely that this is a general effect of 
increased CN expression rather than hyperactivity of particular mutants. During FACS 
sorting cells expressing high levels of GFP, and therefore CNa, were selected. For 
example, prior to sorting the wtCNa transduced culture expressed 3.3 fold more CNa 
than UT, however after sorting the cells expressed 8.4 fold more CNa. After FACS 
selection, CNa transduced cells secreted 280-380% of the amount of IL-2 secreted by 
untransduced Jurkats in the absence of CN inhibitors. However, it is interesting to note 
that despite this increase, cells transduced with wtCNa are not rendered resistant to 
FK506 or CsA, indicating that  in our assay simple  over-expression of CNa is not 
sufficient to enable IL-2 secretion in the presence of even low levels of either drug. 
This is in contrast to some previous studies which find that over-expression of wtCNa 
results in some resistance to CsA in a transfected Jurkat cell system, increasing the 
IC50 by 2.5-5 fold (Zhu, et al 1996). It is possible that our assay was not sufficiently 
sensitive to detect small changes as we have focused on resistance to therapeutic levels 
of CN inhibitors.Chapter three
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Figure 27: CNa mutants transduced, FACS sorted Jurkat cells are able to secrete 
IL-2 in the presence of FK506 (a) or CsA (b). Mean and SEM of three experiments 
shown.  Dotted  line  indicates  secretion  by  stimulated  UT  Jurkat  cells  without  CN 
inhibitors (100%).Chapter three
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Cells transduced with CNb were also sorted to express equivalent GFP, and re-tested
(see  Figure  28).  As  measured  by  IL-2  secretion  compared  to  UT  without  CN
inhibitors, CNb30 conferred 85% resistance to 10ng/ml FK506 and 43% resistance to 
200ng/ml CsA. It is striking that, despite sorting to a higher level of GFP expression in 
CNb transduced cultures, little over-expression of IL-2 was seen from CNb compared 
to CNa transduced cells. CNb26 and CNb30 resulted in some hyper-activity compared 
to  stimulated  untransduced  cells  without  CN  inhibitors  (184/216%  and  153/184%
respectively in the FK506/CsA experiments), however this is much less than that seen 
from CNa transduced cells.Chapter three
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Figure 28: CNa mutants transduced, FACS sorted Jurkat cells are able to secrete 
IL-2 in the presence of FK506 (a) or CsA (b). Mean and SEM of three experiments 
shown.  Dotted  line  indicates  secretion  by  stimulated  UT  Jurkat  cells  without  CN 
inhibitors (100%).Chapter three
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These data guided the selection of CNa12, CNa22 and CNb30 as those to pursue in 
further experiments.  CNa12 conferred 85%  resistance to  FK506,  CNa22  conferred 
368%  resistance  to  CsA  and  CNb30  conferred  resistance  to  both  CN  inhibitors
(85%/43% to FK506/CsA respectively). 
3.3.7. Codon optimisation of selected CN mutants
To investigate the possibility of improving resistance by increasing expression of CN 
mutants, the selected constructs were codon optimised. This process altered the codon 
usage to reflect tRNAs that are commonly used in human cells, thus improving the 
efficiency of translation which may improve protein expression, potentially increasing 
resistance. In addition, during this process, GC content was raised to 70%, hairpins 
and literal repeats reduced to a minimum and splice sites avoided. An example of this 
codon optimisation is shown in Figure 29.
We  also  generated  bi-cistronic  constructs  carrying  both  CNa  and  CNb  mutants
separated by a 2A sequence to investigate the effect of transduction with both genes
together.  Following  generation  of  retroviral  supernatant  encoding  codon  optimised 
mutants, Jurkat cells were transduced, FACS sorted to equalise GFP expression, and 
CNa and CNb was quantified by Western blotting (see Figure 30).Chapter three
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Figure 29: Example of codon optimisation of CN sequence. Panel (a) shows the 
original CNb sequence, panel (b) shows the optimised sequence. Amino acid sequence 
is shown on the top line, with the most common mammalian codons shaded in white, 
less common codons shown in pink and rare codons shown in red. The DNA sequence 
is shown below the coded amino acids.
Western blot data of Jurkats transduced with codon optimised CN mutants shows that 
transduction with CNa12 or 22 results in a 22-fold increase in expression of CNa, and 
transduction with CNb30 results in a 1.7 fold increase in CNb expression. Comparison 
with the increase in expression seen with non-codon optimised constructs (Table 7 and
Table  8)  suggests  that  codon  optimisation  increases  the  expression  of  CNa12  and 
CNa22 but has little effect on the expression of CNb30.
(a)
(b)Chapter three
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Figure 30: Jurkat  cells  transduced with  codon optimised CN mutants express 
comparably high levels of CNa/CNb. Western blot performed following transduction 
and FACS sorting to the same level of GFP expression. -actin is shown as protein 
loading  control.  Samples  were  stained  for  both  CNa  and  CNb  expression. 
Quantification of bands is shown in Table 9.
Interestingly, transduction of Jurkat cells with CNa mutants also resulted in a 3-4 fold 
increase in expression of CNb. In contrast, transduction of Jurkat cells with CNb did 
not result in increased expression of CNa; indeed CNb transduction resulted in a lower 
increase in CNb than that observed following CNa transduction. Transduction with 
bicistronic constructs containing both CNa and CNb led to increased expression of 
both proteins, however this increase was comparable to that seen after transduction 
with CNa alone (see Table 9).
38 kDa
-actin
UT wtA A12 A22 wtB B30
wtA-
wtB
wtA-
B30
A12-
wtB
A12-
B30
A22-
wtB Mock
49 kDa
62 kDa
CNa
14 kDa
CNbChapter three
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Table 9: Expression of CNa and CNb in transduced Jurkats cells. Bands were 
quantified and normalised to -actin expression to adjust for differences in protein 
loading. Final results are highlighted.
Sample Actin Relative 
actin
CNa Relative 
CNa
CNb Relative 
CNb
Adjusted 
CNa
Adjusted 
CNb
UT 942215 1.27 62776 49623 141396 111769 1.38 1.00
wtCNa 785263 1.05 65949 62550 188284 178581 1.74 1.60
CNa12 966436 1.30 1057383 814883 554607 427414 22.65 3.82
CNa22 800667 1.08 852371 792890 388578 361462 22.04 3.23
wCNb 744794 1.00 60214 60214 155441 155441 1.67 1.39
CNb30 828456 1.11 55634 50016 215322 193578 1.39 1.73
Mock 937877 1.26 45305 35978 154882 122996 1.00 1.10
wtCNa-
wtCNb 1037667 1.39 712964 511736 511419 367075 14.22 3.28
wtCNa-
CNb30 1091225 1.47 884004 603359 747623 510275 16.77 4.57
CNa12-
wtCNb 1033276 1.39 508120 366257 412219 297131 10.18 2.66
CNa12-
CNb30  813048 1.09 335321 307171 283882 260051 8.54 2.33
CNa22-
wtCNb 803955 1.08 162674 150703 212742 197087 4.19 1.76
These data indicate that CNa is likely to be the limiting component of the CNa:CNb 
heterodimer, a theory postulated by Milan et al that is supported by the pattern of 
hyperactivity  seen  when  transduced  Jurkats  are  stimulated (Milan,  et  al  1994). 
Transduction of cells with additional CNa allows an overall increase in cellular CN, 
due to the presence of sufficient native CNb for heterodimer formation. Conversely, 
transduction with CNb does not lead to increased cellular CN heterodimer as limited 
CNa is  available for binding,  therefore  introduced CNb  must  compete  with  native 
CNb.  Increased  overall  CN  may  lead  to  a  heightened  response  when  the  cell  is 
stimulated and therefore increased IL-2 secretion. Figure 31 illustrates this hypothesis.Chapter three
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Figure 31: Illustration of CNa/b heterodimer formation. Relative excess of CNb 
compared to CNa results in CNa limiting the formation of CN heterodimer. Therefore 
transduction with CNa leads to increase in CNb, whereas transduction with CNb does 
not produce increase in either protein.
Following  codon  optimisation  of  selected  CN  mutants,  resistance  of  Jurkat  cells
transduced with these mutants to CN inhibitors was re-tested. These results are shown 
in  Figure 32 and  summarised  in  Table  10. Jurkat  cells  transduced  with  codon
optimised  CN  mutants  showed  a  similar  resistance  profile  to  that  seen  with  the 
corresponding non-optimised constructs. This is perhaps unsurprising for CNb30 as 
expression  was equivalent  between codon  optimised  and non-optimised  constructs. 
CNa  is  limiting.  CNb  degraded 
unless heterodimer formed
Addition  of  CNa  leads  to 
increase in CNa and CNb
Addition of CNb does not produce 
increase in either as not bound by 
limiting CNa.
CNa CNb CNb
CNb
CNa CNb
CNa CNb
CNa CNb
CNa CNb
CNb
CNb
CNb
CNb
CNa CNb
CNa CNb
CNa CNb
CNa CNb
CNa CNb
Addition  of  CNa  and  CNb  leads  to 
increase in both.Chapter three
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However,  despite  a  considerable  increase  in  the  expression  of  CNa  detected  by
Western blot, resistance to CN inhibitors was not increased after codon optimisation. It 
is possible that the limit of IL-2 secretion, and maximal resistance to CN inhibitors in 
this assay had been reached. A summary of the resistance profile observed in three 
experiments with non-optimised compared to codon optimised mutants is shown in
Table 10. It is interesting to note that there is no further increase in hyper-activity as a 
result of either codon optimisation or co-expression of CNa and CNb together. As 
there  is  an  increase  in  both  CN  expression  and GFP  expression (data  not  shown)
following codon optimisation, we continued experiments with these sequences into 
primary cell lines.
Therefore,  for  testing  in  EBV-CTLs,  CNa12  was  selected  to  confer  resistance  to 
FK506, CNa22 for resistance to CsA, and CNb30 for resistance to both CN inhibitors. 
In addition the bicistronic construct of CNa12-CNb30 was selected which is able to 
render Jurkat cells resistant to both FK506 and CsA more effectively than CNb30 
alone in the Jurkat IL-2 secretion assay.Chapter three
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Figure 32: Transduction of Jurkat cells with codon optimised CN mutants allows 
IL-2 secretion in the presence of FK506 (a) or CsA (b). Mean and SEM shown 
(n=3).  Dotted  line  indicates  secretion  by  stimulated  UT  Jurkat  cells  without  CN 
inhibitors (100%).Chapter three
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Table  10:  Summary  of  resistance  conferred  by  codon  optimised  CN  mutants.
Jurkat cells retrovirally transduced with CN mutants were FACS sorted to equivalent 
MFI for GFP expression, stimulated with PMA and Ionomycin and IL-2 secretion in 
the presence of FK506/CsA was assessed by ELISA. IL-2 secretion was compared to 
that  by  stimulated  untransduced  cells  in  the  absence  of  CN  inhibitors  to  give  % 
resistance.  The  resistance  conferred  by  non-codon  optimised  and  codon  optimised 
constructs are shown. Data are the mean of three experiments.
CN mutant %  Resistance 
to  FK506  pre 
optimisation
%  Resistance 
to FK506 post 
optimisation
%  Resistance 
to  CsA  pre 
optimisation
%  Resistance 
to  CsA  post 
optimisation
UT - - - -
wtCNa - - - -
CNa12 85 85 - -
CNa22 - - 368 209
wCNb - - - -
CNb30 85 57 43 37
Mock - - - -
wtCNa-wtCNb - - - -
wtCNa-CNb30 - 108 - 127
CNa12-wtCNb - 42 - -
CNa12-CNb30  - 109 - 80
CNa22-wtCNb - - - 104
3.4 Conclusions
In  conclusion,  we  have  designed  and  generated  a  panel  of  CN  mutants  to  confer 
resistance to either or both of the CN inhibitors FK506 and CsA. Several rounds of 
mutant design were undertaken, combining those mutations that showed some effect in 
earlier  rounds.  We  have  established  and  optimised  a  transient  luciferase  screening 
assay in 293T cells to allow preliminary testing of all 54 CN mutants, which enabled
selection of 17 mutants that confer resistance to FK506 or CsA. 
Whilst a success rate of one third was achieved by this protein engineering with 17 of 
the 54 designed mutants retaining some activity in the presence of CN inhibitors, these 
activities  did  not  always  correlate  to  that  predicted  during  design.  For  example, 
mutants  CNa18-20  were  intended  to  confer  resistance  to  both  CN  inhibitors  by Chapter three
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disruption of a residue involved in both interactions, however resistance to CsA only 
was observed.  In contrast,  mutants  containing an insertion after CNb  position  125 
were  anticipated  to  confer  resistance  to  FK506  alone,  however  cells  were  also 
rendered resistant to CsA.  These results demonstrate that the effect of  amino acid 
mutations  and  insertions  on  the  overall  function  of  a  protein  can  not  easily  be 
predicted, however successful design of resistant CN mutants was achieved.
Following identification of suitable mutants, we established and optimised a second 
screening assay to select those conferring the highest resistance to CN inhibitors in the 
Jurkat  T  cell  line.  Retroviral  transduction  of  Jurkat  cells  with  several  of  the  CN 
mutants allowed IL-2 secretion in the presence of therapeutic doses of FK506/CsA, 
three of which were selected. These mutants were then codon optimised to improve 
expression. Despite this procedure, expression of CNb30 did not increase following 
codon optimisation. This is consistent with the hypothesis illustrated in Figure 31,
demonstrating that CNa is required to stabilise CNb and that without increasing CNa, 
no additional CNb can be detected despite potential improvements to the efficacy of 
expression.  In  addition,  no  increase  in  resistance  was  noted  following  codon 
optimisation despite an increase in CNa12/22 expression. It is possible that the limit of 
this assay has been reached and that additional over-expression of CN can not further 
increase  either  IL-2  expression  or  resistance.  For  example,  at  lower  levels  of  CN 
expression, our results indicate that CN is the limiting step in cellular activation when 
stimulated  with  mitogens.  With  increasing  CN  present  in  the  cell,  however,  it  is 
possible  that  CN  reaches  excess  levels  therefore  the  availability  of  Calmodulin, 
NFAT,  or  another  component  of  the  activation  pathway  may  become  limiting  in 
cellular activation, thus preventing any effect of further increases in CN expression. 
Although we were unable to determine the effect of codon optimisation on resistance 
in  this  assay,  we  established  that  improvements  were  made  in  CNa  expression 
following  this  process.  In  addition,  screening  in  this  Jurkat  IL-2  secretion  assay 
enabled selection  of the  three mutants  that  conferred the highest  resistance to  CN 
inhibitors for further study in EBV-CTL lines.
In Jurkat cells, transduction with wtCNa or CNa mutants resulted in increased IL-2 
production by those cells upon stimulation with mitogens. It is likely that increased Chapter three
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CN expression leads to amplification of the activation signal, additional NFAT activity 
and a degree of hyper-reactivity to stimulation in this Jurkat cell line. Interestingly, 
Western blot data showed increased expression of CNb upon transduction with CNa 
and limited increase in CNb following transduction with CNb, indicating that CNa 
may  be  the  limiting  component  of  the  CN  heterodimer.  This  is  supported  by  the 
observation that hyperactivity of Jurkat cells is observed to a higher degree upon CNa 
transduction compared to CNb transduction. However, it is important to note that no 
IL-2 secretion was observed in the absence of stimulation, indicating that these cells 
remain  dependent  on  stimulation  for  activation,  and  that  increased  CN  expression 
alone does not confer resistance, as demonstrated by transduction with wtCNa. 
In summary, these results demonstrate that CNa and CNb mutants can be generated to 
confer resistance to either FK506, or CsA or both CN inhibitors. CNa12 conferred the 
highest levels of resistance to FK506, CNa22 to CsA and CNb30 conferred resistance 
to both drugs. Transduction with these mutants allows expression of Luciferase from 
293T cells or IL-2 from Jurkat T cells in the presence of therapeutic doses of these 
drugs. These CN mutants were then tested in primary CTL lines.Chapter three
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3.5 Final conclusions
 We have successfully generated a panel of CNa and CNb mutants to confer 
resistance to FK506 or CsA in two cell line assays.
 Three  mutants  retaining  the  highest  activity  in  the  presence  of  therapeutic 
levels of FK506 or CsA were identified.
 Codon optimisation of these three mutants improved expression of CNa12 and 
CNa22  but  not  CNb30  in  Jurkat  cells,  but  did  not  improve  the  level  of 
resistance observed to FK506 or CsA.
 Bicistronic vectors combining a CNa and CNb mutants may increase resistance 
further.Chapter four
Evaluation of CN mutants in primary EBV-
CTL linesChapter four
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4.1 Aims
 To generate EBV-CTL lines from healthy donors.
 To transduce CTLs with CN mutants and evaluate the effect of transduction on 
phenotype, cytokine secretion and cytotoxicity.
 To assess the ability of the selected CN mutants to render EBV-CTL lines 
resistance to FK506/CsA.
4.2 Introduction
Following the identification of CN mutants capable of conferring resistance to CN
inhibitors in Jurkat cells, the activity of these mutants in primary cells was examined. 
CN inhibitor resistant EBV-CTLs may be of therapeutic use in the treatment of PTLD 
post SOT, therefore this model was selected to examine resistance to CN inhibitors in 
primary cells. In addition, our laboratory has expertise in the generation and culture of 
EBV-CTLs, which can be maintained in vitro for a sufficient length of time to assay 
various end points. 
In order to assess the effect of CN mutants, the effect of CN inhibitors on in vitro
generated UT EBV-CTLs must be established. Whilst it is clear that pharmacological 
suppression of EBV immunity plays a role in the development of PTLD, previous 
studies have shown differential effects of CN inhibitors on ex vivo expanded T cells 
compared  to  naïve  T  cells  when  studying  graft  versus  host  disease  (GVHD)
(Contassot, et al 1998) and on committed CTLs compared to naïve CD8+ T cells in 
heart transplant rejection (Vaessen, et al 1994). These data suggest that activated cells 
are suppressed less effectively than naïve cells. In contrast, studies of CMV-CTLs
derived from patients receiving immunosuppressive therapy have demonstrated that 
CMV specific CD8+ CTLs are present but display reduced functionality following Chapter four
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withdrawal from the patient, indicting that these cells are indeed suppressed by CN 
inhibitors (Engstrand, et al 2003). In addition, it has been shown that proliferation and 
secretion of  IFN- by EBV-specific CTLs in vitro are affected by addition  of CN 
inhibitors  to  culture  conditions (Savoldo,  et  al  2001).  Previous  data  regarding  the 
effect of CN inhibitors on the cytotoxicity of CTLs is conflicting. Some studies find 
that, in contrast to proliferation and cytokine secretion, cytotoxicity is unaffected by 
the presence of FK506 or CsA (Savoldo, et al 2001), whereas others have shown that 
cytotoxicity is inhibited by long term culture in CN inhibitors (Zhan, et al 2003). In 
summary, data on the effect of CN inhibitors on the functionality of ex vivo expanded 
EBV-CTLs are conflicting, particularly with regard to cytotoxicity. Further work is 
thus required to clarify the effects of CN inhibitors on EBV-CTLs. We have therefore 
initially studied the effect of CN inhibitors on untransduced EBV-CTL lines expanded 
in vitro from healthy donors in order to identify end points that are affected by these 
drugs to allow determination of whether transduction with CN mutants restores these 
suppressed functions.
The potential effects of transgene expression within the target cells have also been 
evaluated.  Calcineurin  is  critically  involved  in  the  activation  of  T  cells,  therefore 
several possibilities could arise from increased expression of this gene. Higher levels 
of CN may lead to increased NFAT activity and hyper-responsiveness to stimulation,
as shown in Jurkat cell lines. Alternatively, if Calmodulin or NFAT are saturated, 
additional CN expression may have no effect on T cell activation. As demonstrated in 
chapter three, transduction with CNb mutants appears to lead to only a limited increase 
in intracellular CN levels, and no hyperactivation in Jurkat cells, therefore mutants of 
this gene may be less likely to confer side effects of increased CN activity. We have 
additionally addressed the important issue of whether transduction with CN mutants 
confers on  EBV-CTLs the  ability  to  proliferate  independently  of  specific  antigen 
stimulation.  As  cellular  activation  requires  the  interaction  of  several  independent 
pathways, we felt that increased signalling through CN was unlikely to render EBV-
CTLs  stimulation  independent  and  lead  to  inappropriate  growth,  and  have 
demonstrated this to be the case. Finally, as primary EBV-CTLs are more biologically 
relevant than transformed cell lines and therefore subject to normal cellular regulation 
mechanisms, hyperactivation of CN may lead to the induction of activation induced Chapter four
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cell  death  or  anergy,  rather  than  increased  proliferation.  Although  cell  lines  are  a 
useful model for initial in vitro studies, the effect that these manipulations may have 
on primary cells can not always be accurately predicted. Therefore we examined the 
effect  of  transduction  with  CN  mutants  on  EBV-CTLs in  both  the  presence  and 
absence of CN inhibitors.
4.3 Generation of EBV-CTL lines
4.3.1 Generation and characterisation of EBV-CTLs
Several optimisation experiments were performed to establish the EBV-CTL model 
and determine suitable end points for identifying resistance to CN inhibitors. First we
confirmed that generation of EBV-specific CTLs was possible from healthy donors,
and that  these  cells  could  proliferate,  secrete  cytokines  and  kill  autologous  LCL 
targets.  Next  the  effect  of  FK506  on  proliferation  and  cytokine  secretion  was 
determined to identify measures of suppression by and resistance to CN inhibitors.
EBV  CTL  lines  were  generated  from  healthy  donors  as  outlined  in  methods.  In 
response to weekly stimulation with irradiated autologous LCL, good proliferation of 
EBV-CTLs was observed as shown for two representative donors in Figure 33, where
expansion from 10
6 to 32/53x10
6 CTLs occurred over 5 weeks. As noted by other 
investigators (Wilkie, et al 2004), the proliferation rate of EBV-CTL lines is variable 
between donors with typical expansion of approximately 2-3 fold per week. Therefore, 
sufficient cells to perform functional assays can consistently be generated following 4-
5 weeks culture. Chapter four
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Figure 33: Expansion of EBV-CTLs in vitro. EBV-CTL proliferation in response to 
weekly  stimulation  with  autologous  LCL  was  measured  for  5  weeks.  Two 
representative donors are shown.
Supernatant  from  EBV-CTL  cultures  harvested  24  hours  post  stimulation  was
examined to assess secretion of both IL-2 and IFN-. We established that these EBV-
CTL lines secreted low or undetectable levels of IL-2, but high levels of IFN- that 
was easily measurable by both ELISA (data not shown) and ELISPOT (see Figure 34),
with over 9000 spot forming cells per 10
5 identified in two CTL lines tested. This IFN-
  secretion  was  shown  to  be  secreted  specifically  in  response  to  stimulation  with 
autologous LCL and not in response to stimulation with MHC-mismatched third party 
(allogeneic) LCL, demonstrating that CTLs generated using this protocol are MHC-
restricted.Chapter four
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Figure 34: IFN- secretion from EBV-CTL line. (a) IFN- secretion in response to 
stimulation with autologous or allogeneic LCL  was measured by ELISPOT. Wells 
tested in triplicate. 4 doubling dilutions of CTLs were tested from 4x10
4 to 5x10
3 per 
well, 3 doubling dilutions of PBMC tested from 2x10
5 to 5x10
4 per well both alone, or 
with either autologous/allogeneic LCL stimulators. One representative donor of three
is shown.
Finally, cytotoxicity assays were performed to confirm that killing by these EBV-CTL 
lines was EBV-specific and MHC restricted, examining cytotoxicity towards either 
autologous or allogeneic LCL targets. HSB-2 target cells were included to determine 
the level of LAK/NK-mediated killing by these lines. Figure 35 shows that EBV-CTL
lines are indeed MHC restricted, demonstrating high killing of autologous targets, with 
a range of between 40 and 60% of maximal release at effector:target ratios of 30:1. 
Killing of allogeneic LCL was low (consistently <10%) showing that the observed 
cytotoxicity was MHC restricted. The degree of HSB-2 lysis seen was generally low 
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but variable between donors, ranging from 5-45%, reflecting the low level of LAK/NK 
activity in the majority of CTL lines. Following establishment of a reliable protocol 
for expansion of EBV-specific T cells to generate EBV lines from healthy donors, the 
effect of introducing FK506 into culture conditions was examined.
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Figure 35: EBV-specific cytotoxicity of EBV-CTL lines. Killing of autologous or 
allogeneic LCL targets, or HSB-2 cells was measured by 
51Chromium release in a 
standard 4 hour assay. Mean and SEM shown (n=3). E:T = effector to target cell ratio.
4.3.2 Suppression of untransduced EBV-CTLs by calcineurin inhibitors
To confirm that EBV-CTL lines were suppressed by the addition of CN inhibitors, 
increasing concentrations of FK506 were added to culture conditions and the effect on 
proliferation and cytokine secretion was assessed. IFN- was chosen as a candidate 
end point for measurement to monitor suppression by CN inhibitors, due to both the 
high  level  of  secretion  observed  from  EBV-CTLs  following  stimulation,  and  the 
presence  of  NFAT  responsive  elements  in  the  promoter  region  of  the  IFN-  gene 
(Kiani, et al 2001). As NFAT is involved in regulation of IFN- expression, it was 
anticipated that addition of either CN inhibitor to UT EBV-CTL culture conditions 
would result in reduced IFN- secretion. Secretion of IFN- was assayed by ELISA 24 
hours after EBV-CTL stimulation in the presence of 0, 1 or 10ng/ml FK506. This Chapter four
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confirmed a dose dependent reduction in the level of IFN- secretion. When compared 
to secretion in the absence of FK506, a mean 24% secretion with 1ng/ml and 10% 
secretion with 10ng/ml was observed (see Figure 36). 
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Figure 36: IFN- secretion by EBV-CTLs is prevented by addition of FK506. Two 
EBV-CTL  lines  were  stimulated  with  autologous  LCL  in  the  presence  of 0,  1  or 
10ng/ml FK506. Secretion of IFN- was assessed after 24 hours by ELISA.
To assess the effect of CN inhibitors on EBV-CTL expansion, increasing doses of 
FK506  were  added  to  two  EBV-CTL  lines  at third  stimulation,  and  growth  was 
monitored for three further weeks. FK506 concentration was measured and found to 
have a half life of approximately 3 days in CTL cultures (data not shown). Therefore, 
FK506 was changed half weekly synchronous with half media and IL-2 change. As 
shown for IFN- production, a dose dependent reduction in proliferation was observed.
Compared to growth in the absence of FK506, EBV-CTL expansion was reduced to
66% in 0.1ng/ml, 20% in 1ng/ml, 7% in 5ng/ml and <5% in 10 or 20ng/ml FK506 (see 
Figure 37). 
These experiments confirm that EBV-CTL lines generated from healthy donors are 
indeed  susceptible  to  suppression  by  FK506  in  vitro,  which  is  measurable  by 
monitoring  both  cellular  proliferation  and  secretion  of  IFN-.  Therefore  these  end 
points were used to detect resistance to CN inhibitors conferred by transduction with
CN mutants.Chapter four
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Figure  37:  Proliferation  of  EBV-CTLs  during  in  vitro  culture  is  inhibited  by 
FK506. Two EBV-CTL  lines  were  established  and  increasing  concentrations  of 
FK506  were  added  from  stimulation  3  onwards  (indicated  by  arrow).  Cells  were 
counted and re-stimulated weekly. FK506 was changed half weekly. Proliferation of 
two representative donors is shown (panels a and b).Chapter four
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4.4 Transduction of EBV-CTL lines
4.4.1 Transduction of EBV-CTL lines with retroviral vectors
Following optimisation of generation of untransduced EBV-CTLs and demonstration 
of suppression by CN inhibitors, the optimal conditions for CTL transduction were
determined. Based on published data and previous experience in our laboratory, CTLs
were transduced with retroviral supernatants using Retronectin (RN) and spinfection
as  outlined  in  methods. This  was  performed  3-4  days  after  the  second  or  third 
stimulation with LCL, following the same protocol used for Jurkat transduction. This 
time point was chosen because it allows establishment of EBV-specificity of CTL 
lines  but  leaves  sufficient  time  to  assess  expansion  of  transduced  CTLs  over  the 
subsequent five weeks without exhaustion of the line (Wilkie, et al 2004). Several 
variables  were  investigated  to  maximise  transduction  efficiency,  including  virus
loading onto RN prior to addition of target cells, additional centrifugation on days 
subsequent to transduction, and performing two rounds of transduction on consecutive 
weeks. 
Previous  work  by  Quintas-Cardama  investigating  the  optimal  procedure  and 
conditions for RV transduction of T cells led to the following conclusions: pre-loading 
of RV onto RN prior to addition of T cells does not increase transduction efficiency, 
additional  spinoculation  on  two  consecutive  days  following  transduction  improves 
transduction  efficiency  and  spinoculation  at  room  temperature  or  higher  is  most 
effective (Quintas-Cardama, et al 2007). We therefore examined the effect of these 
alterations  to  our  transduction  protocol  in  two  EBV-CTL  lines.  Our  data  are  in 
agreement  with  Quintas-Cardama  regarding  pre-loading  of  RV  onto  RN,  with  no 
benefit  of  this  additional  step  observed  (Table 11a).  In  contrast,  we  observed  no 
increased  transduction  efficiency  when  further  spinoculations  were  performed 
following the initial procedure (Table 11b). There are several differences between our 
investigations  and  the  study  of  Quintas-Cardama  that  could  account  for  this 
discrepancy. Firstly, their study investigates gene transfer into T cells that are non-
specifically activated with PMA or CD3/CD28 beads, which results in activation of all 
T cells present, whereas we have generated and transduced EBV-specific cells only. It Chapter four
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is likely that a main factor limiting transduction efficiency into antigen specific T cells 
is the proportion of cells that are dividing during the period that infectious virus is 
present.  In  addition,  Quintas-Cardama  utilise  RV  pseudotyped  with  the  GALV 
envelope protein rather than RD114. GALV pseudotyped virus has a 13hr T1/2(Uckert, 
et al 2000) therefore additional manipulations 24hr post transduction when little viable 
virus is remaining would not be expected improve transduction efficiency. In contrast, 
RD114  pseudotyped  retroviruses  are  more  stable  at  37
o  with  a  T1/2  of  over  24hr 
(Uckert, et al 2000), therefore additional spinoculations might be anticipated to be 
more  effective.  However,  we  found  that  additional  spinoculation  with  RD114 
pseudotyped  virus  did  not  improve  transduction  efficiency  using  our  protocol.
Therefore we continued performing transduction with no pre-loading of RN, and no 
additional centrifugation steps.
Table 11: Optimisation of CTL transduction in two cell lines. (a) Effect of pre-
coating RN with SFG_GFP retrovirus before addition of CTLs and additional RV. (b) 
Effect  of  additional  spinfection.  Transduction  efficiencies  as  assessed  by  flow 
cytometry  for  GFP  performed  7  days  after  transduction  from  two  CTL  lines  are 
shown.
(a)
Sample Not pre-loaded RN pre-loaded
Donor 1 27% 26%
Donor 2 34% 34%
(b)
Sample Spun once Spun twice
Donor 1 58% 60%
Donor 2 62% 63%
Following  optimisation  of  the  transduction  protocol,  we  assessed  the  effect  of 
performing an additional  round of transduction one week after initial transduction. 
EBV-CTLs  were  transduced  with  a  variety  of  retroviral  vectors  either  once  only 
following  the  second  stimulation,  or  following  both  the  second  and  third  LCL 
stimulations. GFP expression increases for the first week after transduction and then 
stabilises. Transduction efficiency resulting from a single round of infection was 50-
65% (see Figure 38a). Performing a second round of transduction improved this to 70-Chapter four
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85%  (see  Figure 38b),  therefore  as  measured  by  the  proportion  of  cells  that  are
expressing the transgene a 20% increase was observed as a result of performing two 
rounds of transduction. 
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Figure 38: Increase in transduction efficiency with two compared to one round of 
transduction. Two EBV-CTL lines were transduced with retroviral vectors encoding 
GFP alone or with CN mutants A12, A22 or B30. GFP expression was measured by 
flow  cytometry  at  each  stimulation  following  either  one  (a)  or  two  rounds  (b)  of
transduction. Mean and SEM shown (n=2).Chapter four
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However, it was subsequently noted that CTLs undergoing two rounds of transduction 
proliferated  considerably  slower  than  those  transduced  once.  Over  three  weeks
following a single round of transduction, two CTL lines expanded between 128 and 
255 fold, whereas in the three weeks following two rounds of transduction the same
CTL  lines  expanded  40-70  fold  (see  Figure 39a  and  b).  There  are  two  likely
explanations for this observation: it is possible either that expression of a higher level 
of transgene is detrimental to the cells and could inhibit proliferation/lead to cell death, 
or that the additional manipulation involved in the transduction procedure itself has a 
negative effect on the cells. The former suggestion would also be expected to lead to a 
reduction in the overall proportion of transduced cells with time, as they would have a 
proliferative disadvantage compared to the untransduced cells within the same line. As 
this is not observed (Figure 38b), the possibility that CTLs are sensitive to increased 
manipulation in vitro may be more likely. This is confirmed by the observation that 
UT  cells  also  proliferate  more  slowly  after  two  rounds  of  mock  transduction. 
Therefore, since good transduction efficiency can be achieved by only one infection, 
in  further  experiments  EBV-CTLs  were  transduced  once  following  the  second 
stimulation, GFP expression was measured after 7 days and subsequent experiments
and monitoring were performed from the fourth stimulation onwards.Chapter four
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Figure  39:  EBV-CTL  proliferation  is  reduced  following  two  rounds  of 
transduction. Cell growth was monitored for three weeks following either one (a) or 
two (b) rounds of transduction with retroviral vectors encoding GFP alone or with the 
CN mutants shown. Mean and SEM shown (n=2).
4.4.2 Generation of stable retrovirus producer lines
Following optimisation  of  EBV-CTL  generation  and  transduction,  cell  lines  stably 
producing  RV  encoding  the  selected CN  mutants  were  generated. This  allows  the 
production of large volumes of consistently high titre RV supernatant. As illustrated in 
Figure 40, multiple transductions of the packaging cell line FLYRD18 were performedChapter four
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with  GALV  pseudotyped  CN  retrovirus.  This  resulted  in  a  bulk  population  of 
FLYRD18 cells, likely with several RV integrants per cell, expressing high levels of 
CN and GFP. These cells were FACS sorted to obtain those with the highest MFI and 
clonal populations were produced by limiting dilution (this procedure was performed 
by  Dr  Martin  Pule).  These  clones  were  assayed  flow  cytometrically  for  GFP 
expression  and  those  displaying  the  highest  MFI  were  selected.  Titration  of 
supernatants from these highly transduced cells allowed identification of those that 
produced  the  highest  titre  RV.  These  clones  were  selected  for  use  in  subsequent 
experiments.
Figure  40:  Schematic  illustration  of  high  titre  stable  retrovirus  producer  line 
generation. Multiple transductions of FLY-RD18 packaging cells were performed, 
followed by limiting dilution and selection of the highest GFP expressing cells.
Following generation of stable producer lines, supernatant was titred on 293T cells 
alongside transiently produced RV supernatant for comparison. As shown in Figure
41,  supernatant  from  stable  producer  cell  lines  contained  half  to  one  log  more
infectious  particles  per  millilitre  compared  to  virus  generated  using  a  standard 
transient method of production. Using a standard transduction procedure of 2ml RV 
supernatant per 0.5x10
6 CTLs, supernatants with a titre of ~6x10
5 as produced by 
these  stable  producer  lines  result  in  a  multiplicity  of  infection  of  2.5  infectious 
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particles per cell, compared with approximately 0.6 achieved using transient retroviral 
supernatant.
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Figure 41: Stable producer lines generate higher titre RV supernatant compared 
to transient methods. Transient retroviral supernatants and those produced by stable
retroviral producer lines were titred in parallel on 293T cells. Half to one log increase 
is seen from stable producer supernatants.
Following these optimisation experiments, the protocol for generation of EBV-CTLs, 
the  end  points  for  determining  sensitivity  to  CN  inhibitors  and  the  procedure  for 
transduction of EBV-CTLs were established. In addition, stable RV producing cell 
lines had been generated. Subsequently, the effect of transduction with CN mutants 
CNa12,  CNa22  and  CNb30  in  primary  EBV-CTL  lines  from  healthy  donors  was 
investigated.Chapter four
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4.5 Evaluation of CN mutants in primary EBV-CTL lines
4.5.1 Transduction of primary EBV-CTL lines with CN mutants
EBV-CTL lines were generated from five healthy donors and transduced after two 
stimulations  with  RV  supernatant  produced  from  FLYRD18  stable  producer  lines
encoding  GFP  alone  or  with  CNa12,  CNa22  or  CNb30  transgenes.  Transduction 
efficiency  was  assessed  by  flow  cytometry  to  determine  GFP  expression  7  days 
following infection. Transduction efficiencies of between 52 and 82% were seen for 
all 5 donors, with a similar proportion of transduced cells for all constructs, but an 
increased MFI observed with the SFG_GFP alone vector compared to vectors also 
containing CN mutants (see Table 12 and Figure 42). This is likely to be due to GFP
expression  being driven  by  viral  LTRs  in  the  control  construct,  but  following  a 
transgene utilising an IRES in the mCN test constructs, as translation from an IRES is 
less efficient than that driven directly by the LTR.
Table 12: Comparable transduction efficiency of five EBV-CTL lines transduced 
with CN mutants. GFP expression in CTL lines was assessed by flow cytometry 7 
days after transduction. Percent transduced cells is shown.
Donor GFP alone CNa12 CNa22 CNb30
1 54 52 56 63
2 56 68 53 65
3 77 75 81 82
4 63 66 64 73
5 68 60 60 74
Mean 64% 64% 63% 71%Chapter four
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(a)
(b)
Figure  42:  Light  and  UV  microscope  images  of  transduced  EBV-CTLs. (a) 
Transduced  with  SFG_CNb30_eGFP  and  (b)  SFG_eGFP  alone  control.  20x 
magnification.
Following  improved  resistance  in  Jurkat  cells  when  CNa  and  CNb  mutants  were 
expressed together, EBV-CTLs were also transduced with the bicistronic construct 
CNa12-CNb30. However, reduced transduction efficiency was observed when CTLs
were transduced with both genes compared to transduction with CNa or CNb alone. It 
is possible that this was due either to production of retroviral supernatant with a lower 
titre, or to lower expression of the eGFP reporter from the triple construct following 
two transgenes. The contribution of these factors is difficult to separate however, as 
expression  of  eGFP  is  the  parameter  used  to  titre  the  retroviral  preparations. 
Furthermore, cells transduced with the triple CNa_CNb_eGFP construct proliferated 
poorly following transduction (data not shown). It is possible that expression of both 
CN genes in primary EBV-CTLs leads to greatly increased CN expression, therefore Chapter four
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stimulation with autologous LCL results in amplified signalling to the nucleus leading 
to  activation  induced  cell  death.  Due  to  these  poor  initial  results  with  bicistronic 
constructs, transduction with both CN genes concurrently was not explored further.
4.5.2  Transduction  with  CN mutants  does  not  affect  proliferation or 
phenotype of CTL lines
To determine the effect of transduction with CN mutants on the characteristics of the 
cell population, the phenotype of the EBV-CTL lines was examined. Expression of 
cell surface markers was assessed by flow cytometry four days after stimulation 5. 
Expression  of  CD3/4,  CD3/8,  CD16/56,  CD3/16/56  and  CD25  were  unchanged 
between  transduced  and  untransduced  lines  (see  Figure 43a,  p=0.77,  two-way 
ANOVA), indicating that transduction and expression of the CNb30 transgene does 
not alter the CD4/CD8  subset distribution, NK/CIK content or activation status of 
EBV-CTL lines. In addition, the distribution of memory subsets was analysed and no 
difference was observed in the proportion of central memory, effector memory, naïve 
or  terminally  differentiated  cells  between  transduced  and  untransduced  CTLs  (see 
Figure 43b, p=0.984, two-way ANOVA). These results confirm that the phenotype of 
these EBV-CTL lines was predominantly CD8+, central or effector memory T cells,
and importantly that this was not affected by transduction with CN mutants.Chapter four
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Figure 43: Expression of phenotypic markers on EBV-CTLs is not affected by 
transduction with CNb30. (a) Four days following their 5
th stimulation, CTLs were 
analysed for surface expression of CD3, 4, 8, 16/56 and CD25 by flow cytometry. (b) 
Distribution of memory subsets in UT and CNb30 transduced CTL lines. CM=Central 
memory (CD45RO+, CD62L+), EM=Effector memory (CD45RO+, CD62L-), Naïve 
(CD45RO-, CD62L+), TD=Terminally differentiated (CD45RO-, CD62L-). Mean + 
SEM of 5 CTL lines shown.
EBV-CTL  lines  transduced  with  CN  mutants  were  cultured  in  the  absence  of 
immunosuppression to examine the effect of transduction on cell growth. Transduction 
was performed three days after the second stimulation, transduction efficiency was 
assessed one week later and cell growth monitored from stimulation four for three 
weeks. EBV-CTL lines proliferate well in vitro for approximately 7-8 stimulations, at 
which  point  senescence  generally  occurs  and  a  plateau  is  observed (Wilkie,  et  al
2004). Therefore, in vitro experiments were terminated at stimulation 7 to avoid this 
plateau  confounding  the  results  obtained.  No  significant  difference  was  observed 
between UT CTL expansion and those transduced with either GFP alone or any of the 
three CN mutants (see Figure 44). 85 fold expansion was observed for UT CTLs, and 
between 66 and 100 fold expansion for the transduced CTLs (p=0.96, expansion of all 
CTL  lines  compared  with  one-way  ANOVA).  These  results  demonstrate  that  no
proliferative  advantage  is  conferred  upon  EBV-CTLs  by  transduction  with  CN 
mutants, or any disadvantage as a result of a single transduction procedure.Chapter four
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Figure 44: Comparable expansion  of transduced and untransduced EBV-CTL 
lines  in  the  absence  of  CN  inhibitors. EBV-CTLs  were  transduced  between 
stimulations 2 and 3, and proliferation monitored for 3 weeks from stimulation 4. No 
significant  difference  between  the  proliferation  of  UT  and  transduced  CTLs  was 
observed. Mean and SEM shown (n=5).
As discussed in section 4.2, CN is a pivotal molecule involved in activation of T cells, 
therefore  raising  the  overall  level  of  expression  of  CN  by  transduction  with  CN 
mutants, may have the potential to allow inappropriate proliferation of the transduced 
cell. Our data on CTL expansion in response to LCL stimulation confirm that EBV-
CTLs transduced with CN mutants do not proliferate at a greater rate than UT EBV-
CTLs. Next, proliferation of transduced and UT CTLs in the absence of stimulation 
was examined to determine if transduced CTLs can proliferate autonomously without 
T  cell  receptor  stimulation.  Transduced  and  UT  CTLs  were  grown  for  four 
stimulations  as  normal,  receiving  weekly  challenge  with  autologous  LCL.  LCL 
stimulation  was  subsequently  withheld  and  CTL  proliferation monitored,  with  or 
without  continued  supplementation  with  exogenous  IL-2.  As  shown  in  Figure 45,
neither  UT  nor  EBV-CTLs transduced  with  SFG_CNb30_eGFP  were  able  to 
proliferate without autologous LCL stimulation, even with continued addition of IL-2. 
No difference in proliferation was observed between transduced and UT EBV-CTLs
when LCL stimulation was withheld (p=0.994 with IL-2 supplementation, p=0.991
with no IL-2, one-way ANOVA).Chapter four
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Figure 45: EBV-CTLs do not proliferate in the absence of LCL stimulation. (a) 
CTLs receiving stimulations 5 and 6 with autologous LCL expand as expected. No 
proliferation  is  observed  from the  same  EBV-CTL  lines  not  stimulated  with 
autologous LCL either with (b) or without (c) continued addition of exogenous IL-2.
No difference is seen between transduced and untransduced cell lines. Mean and SEM 
shown (n=5).
4.5.3 Transduction with CN mutants allows proliferation in the presence 
of FK506 or CsA
We next examined the ability of CN mutants to confer resistance to CN inhibitors. 
Transduction  efficiencies  of  60-80%  were  achieved  for  all  lines  and  therefore  no 
enrichment  of  the  transduced  CTLs  by  cell  sorting  was  performed.  Therapeutic 
concentrations of FK506 (10ng/ml) or CsA (200ng/ml) were added to CTL cultures at
the 4
th stimulation and cell expansion and expression of GFP was monitored at every 
stimulation thereafter. Chapter four
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4.5.3.1  CN  mutant  transduced  CTLs  show  a  selective  growth  advantage  in  the 
presence of CN inhibitors
It was anticipated that in the presence of CN inhibitors, cells transduced with mutants 
conferring resistance would continue to proliferate whereas untransduced cells would 
not. Therefore, within a transduced line the non-transduced cells would be suppressed 
whereas the transduced fraction would proliferate, leading to an enrichment of GFP 
positive  cells.  This  was  indeed  observed:  in  the  presence  of  FK506  the  mean 
proportion of CTLs expressing GFP in CNa12 transduced cultures increased from 64 
to 82% (p=0.0018) and in CNb30 transduced cultures from 71 to 90% (p=0.01). In the 
presence of CsA, GFP expression in CNa22 transduced cells rose from 63 to 76% (n/s, 
p=0.1) and in CNb30 transduced cultures from 71 to 91% (p=0.01, GFP expression 
compared between stimulations 4 and 7, all assessed using paired t test). These data 
indicate that transduction with our selected CN mutants confers a selective growth
advantage in the presence of CN inhibitors. In contrast, expression of GFP in CTL 
lines grown with no immunosuppression remained stable throughout the study period 
for GFP, CNa12 and CNb30 transduced cells, indicating that transduced CTLs do not 
have an intrinsic growth advantage over non-transduced cells. However, a drop in the 
number of GFP expressing cells was observed in CNa22 transduced CTL lines in the 
absence of immunosuppression (see Figure 46). Interestingly, mutant CNa22 allowed 
the highest level of IL-2 secretion from Jurkat cells, and also the highest degree of 
hyper-activation  upon  stimulation  in  our  previous  cell  line  work.  In  line  with  the 
suggestion that proliferation of EBV-CTLs transduced with bicistonic constructs is 
poor  due  to  the  induction  of  activation  induced  cell  death,  it  is  possible  that 
transduction with this active CN mutant also leads to induction of activation induced 
cell  death  in  primary  EBV-CTLs.  This  would  result  in  the  observed  reduction  in 
proliferation and gradual drop in expression of CNa22 where there is no selective 
advantage due to the presence of CsA.Chapter four
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Figure 46: GFP expression in transduced EBV-CTL lines grown in the presence 
or absence of CN inhibitors. GFP expression was monitored by flow cytometry at 
each stimulation for all CTL lines (a) in the absence of CN inhibitors, (b) when grown 
with 10ng/ml FK506, or (c) when grown in 200ng/ml CsA. Mean and SEM shown 
(n=5).
4.5.3.2  Transduction  of  EBV-CTLs  with  CN  mutants  allows  proliferation  in  the 
presence of CN inhibitors
Proliferation of transduced and UT EBV-CTL lines in the presence or absence of CN 
inhibitors was monitored from stimulation four to seven. An 85 fold expansion of UT
EBV-CTLs was observed in this time in the absence of CN inhibitors. Addition of 
either 10ng/ml FK506 or 200ng/ml CsA to EBV-CTLs markedly inhibited growth of 
both untransduced and GFP transduced lines (Figure 47(i) and (ii), p=0.001, one-way 
ANOVA comparing expansion in absence of IS to expansion with FK506/CsA). 
In contrast, as shown in Figure 47(iii), CNa12 transduced CTLs were able to expand in 
the presence of FK506 (p=0.216) but not CsA (p=0.001). CNa22 transduced CTLs
grew in the presence of CsA (p=>0.999) but not FK506 (p=0.004) (Figure 47(iv)) and 
CNb30 transduced CTLs were able to proliferate in the presence of either CN inhibitor 
(FK506  p=0.649,  CsA  p=>0.999,  all  assessed  by  one-way  ANOVA  compared  to 
expansion of UT CTL in absence of IS. See Figure 47(v)). When compared to 85-fold 
expansion of UT CTLs in the absence of immunosuppression, expansion of CNa12 
CTLs in FK506 was 53% (44 fold), expansion of CNa22 CTLs in CsA was 106% (90
fold) and proliferation of CNb30 CTLs was both 67% in FK506 (57 fold) and 88% in 
CsA (75 fold).Chapter four
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Figure 47: Transduction of EBV-CTLs with CN mutants allows proliferation in 
the presence of FK506/CsA. EBV-CTLs were transduced after stimulation 2. CN 
inhibitors were added at stimulation 4 and CTL growth was monitored for 3 weeks 
(Mean and SEM shown, n=5). (i) Untransduced CTLs are suppressed by either FK506 
or by CsA.  (ii)  GFP transduced CTLs are suppressed  by either  CN  inhibitor.  (iii) 
CNa12 transduced CTLs proliferate when grown in FK506 but not CsA. (iv) CNa22 
transduced  CTLs  proliferate  in  CsA  but  not  FK506.  (v)  CNb30  transduced  CTLs
proliferate in either FK506 or CsA.
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These  results  were  confirmed  by  performing 
3H-thymidine  uptake  assays  after 
stimulation 6, following three weeks growth in CN inhibitors. In the absence of CN 
inhibitors,  proliferation  of  all  transduced  CTLs  was  comparable  to  UT  CTLs
(p=0.876, one-way ANOVA). As shown in Figure 48, the observed resistance profile 
in this assay was similar to that seen above. Untransduced or GFP transduced CTLs
showed reduced proliferation in the presence of either 10ng/ml FK506 or 200ng/ml 
CsA, CNa12 transduced CTLs were able to proliferate in the presence of FK506 but 
not  CsA  and  CNa22  showed  the  converse  pattern. Once  again,  transduction  with 
CNb30 enabled CTL proliferation in the presence of either FK506 or CsA. Compared 
to  proliferation  of  UT  CTLs  in  the  absence  of  immunosuppression,  CNa12  CTLs
proliferated  86%  in  FK506  (p=>0.999),  CNa22  CTLs  proliferated  103%  in  CsA 
(p=>0.999) and CNb30 CTLs proliferated both 83% in FK506 (p=0.996) and 86% in 
CsA (p=0.999, all assessed by one-way ANOVA).
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Figure 48:  Transduction  with  CN mutants allows 
3H-thymidine uptake in  the 
presence  of  FK506/CsA. A 
3H-thymidine  uptake  assay  was  performed  following 
three weeks of growth in CN inhibitors. Mean and SEM shown (n=5).Chapter four
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Furthermore,  the  ability  of  CNb30  transduced  EBV-CTLs  to  proliferate  in 
supratherapeutic  concentrations  of  CN  inhibitors was  assessed in  two  donors.  UT, 
GFP or CNb30 transduced CTLs were cultured for two weeks in 40ng/ml FK506 or 
800ng/ml CsA, a four fold increase compared to the normal target dose. Once again, 
proliferation was assessed by 
3H-thymidine uptake assay and these results confirmed 
that CNb30 transduced EBV-CTLs are capable of proliferation in increased doses of 
CN  inhibitors  (see  Figure 49).  Compared  to  UT  CTL  proliferation  without  CN
inhibitors,  CNb30  transduced  CTL  proliferation  from  two  cell  lines  was  117%  in 
FK506 and 60% in CsA.
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Figure  49:  Transduction  with  CNb30  allows  proliferation  in  supratherapeutic 
doses  of  FK506/CsA. Proliferation  of  CTLs  was  assessed  by  thymidine  uptake 
following two weeks of culture in the presence of supratherapeutic concentrations of 
CN inhibitors. FK506 40ng/ml, CsA 800ng/ml. Mean and SEM shown (n=2).
These  results  confirm  that  transduction  of  EBV-CTLs  with  CN  mutants  confers 
resistance to suppression of proliferation by CN inhibitors. We have generated one 
mutant  that  confers  resistance  to  FK506  but  not  CsA  (CNa12),  one  that  confers 
resistance to CsA but not FK506 (CNa22) and one that confers resistance to both CN 
inhibitors (CNb30).Chapter four
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4.5.4 Transduction with CN mutants allows secretion of IFN- in the 
presence of FK506 or CsA
To  further  examine  the  functionality  of  EBV-CTL  lines  transduced  with  our  CN 
mutants,  the  ability  of  transduced  CTLs  to  secrete  cytokines  in  the  presence  of 
immunosuppressive agents was assessed. As shown previously, EBV-CTLs produce 
high  levels  of  IFN-  in  response  to  stimulation  with  autologous  LCL  and  we 
confirmed that IFN- secretion from transduced cells in the absence of CN inhibitors is 
comparable to that from UT EBV-CTLs (p=0.984, one-way ANOVA). However this 
is abrogated by the addition of either FK506 or CsA. Following two weeks growth in
CN inhibitors, culture supernatant was harvested for analysis of IFN- secretion by 
ELISA. 
IFN-  secretion  by  UT  or  GFP  transduced  EBV-CTLs  was  abrogated  by 10ng/ml 
FK506 or 200ng/ml CsA. In contrast, as shown in Figure 50, EBV-CTLs transduced
with CNa12 were able to secrete IFN- in the presence of FK506 (mean 66% secretion 
compared to untransduced CTLs in the absence of CN inhibitors (p=0.914)), but not 
CsA (mean 17% secretion, p=0.062). CNa22 transduced CTLs secreted IFN- in the 
presence of CsA (mean 66%, p=0.917), but not FK506 (mean 16%, p=0.059). As 
expected, CTLs transduced with CNb30 were able to secrete IFN- in the presence of 
either  FK506  (mean  92%,  p=>0.999)  or  CsA  (mean  100%,  p=>0.999,  one-way 
ANOVA).Chapter four
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Figure  50:  CN  transduced  EBV-CTLs  secrete  IFN-  in  the  presence  of 
FK506/CsA. Transduced and UT EBV-CTLs were grown in the presence or absence 
of  FK506/CsA  for  2  weeks.  IFN-  secretion  was  measured  by  ELISA  24  hours 
following the 6
th stimulation. Mean and SEM shown (n=5).
4.5.5 Effect of transduction on EBV-CTL cytotoxicity
As  discussed  in  section  4.2,  discrepancies  are  present  in  the  published  literature 
regarding the effect of CN inhibitors on CTL cytotoxicity. Therefore, to determine the 
effect of transduction with either GFP alone or CNb30 on the cytotoxicity of EBV-
CTLs,  killing  of  LCL  targets  by  transduced  and  untransduced  EBV-CTLs was 
examined. Subsequently, the effect of addition of CN inhibitors to the culture both
prior to and during the cytotoxicity assay was examined.
These results demonstrated that transduction of EBV-CTLs with either GFP alone or 
CNb30  had no effect on  cytotoxicity towards  autologous  LCL,  allogeneic  LCL or 
HSB-2 target cells (Figure 51, p=0.821, all groups compared by one-way ANOVA).
Specific killing of autologous LCL of between 25 and 30%, 5-7% killing of allogeneic 
LCL and 22-26% killing of HSB-2 cells was observed by both UT and transduced Chapter four
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CTLs for  all  lines.  The  modest  level of  cytotoxicity against  autologous  LCL  may 
reflect the early transduction procedure which was performed between stimulations 2 
and  3  in  order  to  complete  the  planned  assays  prior  to  the  expected  proliferation 
plateau after stimulation 7. Likewise, the early addition of high concentrations of IL-2 
(100U/ml) to these CTL lines is likely to contribute to higher non-specific kill of HSB-
2 targets. Nonetheless, it is clear from these experiments that cytotoxicity towards all 
targets was not affected by transduction with either GFP or CNb30.
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Figure 51: Cytotoxicity of EBV-CTLs is unaffected by transduction with CNb30 
or GFP. 4 hour 
51Chromium release killing assay was performed after stimulation 5 
with autologous LCL, allogeneic LCL and HSB-2 targets at an E:T ratio of 30:1. Mean 
and SEM shown (n=5).Chapter four
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4.5.6 Effect of CN inhibitors on EBV-CTL cytotoxicity
To  determine  the  effect  of  CN  inhibitors  on  cytotoxicity  of  EBV-CTLs,  10ng/ml 
FK506  or  200ng/ml  CsA  were  added  to  culture  conditions  at  stimulation  4. 
Cytotoxicity assays were performed on the day of the 6
th or 7
th stimulation, when cells 
had been growing for either two or three weeks in these CN inhibitors. FK506 or CsA 
were also included in the cytotoxicity assay. As shown in Figure 52, in our hands, 
prior growth in CN inhibitors and addition of these to the cytotoxicity assay had no 
effect on killing of target cells by EBV-CTLs. Lysis of autologous LCL was 24-34% 
by both transduced and UT CTLs and was comparable with or without CN inhibitors. 
There  were  no  significant  differences  as  a  result  of  CN  inhibitor  addition  (UT 
p=0.841,  GFP  p=0.728  and  CNb30  p=0.9,  both  transduction  and  addition  of  IS 
compared by two-way ANOVA). Lysis of allogeneic LCL was 3-10% and lysis of 
HSB-2 cells was 22-33% for all conditions.
These data confirm that cytotoxicity of EBV-CTLs is not affected by transduction with 
CN mutants. Furthermore, in a standard 4 hour chromium release assay, no difference 
was detected in cytotoxicity of CTL lines as a result of CN inhibitor addition.Chapter four
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Figure 52: Addition of CN inhibitors does not affect cytotoxicity of transduced or 
untransduced EBV-CTLs. (i) UT (ii) GFP transduced and (iii) CNb30 transduced 
EBV-CTLs  were  grown  without  CN  inhibitors  (grey  bars),  with  10ng/ml  FK506 
(yellow bars) or with 200ng/ml CsA (blue bars) for 2-3 weeks prior to performing a 
cytotoxicity assay against autologous LCL, allogeneic LCL and HSB-2 targets. Mean 
and SEM at an E:T ratio of 30:1 are shown (n=5).Chapter four
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4.6 Conclusions
We have established a protocol for the efficient generation and transduction of EBV-
CTL lines with CN mutants. As previously reported, EBV-specific CTLs can routinely 
be generated from peripheral blood samples of healthy donors and transduced with a 
typical efficiency of 50-80% (Quintas-Cardama, et al 2007, Wilkie, et al 2004). CTLs
are not adversely affected by this procedure and subsequently continue to proliferate 
as normal. Importantly, we have confirmed that transduction with CN mutants does 
not lead to hyperactivation in terms of increased proliferation or IFN- secretion from 
transduced cells, and that these lines remain dependent on stimulation with specific 
antigen  for  continued  growth.  This  confirms  that  raised  intracellular  CN  does  not 
allow activation in the absence of TCR stimulation, or enhanced activation responses 
upon stimulation. No aberrant proliferation or cytokine secretion was observed from 
transduced EBV-CTLs.
Proliferation of UT EBV-CTL lines is inhibited by addition of either FK506 or CsA to 
cultures. In contrast, EBV-CTL lines transduced with our selected CN mutants retain 
the ability to proliferate in the presence of the appropriate CN inhibitor. We have 
tested three CN mutants and shown that CTLs transduced with CNa12 proliferate in 
the presence of FK506, those transduced with CNa22 proliferate despite the addition 
of  CsA,  and  those  transduced  with  CNb30  proliferate  as  normal  with  either  CN 
inhibitor. This was demonstrated by monitoring cellular expansion in CN inhibitors 
over a three week culture period, and confirmed by performing a 
3H-thymidine uptake 
proliferation assay. This confirmed a selective growth advantage to transduced CTLs
in the presence of CN inhibitors, leading to enrichment of transduced CTLs within 
cultures.
Furthermore, we have examined the functionality of these transduced EBV-CTLs to 
confirm that they retain the ability to secrete the important Th1 cytokine IFN- in the 
presence of CN inhibitors. UT EBV-CTLs secrete high levels of IFN- in response to 
stimulation with autologous LCL, but this secretion is sensitive to suppression with 
FK506/CsA and is abrogated by their addition. Analogous to our data on proliferation, 
we have shown that EBV-CTLs transduced with our CN mutants are also resistant to Chapter four
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suppression of IFN- secretion, and continue to secrete normal levels of this cytokine 
in the presence of FK506 (CNa12), CsA (CNa22), or both (CNb30). 
Finally, we examined the effect both of CN transduction and addition of CN inhibitors 
on  the  cytotoxicity  of  EBV-CTLs.  We  have  demonstrated  that  transduction  with 
CNb30 has no effect on killing of autologous LCL, allogeneic LCLs or HSB-2 target 
cells, and also that the presence of CN inhibitors does not affect cytotoxicity. This is in 
contrast  to  some  previously  published  studies  regarding  cytotoxicity (Zhan,  et  al
2003), however in our hands 2 weeks of prior culture in CN inhibitors and inclusion of 
these  in  the  killing  assay  did  not  lead  to  any  reduction  in  cytotoxicity  for  UT  or 
transduced CTL lines. Previous studies of CTL cytotoxicity have identified both CN 
dependant and independent cytotoxicity in a murine CTL clone (Kataoka and Nagai 
2000). This may reflect the use of both FasL and cytolytic granule killing pathways by 
CTLs.  These  mechanisms  were  further  elucidated  by  He  and  Ostergaard, 
demonstrating differential regulation of early FasL expression, late FasL expression 
and  perforin/granzyme  degranulation  in  murine  alloreactive  CD8+  clones (He  and 
Ostergaard 2007). Work by Rogers et al suggests that the mechanism for induction of 
FasL cytotoxicity in CTLs contains two synergistic pathways, one sensitive and one 
insensitive to CsA, but that overall cytotoxicity is not affected by the presence of CsA
(Rogers, et al 1997). A detrimental effect of CN inhibitors on CTL cytotoxicity was 
not  observed  here,  however  it  remains  possible  that  alternative  or  more  sensitive 
assays  may  detect  such  differences.  Given  the  restoration  of  other  tested  CN 
dependent  mechanisms  such  as  proliferation  and  IFN-  secretion  in  CN  mutant 
transduced  CTLs,  even  if  this  was  the  case  it  is  likely  that  any  suppression  of 
cytotoxicity by CN inhibitors would also be circumvented.
Taken  together,  these  data  confirm  that  transduction  of  EBV-CTL  lines  with  CN 
mutants can confer resistance to suppression by CN inhibitors. We show restoration of 
the  cellular  events  that  are  dependent  on  intact  CN  signalling,  including  cell 
proliferation  and  secretion  of  IFN-.  No  significant  difference  was  observed  in
comparison of transduced CTL proliferation in the presence of FK506/CsA  to UT 
EBV-CTL proliferation in the absence of CN inhibitors. This was also the case for 
IFN- secretion: transduced CTLs secrete normal levels of IFN- in FK506/CsA when Chapter four
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compared to UT CTLs without CN inhibitors. Thus, we have generated EBV-CTLs
that  appear  to  function  as  normal  despite  the  presence  of  therapeutic  doses  of 
FK506/CsA in vitro. Indeed, expression of CN mutants enabled CTLs to proliferate in 
levels  of  CN  inhibitors  well  above  the  therapeutic  range. This  approach  could 
represent  a  considerable  advance  for  the  prophylaxis/treatment  of  PTLD  arising 
following solid organ transplantation, by enabling transfer of EBV-specific immunity 
without withdrawal of IS, and the ability to render T cells resistant to CN inhibitors 
has wider implications in the application of adoptive immunotherapy.
The  generation  of  mutants  that  confer  different  profiles  of  resistance  could  be 
beneficial in a clinical setting. EBV-CTLs that are resistant to one CN inhibitor remain 
sensitive to suppression with the alternative should an adverse event occur. This would 
allow temporary control rather than permanent deletion of infused cells. For example, 
inflammatory  reactions  have  been  documented  at  sites  of  bulky  disease  following 
immunotherapy  and  such  events  could  be  controlled  by  administration  of  the  CN 
inhibitor  the  CTLs  are  not  resistant  to.  Conversely,  administration  of  CNb30 
transduced EBV-CTLs allows the clinician to choose their preferred CN inhibitor with 
no negative influence on the efficacy of CTL therapy. An additional benefit of CNb30 
over CNa12/22 with regard to vector design is its small size. At approximately 500bp, 
CNb30 could easily be co-expressed with additional genes that may be desirable. For 
example, expression of a suicide gene such as iCasp9 may be required to allay safety 
concerns,  a  cytokine  gene  (IL-2/IL-15)  to  enhance  function,  or  a  conventional  or 
chimaeric T cell receptor to re-direct EBV-CTLs towards tumour antigens are possible 
combinatorial applications.
In light of these considerations, CNb30 was pursued as our preferred mutant in studies 
using a small animal model to demonstrate functionality in the presence of therapeutic 
doses of CN inhibitors in vivo.Chapter four
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4.7 General conclusions
 EBV-CTL lines generated from peripheral blood samples of healthy donors
can be efficiently transduced with RV vectors containing CN mutants.
 Stably transduced retrovirus producer lines encoding CNa12, CNa22, CNb30 
and GFP have been generated.
 Transduction of EBV-CTL lines with CN mutants was shown to have no effect 
on phenotype or function in the absence of CN inhibitors.
 Transduced EBV-CTL lines are rendered resistant to FK506, CsA or both CN 
inhibitors enabling them to proliferate, secrete IFN- and lyse EBV infected 
targets in the presence of these drugs.Chapter five
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5.1 Aims
 To establish a murine model of PTLD development.
 To establish and optimise a Luciferase imaging system for monitoring tumour 
development.
 To  examine  the  efficacy  of  untransduced  EBV-CTLs as  treatment  and 
prophylaxis for PTLD in vivo.
 To assess the effect of CN inhibitors on untransduced or CNb30 transduced 
EBV-CTL activity in vivo.
5.2 Introduction
Following demonstration  that  EBV-CTLs transduced  with  CN  mutants  retain  their 
function in vitro in the presence of CN inhibitors, we wished to demonstrate whether 
this approach would enable CTLs to function in the face of these drugs in vivo prior to 
scale up and planning of clinical trials. As discussed in section 1.6.2, the SCID mouse 
model of PTLD has been widely used to study PTLD development and treatment and 
was therefore utilised for this purpose. Lacerda et al have shown that either i.p. or i.v. 
administration  of  autologous  EBV-CTLs  resulted  in  either  delayed  progression  or 
complete  regression  of  tumours (Lacerda,  et  al  1996).  This  model  has  also  been 
employed by several other groups to examine anti-tumour CTL activity (Foster, et al
2008, Savoldo, et al 2007). 
Our department has previously generated and maintains a breeding colony of triple 
knockout  -chain
-/-/RAG2
-/-/C5
-/-  SCID  mice (3KO)  which  were  used  for  these 
investigations. The mouse was produced to  provide an appropriate model for 
studying reconstitution of the haematopoietic system. The common -chain is integral Chapter five
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in cytokine signalling through IL-2, 4, 7, 9 and 15 and plays an important role in 
lymphoid development, the absence of which in humans results in X-linked severe 
combined  immunodeficiency.  The  murine  homozygous  mutant  -chain  phenotype 
results  in  both  abnormal  lymphopoiesis  and  dysfunction  of  residual  T  cells. 
Importantly,  likely  due  to  absent  IL-15  signalling,  -chain  knockout  mice  lack 
functional NK cells, the activity of which poses a barrier to modelling immunotherapy. 
The absence of RAG2 recombinase activity prevents rearrangement of TCR and BCR 
resulting in a lack of T and B lymphocytes. Therefore double knockout mice have no 
T, B or NK cells (Goldman, et al 1998). In addition, back-crossing of these mice onto 
the naturally C5 deficient A/J strain results in the 3KO model, with additional defects 
in innate immunity which enhances human cell engraftment (M. Blundell, personal 
communication).  3KO  are  entirely  devoid  of  T,  B  and  NK  cells,  therefore  these 
animals must be maintained in individually ventilated cages (IVCs) with sterile air, 
food, water and bedding and handled under sterile conditions. As this strain lacks T, B 
and NK cells it is able to accept human xenografts. Therefore in contrast to CB17 
SCID mice, no NK depletion is required prior to CTL infusion (Wagar, et al 2000). 
We  felt  that  this  represented  a  significant  advantage  over  the  Lacerda  model  and 
therefore have developed a similar PTLD model in 3KO mice to allow in vivo testing 
of CNb30 transduced EBV-CTL activity.
In  addition  we  have  established  and  optimised  bioluminescent  imaging  using  the 
Xenogen  IVIS  system  to  monitor  tumour  development.  Physical  measurement  of 
tumours using callipers has been the end point for previous models of PTLD, however 
this is a subjective method with the potential for considerable inter-operator variation
and  bias.  Bioluminescent  imaging  utilising  Luciferase  expression  represents  a 
powerful method by which cells can be tracked or monitored, the use of which is 
rapidly increasing. Several recent studies have used bioluminescence to monitor both 
tumour  cells and adoptively transferred T cells  (Foster, et al 2008, Savoldo,  et al
2007), and we have used this method to assess tumour progression in our model.
In order to examine the effect of CN mutant transduction on EBV-CTL efficacy in 
vivo, correct dosing to achieve therapeutic levels of CN inhibitors in the animals is 
necessary. Various routes, doses and formulations of administration have been utilised Chapter five
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in the published literature, including i.p. injection, i.v. injection, gavage and osmotic 
pumps (Lopes, et al 2008, McAlister, et al 1999, Medyouf, et al 2007, Yang, et al
2002). These publications have generally studied the effect of a particular dose of drug 
without  confirming  the  resulting  circulatory  concentration.  In  contrast,  we  have 
attempted to determine the appropriate dose required to produce a therapeutic blood 
concentration. 
In order to progress towards treatment of PTLD patients with CN mutant transduced 
CTLs, testing of this protocol in vivo is an essential step. Establishment of the PTLD 
model,  treatment  of  these  tumours  with  EBV-CTLs,  imaging  and  dosing  of  the 
animals with CN inhibitors are all critical elements of this process. We have attempted 
to optimise each of these elements in our studies below.
5.3 Establishing murine model of PTLD development
5.3.1 Subcutaneous engraftment of human LCL in 3KO mice
To  allow  accurate  planning  of  subsequent  experiments,  reliable  development  of 
tumours at a consistent time point is desirable. LCL from six donors were examined 
for the ability to produce tumours in SCID mice. 10
7 LCL in matrigel were injected 
s.c. and the animals monitored three times weekly for up to 8 weeks. Three 3KO mice 
were  evaluated  for  each  line  to  assess  the  consistency  of  kinetics  of  tumour 
development. This resulted in the detection of palpable tumours generated from the 
LCL of all but one donor (see Table 13). Chapter five
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Table 13: Development of subcutaneous LCL tumours from 5 of 6 donors
Donor Number 
of animals
Tumour 
development?
Average  time 
(days) Range
A 3 Yes 21 20-22
B 2 No - -
C 2 Yes 10 10
D 2 Yes 13 10-16
E 3 Yes 7 7
F 2 Yes 10 10
These  results  show  that  in  5  evaluable  LCL  lines,  development  of  subcutaneous 
tumours is both reliable and showed consistent kinetics, with tumours from the same 
donor appearing in different animals within a window of a few days. Tumour samples 
were  sectioned  and  stained.  Haematoxylin  and  eosin  (H&E)  stains (Figure 53a)
showed the tumour to be histologically similar to human PTLD with the appearance of 
a  diffuse  large  B-cell  lymphoma  (work  performed  by  Dr.  Neil  Sebire,  consultant 
histopathologist,  GOSH).  Staining  with  a  monoclonal  antibody  reactive  to  human 
CD20  showed  that  the  tumour  is  composed  of  human  CD20  positive  B  cells, 
confirming that the tumour develops from the subcutaneously injected human LCL 
(Figure 53b).
  
Figure 53: Staining of excised subcutaneous tumour demonstrates LCL origin.
Tumour  excised  from  SCID  mouse  10  days  after  LCL  injection.  (a)  200x 
magnification  of  H&E  stain.  (b)  100x  magnification  of  human  CD20  monoclonal 
antibody staining.
b aChapter five
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5.4 Luciferase imaging of tumours in vivo
Following confirmation that subcutaneous injection of LCL induces formation of B 
cell  tumours  in  3KO  mice,  we  focussed  on  optimising  tumour  imaging  using 
bioluminescence.  Using  the  IVIS  imaging  system  to  detect  light  output  following 
intraperitoneal (i.p.) injection of D-Luciferin, the amount of Luciferase expression can 
be measured as a surrogate for tumour size. 
5.4.1 Transduction of LCL with FLuc
LCL from three donors were transduced with an SFG retroviral vector encoding green-
shifted Firefly Luciferase (FLuc), and one week after transduction, LCL were FACS 
sorted based on expression of the eBFP reporter gene, to select for transduced cells. 
Figure 54 shows FLuc-eBFP transduction and FACS sorting of three donor LCL lines.
10
7 sorted FLuc transduced LCL were injected subcutaneously in matrigel into 3KO 
animals to optimise imaging of the LCL population in vivo. Chapter five
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Figure 54: Transduction of LCL lines from 3 donors with FLuc. Expression of 
eBFP was assessed before and after FACS sorting.
Green-shifted  FLuc  contains  mutations  at  the  following  positions:
V241I/G246A/F250S  (Branchini,  et  al  2007),  which  may  facilitate  conformational 
changes of the enzyme and in addition may increase the hydrophobicity of the emitter 
site, resulting in light emission at 544nm rather than 558nm. This is advantageous as it 
can be combined with red-shifted FLuc which emits at 612nm and the two enzymes 
imaged  together  with  green  and  red  filters,  therefore  two  cell  populations  can  be 
imaged following injection of a single substrate. In contrast, transduction of one cell 
population with FLuc and another with RLuc requires administration of two different 
substrates (D-Luciferin and coelenterazine respectively) and separate imaging. Thus, 
potentially  the  use  of  red  and  green-shifted  FLuc  should  allow  single  substrate 
imaging and detection of both transduced LCLs and CTLs in the future. However, for 
our work to date, a single population of green-FLuc transduced LCL was imaged. 
Transduced 
pre-sort
Transduced 
post-sort
Donor D
Untransduced
Donor E
91% 70%
53% 88%
95% 16%
Donor F
FSC
eBFPChapter five
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Figure 55: IVIS imaging system. (a) Induction chamber, (b) anaesthesia control and 
(c) imaging chamber are indicated.
5.4.2 Imaging in IVIS system
To  carry  out  imaging  of  mice  injected  with  FLuc  expressing  cells,  anaesthesia  is 
induced by inhalation of 2% isofluorane and oxygen in the induction chamber. The 
imaging chamber contains three outlets to maintain anaesthesia during imaging (see 
Figure 55).  The  terms  of  project  licence  PPL70_5249,  under  which  these
investigations are carried out, stipulates that animals can be monitored in this way for 
up to 60 minutes before recovery individually in warmed chambers.
a
b
cChapter five
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Figure 56: Example of imaging animals using IVIS system. Three 3KO mice were 
injected subcutaneously with 10
7 FLuc transduced LCL and bioluminescent imaging 
performed after 12 days. The region of interest was identified around each tumour and 
the light emission from that area quantified.
An example of output from the IVIS imaging system is shown in Figure 56. A light
photograph of the animals is captured and merged with the light emission image to 
allow identification of the area of interest. A region of interest (ROI) is delineated 
around the tumour, and the number of counts per second emitted from that area can be 
calculated. As a result of high FLuc expression in sorted LCL, the brightness of signal 
from FLuc and low light emission from normal tissues, negligible background and 
clear signal regions can be identified in these images.
5.4.3 Timing of D-luciferin injection
Following injection of the Luciferase substrate into the peritoneum of an animal, D-
luciferin is  absorbed  into  the circulation and transported  to  the site  of  the tumour 
where it is catalysed by  Luciferase to produce light. However, in addition  to this, 
luciferin is metabolised by the liver and excreted by the kidneys of the mouse (Berger, 
et al 2008b). Therefore, following an increase in signal as Luciferin is absorbed and Chapter five
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the  circulatory  concentration  gradually  rises,  the  substrate  is  metabolised,  blood 
concentration drops and the light emitted plateaus then declines. Breakdown of D-
luciferin is therefore affected by the metabolic rate of the mouse which introduces 
additional practical considerations for imaging. As can be seen in Figure 57a, injection
of D-luciferin into anaesthetised mice leads to a gradual rise in signal, which then 
plateaus approximately 25-35 minutes  following injection.  In contrast,  injection  of 
substrate into a conscious mouse followed by induction of anaesthesia and imaging 
leads to a much more rapid rise, plateau and fall in signal, such that the plateau has 
passed upon imaging at 15 minutes (Figure 57b), reflecting the increased metabolic
rate when the mouse is conscious. 
Figure 57: Kinetics of FLuc signal following substrate administration. The same 
animal was imaged after administration when (a) anaesthetised or (b) awake. When 
anaesthetised, signal rises for 25 minutes, plateaus for approximately 10 minutes and 
drops slowly. When awake, plateau occurs prior to imaging from 14 minutes onwards.
0
20000
40000
60000
80000
100000
120000
140000
00:02:26 00:06:35 00:10:30 00:14:24 00:18:19 00:22:15 00:28:29 00:32:24 00:36:19
C
P
S
0
20000
40000
60000
80000
100000
120000
140000
00:02:15 00:06:05 00:10:25 00:14:07 00:17:20 00:21:15 00:25:09 00:31:05
C
P
S
(a)
(b)
Time since Luc injectionChapter five
_____________________________________________________________________
183
These  data  highlight  the  need  for  consistency  of  protocol. Administration  of  D-
luciferin substrate following anaesthesia allows monitoring of the rise, plateau and fall 
of  signal  as  the  substrate  is  absorbed  and  metabolised.  Although  the  time  of 
anaesthesia is increased using this method, consistent results can be reliably obtained 
therefore this protocol was used throughout subsequent experiments.
5.4.4 Consistent expression of Luciferase from LCL
When monitoring biological processes based on  expression of a transgene such as 
Luciferase, an important consideration is the continued and stable expression of the 
reporter gene. Fluctuations in the level of FLuc expression from LCL in vivo would 
result in signal changes and be interpreted as changes in tumour size; therefore it is 
necessary to determine that expression of FLuc is not silenced and that expression 
remains stable over the experimental period in vivo. Therefore, expression of FLuc 
from transduced  LCL  was assessed prior to  subcutaneous  injection.  Following 3½ 
weeks of growth in vivo the resulting tumour was excised and expression examined 
again  (see  Figure 58).  Prior  to  administration,  85%  of  LCL  expressed  eBFP. 
Following excision, the tumour sample was homogenised and stained with anti-human 
CD45  and  CD19  antibodies  before  analysis  by  flow  cytometry.  83-85%  of  cells 
expressing either human CD45 or human CD19 from the tumour sample remained 
eBFP positive. These results demonstrated that during 3½ weeks in vivo, silencing of 
the transgene was not observed.Chapter five
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Figure 58: Expression of FLuc remains stable over 3.5 weeks in vivo. Analysis of 
eBFP reporter gene expression in (a) LCL line prior to injection. (b) Blood sample 
from mouse after 3½ weeks bearing LCL tumour.  (c,d) excised tumour sample gated 
on cells expressing human CD19 or CD45 from two different mice.
5.5 Treatment of EBV-PTLD with EBV-CTLs
5.5.1 EBV-CTL induced regression of LCL tumours
A pilot experiment was carried out to establish whether i.v. injection of autologous 
EBV-CTLs from three donors resulted in regression of LCL tumours in vivo. Three 
donors of the five whose LCL led to tumour formation in previous experiments were 
selected. Cryopreserved EBV-CTLs frozen after two stimulations were available for 
injection from these donors. Three mice per donor received 10
7 LCL s.c. and were 
monitored for the presence of palpable tumour, whereupon the animals were imaged 
and 10
7 viable autologous EBV-CTLs were thawed and injected i.v. into two of the 
84% 86%
85% (a) (b)
(d) (c)Chapter five
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animals, the third remaining untreated. This dose of CTLs was chosen on the basis of 
that used by Lacerda et al in previous studies (Lacerda, et al 1996). Following CTL 
administration, all animals received 2500U recombinant human IL-2 i.p. three times 
weekly.  The  animals  were monitored  biweekly  with  bioluminescence  imaging  and 
three  times  weekly with  calliper  measurement  of  the  tumour  to  determine  tumour 
progression. Imaging results were correlated with tumour size to confirm the accuracy 
of tumour monitoring using bioluminescence.
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Figure  59:  Bioluminescence  and  size  monitoring  of  EBV-CTL  treated  and 
untreated tumours established from Donor E LCL. CTLs were injected into treated 
mice (red lines) on day 0. (a) Absolute light emission from ROI. (b) Light emission 
relative to  signal  on day of CTL  injection.  (c)  Tumour size  measured in  mm.  (d) 
Tumour size relative to size on day of CTL injection.
In our initial experiment, shown in Figure 59, the effect of administration of EBV-
CTLs on the growth of LCL tumours from donor E could not be established. The Chapter five
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tumour carried on the untreated animal doubled in size over the course of 7 days (with 
concurrent increase in bioluminescence), whereupon it became inflamed and ulcerated 
and the animal was sacrificed. Similar increases in size were observed in CTL treated 
mice  with  no  ulceration,  however tumour  development  was  equally  rapid  with  no 
apparent regression or plateau of tumour growth as a result of CTL activity.
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Figure  60:  Bioluminescence  and  size  monitoring  of  EBV-CTL  treated  and 
untreated  tumours  established  from  donor  F  LCL. (a)  Absolute  light  emission 
from ROI. (b) Light emission relative to signal on day of CTL injection. (c) Tumour 
size measured in mm. (d) Tumour size relative to size on day of CTL injection.
Preliminary  data  from  donor  F (Figure 60)  shows  that  under  these  conditions,
administration of autologous EBV-CTLs to mice bearing LCL tumours also did not 
lead to tumour regression or delay in progression. One animal was treated with CTLs
and one untreated with no resulting differences in tumour progression.Chapter five
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Figure  61:  Bioluminescence  and  size  monitoring  of  EBV-CTL  treated  and 
untreated tumours established from donor D LCL. CTLs were injected into treated 
mice (red lines) on day 0. (a) Absolute light emission from ROI. (b) Light emission as 
percent of that on day of CTL injection. (c) Tumour size measured in mm.
However, results obtained from donor D showed a probable effect of CTL infusion, 
with a rapid increase in growth of tumour in the non-treated mouse, and concomitant 
increase in FLuc signal detected on imaging.  In contrast, one of the mice treated with 
EBV-CTLs (CTL2) appeared to experience regression  of the LCL tumour  and the 
other (CTL1) had slower disease progression compared to the untreated control. On 
the day of CTL infusion into animals CTL1 and CTL2, the untreated animal and CTL2 
from  this  donor  showed  clear  signal  from  the  injection  site  from  imaging  data, 
however the palpable tumour was negligible. As the tumours could not be measured 
on  this  day,  adjustment  of  the  subsequent  size  measurements  to  baseline  size  as 
performed for FLuc measurements was not possible. At no point did animal CTL2 
develop a tumour large enough to measure with callipers, and the FLuc signal dropped 
to background, whereas the untreated animal developed  a large tumour  expressing Chapter five
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high levels of FLuc (see Figure 61 and Figure 62). These preliminary results suggested
that the i.v. administration of donor D EBV-CTLs to mice bearing s.c. donor D LCL 
tumours may result in delayed progression, or regression of the tumour. 
Figure 62: Regression of donor D LCL tumour in CTL treated but not untreated 
mouse. CTLs  were  administered  when  LCL  tumour  was  detectable,  mice  were 
monitored by bioluminescence and tumour measurement. Apparent regression of the 
tumour was observed with both methods in the treated animal. In contrast, the tumour 
in the untreated animal grows rapidly.
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In  addition,  it  is  important  to  note  that  the  FLuc  signal  obtained  from  imaging 
correlates with the measured size of tumours. Bioluminescence is considerably more 
sensitive  than  physical  measurement,  being  capable  of  detecting  signal  from 
transduced LCL prior to the presence of a palpable tumour. Furthermore, there is a 
sizable contribution of handler experience in measurement of tumours with callipers, 
compounded by the observation that tumours are more readily detectable by palpation 
when  the  animal  is  anaesthetised  compared  to  a  conscious  animal.  Therefore, 
bioluminescence imaging  with  the  IVIS system  was  subsequently used  to  monitor 
tumour growth.
5.5.2 Identification of human T cell infiltrate in LCL tumour
Tumours  from  the  untreated  animal  and  CTL1  from  donor  D  were  excised  and 
analysed histopathologically. The site of injection from animal CTL2 was examined, 
however  minimal  residual  tumour  was  identified.  As  shown  in  Figure 63,  heavy
infiltration  of  CD3  positive  human  T  cells  was  detected  in  CTL  treated  but  not 
untreated tumours. Tumours from other cohorts not experiencing an effect of EBV-
CTL administration showed either no CD3 infiltrate or only sparse CD3 positive cells 
persisting 12-16 days after administration (data not shown).
Figure  63:  Donor  D  LCL  tumour  section  stained  for  human  CD3  expression 
shows heavy T cell infiltrate. (a) Tumour excised from untreated control negative for 
CD3 staining. (b) Tumour from CTL treated mouse CTL1 shows heavy infiltrate of 
human T cells 9 days post injection. 100x magnification.
(a) (b)Chapter five
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These  preliminary  data  indicated  that  while  there  was  significant  donor  to  donor 
variation in the efficacy of EBV-CTLs in treating/preventing LCL tumours in 3KO 
mice,  our  approach  could  be  tested  in  donor  D.  With  this  donor,  we  observed 
regression or delayed progression of LCL tumours in treated compared to untreated 
animals and demonstrated infiltration of human CD3 positive cells into the tumour by 
histopathological analysis. We therefore designed subsequent experiments to confirm 
these data, and to investigate the effect of infusing cells prophylactically compared to 
treating an established tumour.
5.5.3 Comparison of EBV-CTL prophylaxis and treatment
In order to examine the effect of CTL administration as either prophylaxis or treatment 
for EBV-PTLD, 5x10
8 EBV-CTLs were generated from donor D, and cryopreserved 
following stimulation four for administration when required.
Nine 3KO mice were inoculated s.c. with 10
7 donor D LCL as previously. Three mice
(control cohort) received 2500U IL-2 i.p. three times weekly but no CTLs. A further 
three mice (prophylaxis cohort) were given 10
7 viable EBV-CTLs i.v. on the same day 
as LCLs. All animals were imaged on the day of LCL injection to establish a baseline 
for  signal  from  10
7  LCL.  Subsequently,  animals  were  imaged  twice  weekly  until 
signal from the site of injection increased on two consecutive occasions, indicating
establishment  and  growth  of  the  LCL  tumour.  The  sensitivity  of  bioluminescence 
imaging  is  illustrated  by  the  clear  signal  obtained  on  day  0  of  this  experiment, 
immediately following LCL and D-luciferin administration. Interestingly, FLuc signal 
from the site of LCL injection dropped in all mice treated at 4 days post injection, 
before returning to approximately baseline values on day 8 and increasing by day 11 
(see Figure 64). It is likely that this drop represents the period of LCL engraftment
prior  to  vascularisation  and  establishment  of  the  tumour.  Finally,  a  third  cohort 
(treatment  cohort)  received  EBV-CTLs  i.v.  on  day  11  post  LCL  administration.
Tumour size was then monitored three times weekly and imaged once weekly.Chapter five
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Figure 64: Luciferase signal from the site of LCL injection. Tumour growth was
monitored  bi-weekly  for  11  days.  Signal  dropped  from  all  animals  at  day  4,  but 
subsequently rose at days 8 and 11 (n=9).
Animals  were  imaged  every  5-7  days  following  administration  of  CTLs  to  the 
treatment cohort to monitor tumour progression. As shown in Figure 65, despite the 
previous results obtained from this model using this donor, infusion of EBV-CTLs had 
no effect on tumour growth in either the prophylactic or the treatment cohorts in this 
experiment. 
Tumour samples were once more analysed for T cell infiltrate however, in contrast to 
previous data, sparse scattered T cell clusters only were identified in the treated mice. 
In  addition,  peripheral  blood,  spleen  and  liver  samples  were  analysed  by  flow 
cytometry for the presence of human T cells, with no CD3 positive cells identified at 
any of these sites (data not shown), possibly suggesting that adoptively transferred 
CTLs  do  not  survive  long  term  in  this  mouse  model,  even  with  exogenous  IL-2 
support.
Further  optimisation  of  this  PTLD  treatment  model  is  required  to  determine  the 
parameters necessary to induce reliable tumour regression. The possible approaches to 
this optimisation will be discussed in section 5.7.1.Chapter five
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Figure 65:  Equivalent  tumour progression  in  untreated,  prophylactic  CTL  or 
treatment CTL groups. (a) Absolute counts per second from the injection site. (b) 
FLuc signal normalised to lowest value for each animal. Mean and SEM shown, n=3 
per group. Administration of CTLs in treatment group indicated by arrow. Statistical 
analysis using two-way ANOVA.Chapter five
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5.6 Effect of calcineurin inhibitors on transduced and 
untransduced CTLs in vivo
5.6.1 Administration of CN inhibitors
Prior to assessing the effect of CN inhibitors on the function of EBV-CTLs in vivo, the 
appropriate route and dosage must be determined. Various routes of administration 
including gavage have been employed by investigators in the literature. While this 
approach would not be  possible for the duration of our experiments, these studies 
demonstrate that oral absorption of FK506 is possible and we initially investigated the 
possibility of administering this drug via the drinking water. This would allow long 
term  dosage  of  animals  without  the  need  for  daily  i.p.  injections  which  would 
introduce both practical and licencing issues. Although FK506 is not soluble in water, 
we utilised  an intravenous liquid  preparation which was diluted  to  the appropriate 
concentration and added to the sterile drinking water. The water bottle was agitated 
daily to ensure homogenous delivery of FK506 in water. 
To ascertain the correct concentration of FK506 to be added, an approximation of the 
volume of water consumed per day per mouse was necessary. Therefore the water 
bottles of one cage of two male strain 3KO mice and one singly caged female were 
weighed and monitored over two days. This determined that each mouse consumed 
approximately 8.5ml of water per day. In addition, the mice were weighed and were 
found to weigh an average of 20g per animal. The normal dose of FK506 administered 
to paediatric transplant patients is 300g/kg/day, therefore to achieve similar dosing 
each mouse should consume 6g/day. To account for bottle leakage, it was assumed 
that each mouse drank 6ml water per day and FK506 was added at a concentration of 
1g/ml. There are several potential problems with this route of administration and 
dosage assumptions.  Firstly,  mice caged in  groups  are likely to  consume differing 
volumes of water and will therefore receive different doses of CN inhibitor. Secondly, 
although FK506 has been shown to be stable at room temperature and up to 30
o for 
several days in blood samples (Alak and Lizak 1996), there is the possibility of drug 
breakdown. Finally, and most improtantly, the pharmacokinetics and metabolism of Chapter five
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FK506 in mice is not well established and therefore to obtain an adequate circulatory 
concentration, extrapolation from the human paediatric dose may not be sufficient. 
Therefore, following three days of FK506 administration and upon observation of no 
ill effects, the animals were sacrificed and cardiac puncture was performed to obtain 
sufficient  sample  for  measurement  of  blood  FK506  concentration  (see  Table 14).
These  results  showed  that  FK506  concentration  was  undetectable  (<2ng/ml)  in  all 
three mice. Therefore the experiment was repeated in two animals with a four fold 
higher  concentration  of  FK506  in  the  drinking  water,  to  administer  24g/day  per 
mouse,  equivalent  to  a human  dose  of  1.2mg/kg/day.  In addition,  the  sample  was 
collected from one animal in the morning and one in the evening, representing a peak
and trough concentration respectively as mice consume more water during the night 
compared  to  the  day.  However,  FK506  concentration  in  these  samples  was  again 
undetectable. A repeat of the experiment with administration of a ten-fold increased 
dose  also  produced  undetectable  blood  concentration  of  FK506,  therefore  this 
approach was not pursued (Table 14).
Table 14: Administration of FK506 intravenous preparation orally in drinking 
water does not result in detectable concentrations in circulation.
Sample Dosage (x paediatric dose) Measured  blood 
concentration 
(ng/ml)
1 6g/day (1x) <2
2 6g/day (1x) <2
3 6g/day (1x) <2
4 24g/day (4x) <2
5 24g/day (4x) <2
6 60g/day (10x) <2
7 60g/day (10x) <2
8 60g/day (10x) <2Chapter five
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Finally, dosing mice via the oral route using drinking water was tested using both 
FK506  and  CsA  oral  syrup  preparations.  We  once  again  administered  10  fold 
increased dose of FK506, and CsA to three mice, and measured blood concentrations. 
As shown in Table 15, again FK506 was not present in the blood at a therapeutic 
concentration. In contrast however, CsA was absorbed when administered using this 
route  and  dosage  and  levels  within  and  above  the  human  therapeutic  range  were 
achieved. These results were obtained from three littermates caged together, and our 
data highlights that mice achieve varying plasma concentrations even when drinking 
from the same water bottle. This may reflect either differences in the dose received or 
in drug metabolism between animals.
Table  15:  Successful  administration  of  CsA  but  not  FK506  oral  syrup  via 
drinking water.
Sample Dosage (x paediatric dose) Measured  blood 
concentration 
(ng/ml)
1 60g/day FK506 (10x) <2
2 60g/day FK506 (10x) <2
3 60g/day FK506 (10x) <2
4 CsA 1.2mg/day (10x) 288
5 CsA 1.2mg/day (10x) 564
6 CsA 1.2mg/day (10x) 730Chapter five
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5.7 Conclusions
These results confirm that reliable establishment of human LCL tumours in 3KO mice 
is possible for the majority of donors. LCL establish tumours and become palpable 
within one to three weeks of injection, depending on the donor, with progression to the 
size limit of 10mm stipulated on the project licence within approximately two to five 
weeks. 
We have established and optimised bioluminescent imaging of FLuc transduced LCL 
tumours in 3KO mice, determining the appropriate parameters and protocol to use for 
reliable results. Signal emitted from tumours has been correlated with tumour size as 
measured by callipers, this was confirmed to be a sensitive method of detecting LCL 
immediately following injection, and a reliable indicator of tumour growth. 
Having  established  the  in  vivo  model  of  PTLD  development  and  a  reliable  non-
invasive monitoring technique, we next addressed the efficacy of treatment for EBV-
LCL tumours with autologous EBV-CTLs. Preliminary experiments identified mice 
from one of three donors appearing to respond to CTL treatment with delayed tumour 
progression or indeed regression following infusion of CTLs. This variability between 
donors could be due to a number of factors, including the observation that in the two 
donors not responding to EBV-CTL treatment, the LCLs proliferate more rapidly in in 
vitro culture than those of the successful donor. In vivo this translated in one donor to 
very rapid  tumour  growth and ulceration  at the  tumour  site  after only 7 days. To 
control rapidly proliferating LCLs such as these, it is possible that a higher CTL dose 
would  be  required  for  these  donors. However,  for  the  donor  responding  to  CTL 
infusion, we identified heavy T cell infiltrate in the remaining tumour of one animal, 
and the absence of significant tumour tissue at the injection site for the animal in 
which regression was observed. These results were not replicated in a secondary series 
of experiments from the same donor aiming to compare prophylaxis with treatment of 
LCL  tumours.  Several  possibilities  will  be  explored  to optimise  this  model  and
improve the reliability of responses to CTL infusion.Chapter five
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5.7.1 Further optimisation of EBV-PTLD model
To improve EBV-CTL treatment for LCL tumours in 3KO mice, further optimisation 
is required. Preliminary data in this study gave promising results, therefore successful 
establishment of this model is likely. 
Initially we will focus on practical issues possibly affecting the function of EBV-CTLs
following infusion, such as minimising the delay between preparation of the cells for 
injection and administration of these cells. Currently these two procedures occur at 
different sites within our institution therefore some time elapses which may have a 
detrimental impact on  CTL function.  In further  studies,  CTLs will  be  thawed and 
prepared at the site of animal maintenance, therefore reducing this delay.
Secondly, our  successful  pilot  studies  utilised  EBV-CTLs that  were  cryopreserved 
following two stimulations, whereas in the unsuccessful follow up experiments, EBV-
CTLs  received  four  stimulations  prior  to  cryopreservation.  Gattinoni  et  al
demonstrated that CTLs with a shorter in vitro culture period perform more effectively 
in vivo as a result of improved homing to the tumour site, therefore it is possible that 
this could impact the function of CTLs (Gattinoni, et al 2005). However, CTLs used in 
the  study  by  Lacerda  et  al  had  received  either  three  or  four  stimulations  prior  to 
administration and resulted in dramatic tumour regression (Lacerda, et al 1996).
Next the distribution of the infused CTLs will be examined to determine their fate 
following administration; despite the absence of human T cells from the liver and 
spleen  in  our  final  experiment,  this  analysis  was  performed  17  days  post  T  cell 
injection and CTLs would be unlikely to persist in these sites in the absence of antigen 
stimulation. EBV-CTLs will therefore be transduced with FLuc and these effectors 
administered to mice bearing an LCL tumour, with bioluminescent monitoring to track 
their distribution immediately post injection and in the days following treatment. This 
could  identify  whether  CTLs  home  to  the  tumour  site  but  are  not  sufficiently 
functional to induce tumour regression, or whether they do not localise to the tumour 
but are cleared from the animal by the liver or spleen before arrival and are unable to 
mediate anti-tumour effect.Chapter five
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In  addition  to  these  factors,  providing  the  optimal  cytokine  environment  for  CTL 
survival and function will also be examined. CTLs are currently thawed one day prior 
to injection and rested overnight in 40U/ml IL-2 before administration. Optimisation 
of the cytokine cocktail during this rest period may improve the function of CTLs
following infusion. In addition, 2500U IL-2 is administered to the animals i.p. three 
times  weekly  following  CTL  infusion,  however  it  is  possible  that  this  dose  is 
insufficient  for  CTL  effect  and  persistence,  or  that  administration  of  additional  or 
alternative cytokines such as IL-15 would improve the environment (Mueller, et al
2008, Quintarelli, et al 2007, Rowley, et al 2009). Another approach to provide a
constant source of cytokines, rather than the peaks and troughs that likely result from 
multiple  injections,  would  be  transduction  of  the  LCL  tumour  cells  with  cytokine 
genes. This would provide constant expression of IL-2/IL-15 at the site of the tumour, 
thus enhancing CTL activity to augment the anti-tumour response in vivo. Potentially, 
LCL could also be transduced with other immunostimulatory molecules such as the T 
cell  chemokine  lymphotactin  to  enhance  T  cell  trafficking  to  the  site  of  the  LCL 
tumour (Dilloo, et al 1996).
5.7.2 Optimisation of CN inhibitor administration
To examine the effect of FK506 on transduced compared to untransduced EBV-CTLs
in the treatment of LCL tumours in vivo, it is critical to address the issue of correct 
dosing  of  the  animals.  Several  routes  of  administration  have  been  employed  in 
previously published studies, however resulting blood concentrations have not been 
established. We attempted oral dosing of animals using an i.v. preparation of FK506 
administered in drinking water and observed undetectable blood concentrations with 
up to ten fold increased dose compared to paediatric transplant patients. This result 
was replicated using an oral syrup preparation of FK506 at the same dose, however 
administration of an oral preparation of CsA using this route resulted in considerable, 
although variable, circulatory concentrations. 
These results highlight the difficulty in accurately dosing mice with CN inhibitors 
which are poorly water soluble and metabolised rapidly, requiring administration of Chapter five
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high doses to achieve therapeutic blood concentrations. Potentially however, we could 
use orally administered CsA after further experiments to determine that we are able to 
consistently achieve drug levels within or above the therapeutic range without toxicity. 
While the circulating CsA levels achieved appear variable between mice, given that 
CTLs transduced with CNb30 are able to function at supratherapeutic levels of CsA in 
vitro, this variability may not be critical for our subsequent experiments as long as 
therapeutic drug levels are consistently obtained. 
Other routes of administration described in the literature include i.p. and i.v. injection, 
both of which present practical and licencing difficulties. A further approach currently 
under investigation is the use of osmotic pumps to administer a continuous s.c infusion 
of  drug  over  a  period  of  up  to  four  weeks.  This  will  allow  high  dosage  and  the 
continuous nature should partly address the issue of rapid metabolism in our murine 
model.
In conclusion, establishment of an appropriate system for examining the efficacy of 
transduced  EBV-CTLs  in  the  presence  of  CN  inhibitors  in  vivo  is  underway.
Establishment and monitoring of such tumours is possible, however several factors 
remain to be finalised regarding CTL treatment and CN inhibitor administration, and 
optimisation of these aspects is ongoing.Chapter five
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5.8 General conclusions
 Successful establishment of murine model of PTLD development for in vivo
studies.
 Bioluminescence imaging of LCL tumour growth and regression is possible 
and has been optimised.
 Treatment of murine PTLD with EBV-CTLs has been variably successful and 
requires further optimisation.
 Administration of FK506 via the oral route is not possible using the methods 
tested here. Administration of CsA is possible but results in variable circulating 
drug levels.Chapter six
DiscussionChapter six
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6.0 Discussion
6.1 Study conclusions
The  development  of  EBV-driven  PTLD  following  stem  cell  or  solid  organ 
transplantation is a serious complication of these procedures. Occurring in between 1 
and 30% of patients, PTLD can be an aggressive disease and carries a mortality rate of 
up to 50% at 5 years (Everly, et al 2007, Opelz and Dohler 2004, Taylor, et al 2005, 
Webber, et al 2006). An increasing number of patients undergo transplantation, with 
improved  life  expectancy  due  to  a  combination  of  advances  in  HLA  matching, 
conditioning regimes and immunosuppressive therapy. Therefore, a larger number of 
patients are at risk of developing post transplant complications such as PTLD. The 
poor prognosis of this disease has driven the research effort to improve prevention 
strategies  and  investigate  novel  treatments,  many  of  which  focus  on  the  use  of 
immunotherapy.
Adoptive immunotherapy for EBV-driven post transplant lymphoma has proven both 
safe and effective,  with  administration  of EBV-CTLs to  over  200 patients  to  date 
(Merlo, et al 2008). In the setting of stem cell transplantation, this approach has been 
shown to both prevent the development of PTLD when administered prophylactically 
and induce regression of established tumours (Rooney, et al 1998). However, while 
some clinical responses have been observed following the application of this approach 
following solid organ transplant, both the magnitude and persistence of these have 
been limited (Comoli, et al 2002, Comoli, et al 2005, Savoldo, et al 2006, Sherritt, et 
al 2003). Transient reductions in EBV viral load or increases in EBV-CTL precursor
frequency are documented, along with reduction in tumour burden, but the lack of 
CTL persistence following transfer along with relapses observed after this treatment 
raise questions regarding the persistence of such cells in the SOT recipient (Khanna, et 
al 1999). While a recent phase II study of partially HLA-matched third party CTLs
showed good response rates of 52% at 6 months (Haque, et al 2007), the efficacy of 
adoptive  immunotherapy  with  EBV-CTLs  after  SOT  has  generally  been  less 
impressive  than  in  the  SCT  setting.  It  is  likely  that  the  presence  of  ongoing Chapter six
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immunosuppressive therapy may serve to limit the survival and efficacy of the infused 
cells in this environment (Savoldo, et al 2006).
To  address  this  issue,  we  have  generated  EBV-specific  CTL  lines  that  retain 
functionality  in  the  presence  of  CN  inhibitors.  This  approach  may  improve  the 
efficacy  of  adoptive  immunotherapy  in  this  setting,  allowing  continuation  of  the 
immunosuppressive regimen to protect from graft rejection, whilst enabling efficient 
function of the therapeutic product to combat EBV-induced B cell proliferation. To 
this end, we generated a panel of 54 CN mutants designed to resist binding by either or 
both of the CN inhibitors FK506 and CsA. We hypothesised that CN mutants able to 
resist this binding would retain their functionality in the presence of CN inhibitors and 
therefore  confer  resistance  to  these  drugs.  CN  mutants  were  generated  based  on 
previously  identified  resistance-conferring  mutations  in  conjunction  with  structural 
data (Cardenas, et al 1995, Fox, et al 2001, Griffith, et al 1995, Kawamura and Su 
1995, Ke and Huai 2003, Milan, et al 1994). These mutations were designed to disrupt 
the binding of CN by CN inhibitors, whilst preserving both the interaction between 
CNa and CNb and the phosphatase activity of the enzyme. Extensive screening of all 
mutants  using  a  Dual  Luciferase Assay in  293T  cells  enabled  identification  of  17 
mutants that retained some phosphatase activity in the presence of either FK506 or 
CsA,  therefore  these  mutants  were  pursued  in  further  experiments.  Generation  of 
retroviral  supernatants  containing  the  17  selected  CN  mutants  and  transduction  of 
Jurkat T cells allowed assessment of the effect of these mutants on IL-2 secretion by T 
cells in the presence of CN inhibitors. These results confirmed that the introduction of 
mutants CNa12, CNa22 or CNb30 into Jurkat cells conferred the highest resistance to 
suppression  with  CN  inhibitors.  Indeed,  transduction  with  these  three  CN  mutants 
enabled  IL-2  secretion  not  only  at  therapeutic  levels  of  FK506/CsA  but  also  at 
supratherapeutic levels up to four fold higher than this. CNa12 was selected to confer 
resistance to FK506, CNa22 for resistance to CsA, and CNb30 conferred resistance to 
both CN inhibitors (chapter three).
As  described  above,  the  molecular  basis  for  the  ability  to  resist  binding  by  CN 
inhibitors is due to alterations in CN which prevent binding by FK506/CsA (see table 
4). CNa12 contained the novel combination of two mutations T351E and L354A, first Chapter six
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identified by Kawamura (Kawamura and Su 1995). These substitutions were predicted 
to disrupt binding between CNa and the charged surface residues H87-P88 of FKBP12
but should not affect CsA/CyPA binding, resulting in FK506 but not CsA resistance. 
CNa22  contains  the  mutations  V314R,  which  directly  disrupts  CsA  binding  and 
Y341F, which may prevent FKBP12/CyPA binding by inhibition of close contact with 
the body of CNa. CNb30 contains both the point mutation L124T, decreasing the size 
and charge of the side group, and the insertion K125-LA in the latch region, which is 
involved in binding of CNb to CNa and also in binding of FKBP12/CyPA to the CN 
heterodimer. Insertions at this point in the latch region are likely to disrupt the overall 
structure of the loop, resulting in a protrusion outwards and away from contact with 
the immunophilin (Fox, et al 2001).
The three CN mutants identified as conferring resistance during cell line assays were 
subsequently codon optimised  and introduced into primary EBV-CTL lines.  In the 
absence of  CN  inhibitors,  proliferation,  cytokine  secretion,  phenotype,  cytotoxicity 
and dependence upon antigen stimulation were monitored for four weeks in vitro and 
were  established  to  be  unaffected  by  transduction  with  CN  mutants  under  normal 
culture conditions. Therefore neither the transduction procedure nor expression of CN 
mutants has a detrimental effect on EBV-CTL function. 
Addition of CN inhibitors to culture conditions resulted in suppression of UT EBV-
CTLs, with a marked reduction in proliferation and cytokine secretion. In contrast, CN 
mutant  transduced  EBV-CTLs  were  able  to  expand  normally  in  the  presence  of 
therapeutic levels of FK506/CsA, with comparable growth to that seen by the same 
CTL lines in the absence of CN inhibitors (53-106%) as measured by the increase in 
cell  numbers.  This  ability  to  proliferate  was  confirmed  by 
3H-Thymidine  uptake 
assays.  In addition, proliferation of CNb30 transduced EBV-CTLs was examined in 
the  presence  of  supratherapeutic  levels  both  of  FK506  and  CsA  and  found  to  be 
normal.  CTL  functionality  in  the  presence  of  CN  inhibitors  was  examined  by 
measurement  of  IFN-  secretion  in  response  to  stimulation  with  autologous  LCL. 
Normal  levels  of  IFN-  secretion  were  observed  in  the  presence  of  either  FK506 
(CNa12, CNb30) or CsA (CNa22, CNb30) (chapter four). In addition we have shown 
that the cytotoxicity of EBV-CTL lines is unaffected either by growth in CN inhibitors Chapter six
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and inclusion of these drugs in the cytotoxicity assay itself, or by transduction with 
CN mutants. Thus, as determined by the endpoints of proliferation, IFN- secretion 
and  cytotoxicity,  transduction  with  these  CN  mutants  rendered  EBV-CTL  lines 
resistant  to  suppression  with  CN  inhibitors. This  approach  may  therefore  enable 
adoptively transferred CTLs to function in SOT patients at risk of PTLD, or in whom 
PTLD  has  developed,  without  the  need  to  reduce  immunosuppression  with  CN 
inhibitors and the concurrent risk of graft rejection.
The observation that transduced EBV-CTL lines are able to proliferate at CN inhibitor 
doses four-fold above the therapeutic range is likely to be reflective of the mechanism 
of  action  of  the  resistance  conferred  by  CN  mutants.  As  the  CN  inhibitor: 
immunophilin complex is not bound by the CN mutant, the dose of FK506 or CsA 
administered is irrelevant, allowing resistance even at high doses. This finding may 
increase  the  potential  applications  of  CN  inhibitor  resistant  cells,  allowing 
administration in the immediate post-transplant period when doses of CN inhibitors 
are high. In addition, raising the dose of CN inhibitors without having a detrimental 
impact  on  CTL  function  may  enable  the  withdrawal  of  other  immunosuppressive 
drugs such as MMF to allow effective immunotherapy during this time.
The  generation  of  mutants  capable  of  conferring  resistance  to  either  or  both  CN 
inhibitors allows a choice of approach with potential therapeutic advantages to either. 
CTLs  resistant  to  one  CN  inhibitor  could  be  suppressed  using  the  alternative  CN 
inhibitor if necessary. For example, inflammatory reactions at the site of the tumour 
have been documented following infusion of EBV-CTLs when used as treatment for 
established PTLD (Rooney,  et al 1998).  If such  an adverse  event  occurred, CTLs 
resistant to only one CN inhibitor could be suppressed by administration of the other. 
Since CTLs would not be deleted using this approach, EBV-specific memory would 
be retained long term. Conversely, EBV-CTLs resistant to both FK506 and CsA would 
allow a choice of therapeutic agent. Patients experiencing toxicity as a result of CsA 
use could be switched to FK506 without suppression of infused EBV-specific cells. 
An additional benefit of mutant CNb30 is a result of the small size of the CNb gene. 
At  approximately  500bp,  the  size  of  CNb is  well  below  the  packaging  limit  of Chapter six
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integrating vectors, therefore allowing co-expression with other useful transgenes and 
extending the applicability of this approach.
In summary, CN mutants  capable of conferring resistance to suppression with CN 
inhibitors have been generated and examined in both cell line screening assays and 
primary EBV-CTL lines. This approach may improve the efficacy of immunotherapy 
for EBV-driven PTLD arising post SOT.
6.2 Safety
The major safety concerns regarding the use of CN transduced EBV-CTLs are the 
possibility of hyper-activation induced by increased cellular CN, the effects of the 
transduction itself, and the potential for generating allo-reactive CTLs that are resistant 
to CN inhibitors. This study addressed these important issues, confirming both that 
hyperactivity is not observed in transduced EBV-CTLs, that transduction alone does 
not  affect  EBV-CTL  function  and  that  alloreactivity  is  not  increased  by  CN 
transduction.
6.2.1 Risks relating to transgene expression
During CN mutant screening in Jurkat cells, it was noted that transduction with either 
wt or mutant CNa genes resulted in increased secretion of IL-2 from Jurkat cells upon 
stimulation  with  mitogens.  The  observed  hyper-activity  of  Jurkat  cells  following 
transduction  with  CNa  is  likely  due  to  the  presence  of  additional  CN  in  the  cell 
amplifying the activation signal and leading to increased IL-2 production. This finding 
indicates that CN activity is the limiting step in activation of IL-2 secretion by the 
Jurkat  T  cell  line.  Interestingly,  hyper-activation  is  several  fold  more  pronounced 
following transduction with CNa genes than CNb. This result, in combination with 
Western blot data demonstrating increased levels of CNb following transduction of 
cells with CNa, supports the suggestion that CNa is the limiting component of the CN 
heterodimer  and  that  binding  by  CNa  stabilises  CNb,  which  may  otherwise  be Chapter six
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degraded (Milan, et al 1994) (figure 29). Importantly for future clinical studies, this 
suggests  that  transduction  with  CNb  mutants  may  be  capable  of  conferring  CN 
inhibitor resistance whilst not raising cellular CN  levels, therefore  not  resulting in 
hyper-activation or otherwise affecting cellular function. The generation of a cellular 
therapeutic  product  with  the  potential  for  over-activity  or  an  increased  level  of 
functionality is clearly undesirable, as this could potentially result in inappropriate 
proliferation therefore generation of transduced EBV-CTLs that do not display any 
gain-of-function is of utmost importance. Although the development of neoplasia is 
unlikely as we are transducing differentiated T cells, inappropriate T cell activation 
could potentially result in alternative side effects such as the induction  a cytokine 
storm  with  consequent  inflammation.  While  increased  activation  of  Jurkats  was 
observed following PMA/ionomycin treatment, no detectable IL-2 secretion occurred 
in the absence of stimulation either from UT or CN transduced cells. This confirms 
that increased CN appears able to amplify an activation signal, but is not capable of 
initiating such activation itself. Additionally, increased wtCN alone did not result in 
resistance to CN inhibitors; approximately 300% increased levels of IL-2 secretion 
was observed from wtCNa transduced cells upon stimulation, however this excess IL-
2 production remained sensitive to suppression by FK506/CsA, and was abrogated by 
their addition.
Despite the  evident hyper-activation  in  Jurkat  cells  transduced with  CNa,  no such 
effect was observed in EBV-CTLs despite close monitoring for four weeks in vitro. 
Transduced EBV-CTLs were examined in the absence of CN inhibitors by assessment 
of cell expansion, proliferation by 
3H-thymidine uptake assays, and secretion of IFN-. 
These data confirmed that transduction with CN mutants does not result in increased 
proliferation or IFN- secretion by EBV-CTLs even with CNa22, which resulted in the 
highest level of hyper-activation in Jurkat cells. This difference between Jurkat cells 
and primary EBV-CTLs may be as a result of the strength of the activation signal 
provided, which is stronger in the former (PMA/ionomycin) and more physiological in 
the latter (LCL). Alternatively, as discussed in chapter 4, it is possible that EBV-CTLs
overexpressing  CN  mutants  such  as  CNa22  undergo  increased  rates  of  activation 
induced cell death. The observation of a gradual drop in the proportion of CNa22 
transduced CTLs in the absence of CN inhibitors is consistent with this possibility. In Chapter six
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summary, our data indicate that transduction of EBV-CTLs with CN mutants appears 
not to result in hyper-activity.
6.2.2 Risks relating to retroviral gene transfer
The  use  of  viruses  in  gene  transfer  carries  the  risk  of  inappropriate  activation  of 
surrounding  genes  at  the  site  of  integration  into  the  genome.  The  effects  of  such 
insertional mutagenesis have been highlighted by the severe adverse events observed 
in two gene therapy trials in recent years where CD34-selected stem cells have been 
transduced with retroviral vectors (Hacein-Bey-Abina, et al 2008, Hacein-Bey-Abina, 
et al 2003, Howe, et al 2008). These events have driven investigations into developing 
safer viral vectors to reduce the likelihood of insertional mutagenesis. These include 
the development of the self-inactivating vector and the use of lentiviruses rather than 
retroviruses to improve the safety profile of such constructs. However, aside from the 
fact that these vectors have not been utilised in any clinical trial to date, such vectors 
carry several disadvantages such as the production of lower titre supernatants and the 
inability to generate stable producer lines for lentiviral vectors, and the lower titre of 
SIN retroviruses. However, in our approach, we are transducing mature T cells rather 
than  stem  cells,  which  (as  discussed  in  section  1.5.3)  reduces  the  potential  for 
leukaemagenesis. Indeed, transduction of mature T cells with retroviral vectors has not 
been associated with any severe adverse events despite treatment of over 100 patients 
to date with transduced T cells (Blaese, et al 1995, Ciceri, et al 2007, Ciceri, et al
2009, Hale, et al 2008, Tiberghien, et al 2001), including 40 patients treated with 
retrovirally  transduced  EBV-CTLs.  Therefore  in  our  studies  we  have  used  the 
retroviral vector  SFG for transduction of EBV-CTLs, from which it is possible to 
generate high titre, stable producer lines to produce viral supernatant on a large scale, 
resulting in good CTL transduction efficiency. In view of the differentiated nature of 
EBV-CTLs and the existing data from the clinical studies above, we believe that the 
potential benefit from using a conventional retroviral vector outweighs the theoretical 
risk of leukaemagenesis.Chapter six
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In conclusion, investigation of CN mutant transduced EBV-CTLs in the presence or 
absence of CN inhibitors demonstrates that transduction with CN mutants does not 
result in hyper-activity or increased allo-reactivity and that such cells are not adversely 
affected  by  the  transduction  procedure.  Therefore  the  favourable  safety  record  for 
immunotherapy  with  EBV-CTLs is  likely to  be  maintained  in  CN  transduced  cell 
lines. To further increase the safety profile of CN transduced EBV-CTLs, inclusion of 
a suicide gene such as HSV-TK (Ciceri, et al 2009) or iCaspase9 (Straathof, et al
2005) in the CNb30 vector is possible. This would allow elimination of transduced 
CTLs should an adverse event attributable to the administration of these cells occur. 
Alternatively, if CNa12 or CNa22 were used, CsA or FK506 could be used to suppress 
transduced cells. 
6.2.3 Risks relating to CTL use
The  major  risks  associated  with  adoptive  immunotherapy  with  EBV-CTLs  are 
alloreactivity and inflammatory reactions. Due to the potential presence of alloreactive 
cells  in  the  original  PBMC  sample,  EBV-CTL  lines  prepared  for  clinical  use  are 
cultured ex vivo for several weeks prior to reinfusion (Comoli, et al 2005, Khanna, et 
al 1999, Rooney, et al 1995, Wilkie, et al 2004). Multiple stimulation of CTLs with 
autologous LCL during the ex vivo procedure has the dual effect of both enhancing the 
proportion  of  EBV-specific  cells  and  reducing  allo-reactivity,  thus  ensuring  the 
specificity of the cell line and minimising the potential for initiation of either GVHD 
in the SCT setting or graft rejection in SOT patients. During this process, allogeneic 
cells undergo apoptosis due to lack of stimulation, as highlighted by the reduction in 
allo-specific cytotoxicity concomitant with increased number of stimulations in vitro
(Wilkie, et al 2004). This approach appears to effectively deplete alloreactivity, as 
evidenced by the fact that administration of such cells to over 200 patients has not 
been associated with increased GVHD or graft rejection (Heslop, et al 2009, Merlo, et 
al  2008).  Importantly, this  study demonstrated  no increase in  cytotoxicity towards 
allogeneic targets in CTL lines as a result of CN transduction. Therefore, we believe 
that the risk of generating allo-reactive, CN inhibitor resistant CTLs as a result of this 
procedure is minimal. Chapter six
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6.3 Additional obstacles to adoptive immunotherapy
In addition to the ongoing requirement for immunosuppressive therapy, several other 
potential  obstacles  may  limit  the  efficacy  of  adoptively  transferred  CN  inhibitor 
resistant  EBV-CTLs  after  SOT.  These  include  the  use  of  combination 
immunosuppressive regimens, the lack of immunological space, the dependence of the 
infused cells on stimulation with specific antigen, and the possibility of an immune 
response to the transgene, along with practical considerations such as time, facilities 
and resources.
6.3.1 Suppression of CTLs by other immunosuppressive agents
Although CN inhibitors form the cornerstone of many immunosuppressive regimens, 
combination therapy with other agents, particularly Mycophenolate Mofetil (MMF) 
and/or  steroids,  is  usually  employed  (Caillard,  et  al  2005,  Knight,  et  al  2009). 
Therefore, the function of EBV-CTLs that are resistant to FK506/CsA may still be 
impaired by these additional agents when infused post transplant. However, first line 
treatment for EBV-PTLD includes reduction of immunosuppression to as low a level 
as possible, which in many centres involves complete withdrawal of other agents and 
reduction to the lowest allowable dose of CN inhibitors (Everly, et al 2007, Svoboda, 
et al 2006, Tsai, et al 2001). In general, withdrawal of MMF is well tolerated and 
where rejection has been seen this is most frequently due to over-aggressive reductions 
in CN inhibitors. Withdrawal of additional agents would allow the function of CN 
inhibitor  resistant  EBV-CTLs.  Indeed,  since  transduced  EBV-CTLs  function  at 
supratherapeutic levels of CN inhibitors, potentially the dose of CsA/FK506 could be 
increased to compensate for withdrawal of other agents. Alternatively, where EBV-
CTLs are infused prophylactically and maintenance of standard immunosuppression is 
desirable, it may be possible to generate CTLs that are resistant to both CN inhibitors 
conferred  by  CNb30  and  MMF  conferred  by  mIMPDH2.  Transduction  with 
mIMPDH2 has been shown to render T cells resistant to suppression with MMF in 
terms of both proliferation and cytokine secretion (Yam, et al 2006). Therefore our 
laboratory  is  currently  investigating  combining  these  two  approaches  to  produce Chapter six
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FK506/CsA/MMF resistant cells. Because of the small size of CNb30 (500bp) and 
IMPDH2 (1.5kb), it should be possible to achieve reasonable retroviral titres and high 
level expression of both transgenes. Furthermore, a strategy for conferring resistance 
to corticosteroids using RNA knockdown of the glutocorticoid receptor NR3C1 is also 
under investigation in our institute. It may therefore be possible to create a panel of
vectors combining resistance to several combinations of immunosuppressive agents, 
allowing  a  choice  of  preferred  regimen.  Safety  concerns  regarding  a  cell  product 
resistant to suppression by several of the main immunosuppressive agents available 
could be allayed by inclusion of a suicide gene such as iCaspase 9 or HSV-TK. 
6.3.2 Lack of immunological niche and requirement for antigen stimulation
Dramatic in vivo expansion of ex vivo generated EBV-CTLs has been documented 
following administration post SCT (Rooney, et al 1998). One explanation postulated 
to account for this is the presence of an empty ‘immunological niche’ as a result of 
lymphodepletion  during  pre-transplant  conditioning.  This  lymphodepleted 
environment persists for many months post stem cell transplant, providing an ideal 
platform for immunotherapy by eliminating endogenous T cells that compete with the 
adoptively transferred T cells for cytokines. Lymphodepletion enhances the expansion 
in vivo of adoptively transferred tumour specific T cells in both murine and human 
studies (Morgan, et al 2006, Rapoport, et al 2005). In contrast, SOT patients do not 
undergo conditioning  chemotherapy  and the  level  of lymphodepletion  achieved by 
immunosuppression is much less than after SCT. Infused EBV-CTLs must therefore 
integrate into the established immune environment without an empty niche to fill. It is 
likely  however,  that  with  adequate  antigenic  stimulation  from  EBV  infected  cells, 
CTLs will proliferate in vivo even in the absence of lymphodepletion. Consistent with 
this,  CTLs  have  proven  functional  when  administered  as  immunotherapy  for 
neuroblastoma  in  patients  without  prior  lymphodepletion,  therefore  it  would  be 
expected that EBV-CTLs administered post SOT would also have the capability to 
expand and persist (Pule, et al 2008). In addition, the selective advantage conferred 
upon CN inhibitor resistant EBV-CTLs in an immunosuppressed environment may Chapter six
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allow  preferential  expansion  and  establishment  of  a  long-term  EBV-specific 
compartment.
We  have  demonstrated  that  EBV-CTLs  remain  dependent  on  repeated  antigen 
stimulation  for continued expansion in  vitro, even with  continued supplementation 
with exogenous IL-2. Critically, no difference was observed in the proliferation of 
transduced or UT EBV-CTLs in the absence of antigen stimulation, further confirming 
the  safety  of  CN  transduction as  increased  cellular  CN  does  not  provide  de  novo
activation signalling. However, these data highlight an important consideration for the 
efficacy  of  adoptive  immunotherapy  with  EBV-CTLs,  particularly  when  used  as 
prophylaxis: that the critical driving force for cell expansion both in vitro and in vivo
is presence of specific antigen. Human studies examining transfer of both allodepleted 
and virus specific T cells have shown that expansion of these T cells occurs after 
antigen stimulus provided by viral reactivation (Amrolia, et al 2006, Cobbold, et al
2005) and that without such a stimulus, transferred CTLs do not persist or expand 
(Leen, et al 2006). EBV-CTLs infused to treat established PTLD will receive strong 
stimulation at the site of tumour and therefore expand in response. This is also likely 
to be the case when CTLs are given pre-emptively for EBV viraemia. However, in the 
prophylaxis setting this natural stimulus may be absent. Although B cells expressing 
EBV proteins are rarely detected in the healthy patient, the natural history of EBV 
infection involves periodic reactivation of the virus, which may provide occasional 
antigen specific stimulation in vivo. Indeed, this reactivation appears more frequent 
and  prolonged  in  immunosuppressed  patients  undergoing  SOT.  The  observed 
incidence of EBV viraemia in SOT patients depends on the assay used and the patient 
population studied but appears to be in the range of 40-60% (Benden, et al 2005, Lee, 
et  al  2005,  Martelius,  et  al  2009).  Further,  it  is  possible  that  local,  low  level, 
reactivation of EBV in the tonsils and lymph nodes may provide an antigenic stimulus 
for CTLs even when no viraemia is apparent. Although weekly stimulation is required 
for cell  expansion  in  vitro, it  seems that such  frequent exposure  to  antigen is  not 
required in vivo, as evidenced by the remarkable long term persistence of EBV-CTLs 
demonstrated  in  previous  studies (Heslop,  et  al  2009).  Gene-marked  EBV-CTLs 
generated using the protocol employed in this study have been detected in peripheral 
blood of patients many years after infusion, often increasing to in response to a rise in Chapter six
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EBV viral load (Heslop, et al 2009, Pule, et al 2004). This indicates that memory 
EBV-CTLs do not require continual antigen exposure to persist in vivo, and that they 
retain the ability to expand in response to the resurgence of antigen. In addition, our 
phenotyping data reveal a high proportion of central memory cells in transduced EBV-
CTL lines, which may enhance the ability of these cell lines to establish a memory 
population and persist long term in vivo.
6.3.2 Culture duration and memory phenotype of CTLs
Many considerations exist concerning the ideal characteristics of ex vivo generated T 
cells for  immunotherapy,  including  the  effect  of  extended  culture  times  and  the 
advantages of administering naïve compared to memory or effector cells.  EBV-CTLs
administered for the treatment or prevention of PTLD are generally cultured for 4-6 
stimulations ex vivo to  reduce the likelihood of alloreactivity in the CTL line  and 
increase  EBV-specificity.  However,  increasing  EBV-specific  cytotoxicity  by  EBV-
CTL lines is not correlated with improved in vivo function (Haque, et al 2007). Indeed 
a recent study of the efficacy of immunotherapy following ex vivo culture suggests 
that  increased  stimulation  is  associated  with  reduced  rather  than  enhanced 
functionality,  as  homing  markers  drop  and  cells  become  further  differentiated 
(Gattinoni,  et  al  2005).  Gattinoni  et  al  observed  reduced  efficacy  of  late  effector 
compared to naïve or early effector cells in a melanoma model, establishing an inverse 
correlation  between  ex  vivo  culture  and  in  vivo  anti-tumour  efficacy.  The  authors 
suggest  that  current  criteria  for  selection  of  T  cells  for  immunotherapy,  which 
currently include the ability to secrete IFN- and increased cytotoxicity in response to 
target cells may not in fact select those cells that are likely to be most efficacious in 
vivo.
Further investigation by Berger et al recently reported that antigen-specific effector 
clones  (TE)  derived  from  central  memory  (TCM) but  not  effector  memory  (TEM)
populations in vitro are able to revert to TCM in vivo following infusion in a macaque 
CMV model. These cells are then able to persist and are detectable for over 4 months, 
compared to only days for TE derived from a TEM population which do not re-express Chapter six
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CD62L, remain committed and undergo apoptosis following infusion (Berger, et al
2008a).  This  indicates  that  ex  vivo  expansion  does  not  necessarily  lead  to  clonal 
exhaustion of CTLs when returned to an in vivo environment, despite the observed 
plateau in cell expansion when maintained in culture long term.
Despite these findings, immunotherapy with ex vivo expanded EBV-CTLs following 
an extended period of culture and demonstrating an effector memory phenotype has 
been very successful for PTLD treatment in the SCT setting. Persistence of such cells 
has been demonstrated by detection of the neo
R marker gene at up to 85 months post 
infusion, despite their committed phenotype (Hale, et al 2008, Heslop, et al 1996). In 
addition, a recent study of EBV-CTLs transduced with a chimaeric T cell receptor 
recognising the neuroblastoma epitope GD2 demonstrated that CTLs persist for over 6 
weeks in circulation and are capable of expanding in response to stimulation with 
EBV expressing target cells at 24 weeks. These transduced CTLs uniformly displayed
a TEM phenotype at infusion, yet were able to persist in vivo following administration. 
Together, these findings suggest that more committed effector cells are indeed able to 
persist long term following administration, and that the presence of antigen in vivo
may overcome the senescence observed both in vitro and in some animal models. It 
should be noted that the study by Gattinoni et al utilised a tumour model necessitating 
active immunisation in addition to T cell transfer, whereas both the animal model 
utilised by Berger et al and the immunotherapy trials in humans were performed in the 
setting  of  persistent  viral  infection  which  may  reflect  disparate  immunological 
environments.  In  conclusion,  it  is  clear  that  adoptively  transferred  EBV-CTLs  are 
indeed able to persist long term, mediate anti-viral effects and re-activate in response 
to  antigenic  stimulus  despite  multiple  ex  vivo  stimulations  with  autologous  LCL 
leading to a more committed phenotype.
6.3.3 Immunogenicity of CN mutant transgene
The therapeutic use of transduced cells has been limited in some circumstances by the 
generation of an immune response to the transgene or vector. This is commonly seen 
where the transgene is derived from another species. For example seven of 28 patients Chapter six
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treated with herpes simplex virus thymidine kinase (HSV-TK) suicide gene transduced 
T lymphocytes developed anti-TK CD8+ T cells (Traversari, et al 2007, Zaldumbide 
and Hoeben 2007). Such responses are not restricted to non-human transgenes, indeed 
rejection of bone marrow grafts as a result of a single amino acid difference in HLA-
B44 have been documented (Fleischhauer, et al 1990). In addition, alloreactive T cells 
recognising polymorphic minor histocompatibility antigen mismatches mediate graft 
versus  host  disease  in  HLA-identical  sibling  SCTs  (Goulmy  1996,  Goulmy,  et  al
1996).  Furthermore,  minor  histocompatibility  antigens  may  also  play  a  role  in 
rejection  after  SOT  (Dierselhuis  and  Goulmy 2009).  A  maximum  of  three  altered 
amino acids are present in our CN mutants, which minimises the likelihood of such an 
immune response, however the presence of a novel amino acid sequence may generate 
neoepitopes  and  the  possibility  of  an  immune  response  cannot  be  ruled  out. 
Furthermore,  in  our  approach  CN  transduced  EBV-CTLs  will  be  administered  to 
patients  receiving  substantial  immunosuppressive  therapy  designed  to  prevent  an 
allogeneic response, therefore allowing the survival of a foreign organ which is often 
partially  HLA  mismatched.  With  the  degree  of  immunosuppression  required  to 
prevent rejection of an allogeneic organ and impairment of the memory EBV immune 
response, the likelihood of mounting a successful primary immune response towards 
CN mutants is low. 
To further investigate the potential immunogenicity of CN mutants, we have used a 
computer modelling program to predict the likelihood that peptides from the mutant 
CN containing the altered sequences will be presented by the common HLA alleles 
HLA-A1,  A2,  B7  and  B8.  To  this  end  we  have  utilised  the  Bimass  calculator 
(http://www-bimas.cit.nih.gov/molbio/hla_bind/),  which  predicts  the  stability  of  an 
HLA-peptide complex, and can therefore be used as an indicator of the likelihood that 
such a complex will be formed. When compared to the stability of the NLV peptide 
derived  from  CMV  pp65  protein,  an  immunogenic  peptide  presented  in  HLA-A2, 
most peptides derived from mutant CNs were predicted to have very low stability and 
therefore are unlikely to  be formed. The stability of NLV in HLA-A*0201 is 160 
units, whereas most CN peptides containing mutant sequences had a stability of under 
25U. However, one peptide derived from CNa12 beginning at amino acid 346 with the 
sequence FMDVFEWSA contained both amino acid changes introduced into CNa12 Chapter six
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and is predicted to have a binding efficiency of 188U. Although this indicates that the 
HLA-A*0201: FMDVFEWSA complex will be relatively stable, this stability is in fact 
much  reduced  when  compared  to  the  same  peptide  from  the  wtCNa  sequence, 
FMDVFTWSL,  which  has  a  predicted  stability  of  809U.  In  addition,  three  CN 
peptides from CNa12 not containing any mutations have higher predicted stabilities 
than FMDVFEWSA of between 1055U and 201U. Therefore, when considered in the 
context  of  the  other  peptides  available  for  presentation  it  is  likely  that  CNa12 
FMDVFEWSA  will  not  be  the  predominant  peptide.  However,  it  is  possible  that 
peptides derived from CN mutants can indeed be bound and presented by the common 
HLA alleles; therefore the possibility of triggering an immune response  cannot be 
ruled out even in the presence of immunosuppression. In subsequent clinical studies it 
will be important to assess the in vivo survival of CN mutant transduced CTLs and to 
examine if any cellular response against the transgene occurs.
6.3.4 Practical considerations
Finally, a major obstacle to the more widespread use of adoptive immunotherapy in 
many settings is the considerable time, expertise and specialist facilities required for 
generation of the cell products. This is especially the case where autologous cells are 
generated on a patient-by-patient basis. Therefore, the appropriate clinical setting to 
gain  maximal  benefit  from  adoptive  immunotherapy  must  be  carefully  chosen. 
Initially, focussing this approach on those patients likely to gain maximum benefit is 
necessary, and targeting of very high risk groups is a rational approach. Infusion of 
autologous  CN  inhibitor  resistant  EBV  specific  CTLs  may  provide  effective 
prophylaxis  for  PTLD,  for  example  in  patients  undergoing  paediatric  small  bowel 
transplantation, where the risk of PTLD may be as high as 20% (Thompson 1999). In 
lower risk patient groups where prophylaxis is more difficult to justify, CTLs could be 
used as an adjunctive therapy for established PTLD. As illustrated below, we propose 
a possible strategy whereby EBV viral load is closely monitored, with initiation of an 
LCL  line  when  rising  loads  are  detected  (Savoldo,  et  al  2006).  Depending  on 
resources, this could either be done for all patients with rising viral loads, or restricted 
to those at highest risk, for example those experiencing primary EBV infection or Chapter six
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where no EBV-specific immunity is detected. Upon development of PTLD, generation 
of  an  EBV-CTL  line  begins  concurrent  with  withdrawal  of  non-CN  inhibitor 
immunosuppression  and  administration  of  Rituximab  to  control  disease.  After 
generation and testing, EBV-CTLs are administered to maintain remission induced by 
first  line  therapy,  or  treat  remaining  disease.  This  approach  will  allow  targeted 
production of CTL lines for those patients most likely to develop PTLD, in addition to 
circumventing the high risk of partial response and relapse associated with Rituximab 
monotherapy (Choquet, et al 2006, Choquet, et al 2007, Messahel, et al 2006). 
Alternatively,  CN  inhibitor  resistant  EBV-CTLs could  represent  a  therapeutic 
approach for patients relapsing following first line Rituximab therapy as these patients 
have a poor prognosis. Two studies examining the efficacy of Rituximab therapy for 
PTLD  have  demonstrated  that  various  parameters  including  abnormal  lactate 
dehydrogenase  levels,  multivisceral  disease,  CNS  involvement  and  late  onset  of 
lymphoma predispose to a poor response to Rituximab, therefore early initiation of a 
CTL line might be appropriate in such patients (Benkerrou, et al 1998, Choquet, et al
2006).
Targeted  generation of  EBV-CTL lines  for patients  identified as likely to  develop 
PTLD would be the ideal approach to immunotherapy for this disease. However, the 
prediction  of  individual  patients  at  highest  risk  for  PTLD  development  has  been 
problematic  following  SOT.  The  most  accurate  prediction  methods  to  date  utilise 
measures of both  EBV-specific immunity  and  EBV viral load, including  the  IPTLD
index developed by Smets et al (Smets, et al 2002) and the protocol developed by 
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Meij  et  al  utilising  EBV-tetramers  to  measure  EBV  immunity  (Meij,  et  al  2003). 
These methods are not yet in clinical use and present some practical difficulties such 
as the generation of an LCL line for the IPTLD. Advances in the measurement and 
interpretation  of  EBV  loads  possibly  in  combination  with  alternative  measures  of 
general, rather than EBV-specific immunity may allow more accurate identification of 
the highest risk patients in future (Baldanti, et al 2000, Lee, et al 2006a, Sebelin-Wulf, 
et al 2007).  This will allow focussing of resources on those patients most likely to 
require  cellular  therapy,  both  increasing  cost-effectiveness  and  allowing  early 
initiation of cell lines to reduce the delay between diagnosis and treatment.
6.4 Further work and scale-up studies
6.4.1 Further in vitro investigations
Additional  investigations  to  further  examine  the  effect  of  transduction  with  CN 
mutants would strengthen this study. Assessment of V gene usage by spectratyping 
before and after transduction would allow determination of whether expression of CN 
mutants skews the T cell repertoire (Coito, et al 2004, Ferrand, et al 2000, Recchia, et 
al  2006).  Assessment  following  several  weeks  culture  in  CN  inhibitors  would 
determine whether this selective pressure results in the preferential outgrowth of a 
particular clone. 
Examination of phenotypic markers suggest that this is unlikely to be the case (chapter 
4, figure 43), nevertheless demonstration of balanced V usage after transduction and 
culture in CN inhibitors would be of benefit in the progress towards scale-up work and 
subsequent clinical trial. In addition, although transduction with RV does not lead to 
inappropriate proliferation of mature T cells (Recchia, et al 2006), identification of 
integration copy number and sites within transduced EBV-CTL lines would provide 
useful safety data prior to proceeding to clinical studies.Chapter six
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6.4.2 Scale-up studies
EBV-CTLs have been generated on a large scale for use in many clinical trials as 
discussed previously. However, scale-up studies are necessary for generation of large 
numbers  of  CN  transduced  EBV-CTLs  under  conditions  of  Good  Manufacturing 
Practice (GMP). GMP  production of  LCL lines  presents practical  difficulties  as it 
requires the use of EBV virus produced from the B95-8 cell line. As EBV from B95-8 
supernatant is a replication competent virus, it must be handled in a separate GMP 
facility to that utilised for EBV-CTL production. Therefore, LCL lines would need to 
be generated in one facility, irradiated and transferred to another GMP laboratory used 
for EBV-CTL generation. In addition, larger numbers of EBV-CTLs would need to be 
generated to provide sufficient cells for administration to patients compared to that 
needed for these in vitro experiments: In prior clinical studies with EBV-CTLs, cell 
doses  of  between 2x10
7  and  5x10
8  cells/m
2  have been  administered.  This  may  be 
facilitated by use of the Wilson Wolf GP500 bioreactor for large scale production of 
CTLs, which has been shown to improve the growth profile of EBV-CTL lines in vitro
without  any  apparent  detrimental  effect  on  CTL  function  (Vera,  et  al  2008).  The 
production of a larger number  of cells in  a shorter space of time  may also partly 
address the considerable lag time between initiation of cell lines and the availability of 
the therapeutic product. However, shortening the process of CTL generation will have 
limited impact on the overall time required to generate the cell product because of the 
need for first establishing a patient-specific LCL stimulator line. Improved EBV-CTL 
expansion in bioreactors is likely to reduce the time from LCL initiation to availability 
of EBV-CTLs from approximately 8-10 to 6-8 weeks. Until the production of LCLs 
can be achieved in a shorter space of time, or effective alternatives such as artificial 
antigen presenting cells are developed, the generation of EBV-CTLs will be a lengthy 
process.
One alternative to LCLs is the use of peptide pools which can be loaded onto APCs 
such  as  dendritic  cells,  and  used  to  stimulate  effector  cells;  however  this  would 
necessitate the use of much larger volumes of blood than for LCL generation. Such 
peptide pools have been produced for various EBV proteins, including the Peptivator 
mixes (Miltenyi) which cover many epitopes derived from the lytic BZLF-1 or latent Chapter six
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EBNA-1 proteins. Unfortunately, as discussed in section 1.1.4, CD8+ EBV-latency 
specific  effector  cells  recognise  epitopes  mainly  derived  from  EBNA-3  proteins, 
therefore these peptide mixes are not yet optimal for use generating the predominantly 
CD8 EBV-CTL lines necessary for PTLD treatment.
6.4.3 In vivo studies
Following successful demonstration of CN inhibitor resistance in vitro, examination of 
the safety and efficacy of this approach in an in vivo model is necessary as a prelude to 
clinical studies. In this study, the establishment of a xenogenic -chain
-/-/RAG2
-/-/C5
-/-
mouse model was undertaken. Successful engraftment and growth of subcutaneous 
LCL  tumours  was  demonstrated,  along  with  bioluminescent  imaging  for  accurate 
monitoring of tumour growth. However, although reduction of LCL tumours following 
administration of EBV-CTLs was achieved in one set of experiments, this was not 
consistently seen and further optimisation of this system is required in order to obtain 
robust data. Potential approaches to this have been discussed in chapter 5. Briefly, we 
plan to optimise the procedure to reduce unnecessary delays, examine the effect of 
altering the cytokines added both to CTLs prior to and following infusion, as well as 
studying  the  distribution  of  EBV-CTLs  post  infusion  to  establish  that  appropriate 
homing is occurring in vivo. 
Examination of the effect of transduced EBV-CTLs in vivo in this animal model will 
enable assessment of both the safety and efficacy of our approach. Following CTL 
infusion,  several  safety  aspects  will  be  monitored  including  toxicity  to  non-
haematopoietic tissues, reactions at the tumour site and any other adverse effects on 
the animal. The tumour site will be closely monitored for signs of inflammation as a 
result of cell expansion and, if present, the degree to which this is observed will be 
compared between mice receiving transduced and non-transduced CTLs in both the 
presence and absence of CN inhibitors. In addition, mice will be carefully monitored 
for signs of CTL proliferation at alternative sites, which may indicate autonomous 
proliferation of the infused cells. At termination of the experiment, multiple tissues 
will be harvested and examined histologically for signs of CTL persistence, toxicity or Chapter six
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inflammation. In addition to this rigorous safety data, biological efficacy will also be 
examined in the setting of both prophylaxis, with infusion of EBV-CTLs concurrent 
with  LCL  injection,  and  treatment,  with  administration  of  EBV-CTLs  following 
establishment of the LCL tumour. The progress of tumour growth will be carefully 
monitored and compared to a non-CTL treated cohort to determine if administration of 
transduced EBV-CTLs results in tumour regression in the presence of CN inhibitors. 
However, the use of a murine model to examine the behaviour of human CTLs and 
LCL has limitations that must be considered when interpreting the obtained data. For 
both safety and efficacy data, it must be remembered that although APCs are present 
in the form of a subcutaneous LCL tumour, this model utilises human cells in a murine 
environment.  Despite  the  provision  of  recombinant  human  IL-2,  the  full  cytokine 
milieu present in human subjects is not recreated in this animal model. In addition, 
homing molecules and co-stimulatory molecules are of murine origin and may not 
provide  the  optimal  signals  for  human  CTLs.  Therefore  this  model  represents  a 
considerable  simplification  of  the  human  in  vivo  environment.  Despite  these 
limitations,  this  model  has  been  successfully  utilised  for  the  study  of  PTLD 
immunotherapy and we believe it to be the most appropriate model available. The
examination  of  both  transduced  and  untransduced  EBV-CTLs  in  the  presence  and 
absence of CN inhibitors in this mouse model, combined with long-term follow up of 
the animals is expected to provide essential data regarding both efficacy and safety of 
these CTLs in vivo. These data will form the basis of the Investigational Medicinal 
Product  (IMP)  dossier  for  application  to  both  the  regulatory  (MHRA)  and  ethical 
(GTAC) bodies prior to commencement of a clinical trial.
6.6 Clinical applications
6.6.1 Clinical trial in paediatric solid organ transplantation
In conjunction with the paediatric transplant teams at Great Ormond Street Hospital
(GOSH), our laboratory  is working towards the initiation of a clinical trial of CN 
inhibitor  resistant  autologous  EBV-CTLs  in  these  patients.  Paediatric  transplant Chapter six
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recipients experience a higher rate of PTLD development than adult patients as a result 
of  higher  proportions  of  EBV  naïve  patients  pre-transplant.  Therefore  this  patient 
group represent an ideal population in which to study the treatment of PTLD with 
immunotherapy. We aim to establish a phase I/II trial to examine safety and biological 
efficacy of transduced EBV-CTL lines for the treatment of PTLD despite ongoing 
immunosuppression.  This  clinical  trial  will  include  GOSH  patients  undergoing 
paediatric small bowel transplantation at King’s Hospital, London, as well as those 
undergoing kidney, heart and heart and lung transplantation at GOSH, with a predicted 
60  patients  to  be  transplanted  per  year,  and  an  average  of  five  patients  per  year 
developing PTLD.
We envisage that this trial will examine the efficacy of CNb30 transduced EBV-CTL 
as  adjunctive  therapy  to  reduction  in  immunosuppression  and  treatment  with 
Rituximab, as described previously. An LCL line will be initiated upon diagnosis of 
PTLD, followed by a CTL line as soon as the LCL line is established. Patients will be 
treated with Rituximab and reduced immunosuppression during this period. CTL lines 
will be transduced with retrovirus carrying CNb30 to confer resistance to FK506 or 
CsA, and cryopreserved. It is anticipated that a single dose of 2x10
8 transduced EBV-
CTLs per m
2 will be infused. Patients will be monitored closely to ensure that cell 
administration is well tolerated and followed up with attention to several end points. 
The primary end points will include toxicity to the graft and other recipient tissues and 
assessment  of  adverse  reactions  to  cell  administration.  In  addition,  the  circulating 
frequency  of  EBV-specific  cells  will  be  monitored  before  and  after  infusion  to 
determine if an increase in CTL precursor frequency is observed as a result of this 
treatment. Secondary end points for this study will include examination of the long 
term persistence of EBV-CTLs in vivo as well as the incidence of relapse observed in 
this  treatment  group  compared  to  the  previously  observed  57%  relapse  following 
Rituximab monotherapy (Choquet, et al 2007).
It is anticipated that infusion of EBV-CTLs will be well tolerated as such cells have 
previously been administered to over 55 patients following SOT (Comoli, et al 2002, 
Comoli, et al 2005, Haque, et al 2007, Khanna, et al 1999, Savoldo, et al 2006). As 
indicated by the data obtained in this study, transduction of EBV-CTL lines should Chapter six
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allow efficient cell function despite the continuation of ongoing immunosuppression 
with CN inhibitors, therefore clearing remaining disease as well as contributing to the 
long term control of PTLD and reducing the relapse rates associated with Rituximab 
monotherapy.
6.6.2 Alternative applications
Generation  of  cells  that  are  resistant  to  CN  inhibitors  is  not  limited  to  use  in 
autologous EBV-CTL lines post SOT. As discussed in section 1.4.2.3, in response to 
the practical problems of producing autologous EBV-CTLs, an allogeneic EBV-CTL 
bank has been established, the use of cells from which has induced clinical responses 
in over 50% of patients failing conventional treatment. The establishment of this CTL 
bank  enables  rapid  access  to  immunotherapy  for  treatment  of  patients  developing 
PTLD (Haque, et al 2007). Despite these promising results, 48% of patients do not 
maintain  responses  at  six  months  post  infusion  and  this  may  be  due  to  either  the 
continuation of immunosuppressive therapy or the generation of an immune response 
by the recipient against the inevitable mismatches. Transduction of third party EBV-
CTLs from this cell bank with CN mutants conferring CN inhibitor resistance would 
circumvent the former problem and may allow longer term persistence. In addition, 
our approach would allow the continuation of immunosuppressive therapy with CN 
inhibitors at therapeutic levels, potentially reducing the likelihood of an allo-response 
against the infused cells.
In the stem cell transplant setting, the application of immunotherapy has widened in 
recent  years  to  include  the  treatment  of  an  increasing  number  of  viruses. 
Immunotherapy with CMV-specific CTLs generated by repetitive stimulation has been 
used to treat CMV viraemia post SCT. This approach has been shown to augment 
circulating  CMV-specific  responses  and  shows  some  efficacy  for  treating  CMV 
reactivation in patients undergoing SCT from matched sibling donors. In the majority 
of cases, immunosuppression with CN inhibitors was not withdrawn in these studies. It 
is possible that CMV-specific CTLs are less susceptible to the effects of CN inhibitors 
than EBV-specific CTLs, but it is difficult to assess the true efficacy of adoptively Chapter six
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transferred  CTLs  in  the  matched  sibling  donor  setting  where  recovery  of  CMV-
specific T cells infused with the stem cell graft occurs early. Similarly, using LCL 
transduced  with  an  adenoviral  vector  carrying  the  pp65  transgene  as  antigen 
presenting cells, we and others have generated CTLs directed against EBV, CMV and 
adenovirus specific T cells in a single culture for protection from the three main viral 
threats post SCT (Karlsson, et al 2007, Leen, et al 2006). As in the SOT setting, 
transduction of virus-specific CTLs with our CN mutants may enable improved virus-
specific immunity without  the need for early withdrawal of CN inhibitors  and the 
consequent risk of GVHD. Furthermore, viral reactivations are frequently associated 
with immunosuppressive therapy for GVHD, and the use of CN inhibitor resistant 
CTLs in this setting is an attractive option. In this regard, it would be even more useful 
to combine resistance to CN inhibitors and steroids.
Recently  developed  techniques  such  as  the  Miltenyi  -capture  system  enable 
stimulation with viral-antigen presenting APCs and subsequent selection of responders 
to enrich for virus specific cells. Similarly, virus-specific CD8+ T cells can be isolated 
from seropositive donors using HLA-peptide multimers (Cobbold, et al 2005). These 
approaches are being investigated for the pre-emptive treatment of both adenovirus 
and CMV infections post SCT, and could be combined with CNb30 transduction to 
allow effective function despite ongoing GVHD prophylaxis (Cobbold, et al 2005, 
Feuchtinger, et al 2008, Peggs, et al 2003). 
Another approach to provide protection from multiple pathogens is selective depletion 
of alloreactive donor lymphocytes and infusion of the remaining non-alloreactive cells 
to  reconstitute  T  cell  immunity.  In this  approach,  donor  T  cells  are  cultured  with 
recipient APCs to activate allo-reactive T cells which can then be selectively depleted 
using antibodies that recognise activation markers such as CD25, or photodynamic 
purging. This ensures that allo-reactive cells most likely to cause GVHD are removed 
and the remaining allo-depleted population of donor cells can be safely infused with a 
low incidence of GVHD despite increased cell doses. Allodepleted T cells have been 
shown  to  safely  augment  immune  reconstitution  after  both  matched  sibling  and 
haploidentical SCT (Amrolia, et al 2006, Mielke, et al 2008). These approaches could 
be combined with CN inhibitor resistance as an additional safety measure to allow Chapter six
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efficient function of infused  cells following administration  into a patient receiving 
immunosuppressive therapy for GVHD prophylaxis.
Finally, the use of anti-leukaemic T cells following SCT to remove residual malignant 
cells  and  ensure  long  term  remission  has  been  explored  in  recent  years.  Indeed, 
particularly in myeloid malignancies, the graft-versus leukaemia (GVL) activity of T 
cells  infused  with  the  stem  cell  graft  may  play  a  significant  role  in  curing 
haematopoietic malignancies, rather than myeloablation and subsequent replacement 
of  the  haematopoietic  system  itself  (Feng,  et  al  2008).  It  is  clear  that  for  some 
malignancies,  immunotherapy  with  donor  lymphocyte  infusions  to  augment  anti-
leukaemic activity post SCT can be effective in preventing and treating relapse after 
SCT (Bader, et al 2004, van Rhee and Kolb 1995). There is strong evidence to suggest 
that  minor  histocompatibility  antigen  (mHAg)  mismatches  between  the  stem  cell 
donor and the recipient can be the target of either GVHD or GVL responses post SCT 
(Feng,  et  al  2008).  Certain  mHAgs  such  as  HA-1  and  HA-2  are  expressed 
predominantly  on  haematopoietic  tissues  and  as  such  provide  an  ideal  target  for 
enhancement  of  the  GVL  effect  without  the  concurrent  risk  of  increasing  GVHD. 
Anti-mHAg CTL clones have been identified in the circulation of patients receiving 
donor  lymphocyte  infusions  and  correlated  with  the  occurrence  of  remission.
Additionally, such cells have been demonstrated to exhibit anti-leukaemic activity in 
in vitro assays (Marijt, et al 2003). Therefore immunotherapy with ex vivo expanded 
mHAg-specific T cells holds considerable promise for the treatment of haematological 
malignancies in the HLA-matched, mHAg mismatched SCT setting. Using retroviral 
transfer of cDNAs encoding the TCR  and  genes, it is possible to re-direct T cells 
to a desired specificity and the generation of anti-HA-2 specific T cells for clinical use 
via this method is now possible. Although the applicability of this approach may be 
limited  by  the  need  for  the  appropriate  HLA-restriction  and  mismatched  mHAg 
expression by the host, potentially this is an attractive option for this subset of patients.
The ability to confer specificity towards particular epitopes on T cells by TCR transfer 
has  allowed  the  generation  of  cells  directed  towards  other  leukaemia  antigens  for 
immunotherapy.  This  approach  has  already  been  applied  to  non-haematological 
malignant disorders including the first clinical trial by the Rosenberg group utilising Chapter six
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MART-1  TCR  transgenic  CD8+  T  cells,  which  successfully  induced  tumour 
regression in two of fifteen patients with refractory metastatic melanoma (Morgan, et 
al 2006). Another candidate for immunotherapy with TCR transduced T cells is the 
WT-1 antigen,  which is overexpressed in both acute and chronic myeloid leukaemias, 
myelodysplastic  syndrome  and  some  solid  tumours  but  displays low  physiological 
expression in a limited range of tissues. Anti-WT-1 T cells have been generated using 
lentiviral vectors (Stauss, et al 2008) and shown to eliminate human leukaemia cells in 
an in vivo NOD/SCID mouse model (Xue, et al 2005, Xue, et al 2009).
Further developments in the transfer of TCRs to generate T cells with a particular 
specificity  have  resulted  in  the  generation  of  chimaeric  antigen  receptors  (CAR), 
which combine the specificity of an antibody binding domain with signalling regions 
from the TCR, thus removing the need for HLA-matching of the introduced TCR and 
the patient. This approach has proved successful  when applied to the treatment of 
neuroblastoma,  with  half  of  subjects  demonstrating  tumour  regression  or  necrosis 
following  infusion  of  EBV-CTLs  transduced  with  an  anti-diasialoganglioside  GD2 
CAR (Pule, et al 2008).
Many of the approaches described above may have greater efficacy when applied early 
following transplantation in the setting of minimal residual disease. However patients 
are  often  treated  prophylactically  with  immunosuppression  in  the  immediate  post-
transplant period to prevent the development of graft-versus-host disease (GVHD). 
Particularly  for  anti-tumour  therapies,  this  early  window  would  be  ideal  for  the 
application  of  immunotherapy  as  a  result  of  the  low  tumour  burden  and  empty 
lymphoid compartment at this time allowing cell expansion. The use of CN inhibitor 
resistant  CTLs  would  allow  continued  protection  from  GVHD  with 
immunosuppression, concurrent with administration of an effective cell product. Chapter six
_____________________________________________________________________
227
6.7 Conclusions
We  report  the  generation  of  CN  mutants  capable  of  conferring  resistance  to  CN 
inhibitors  in  cell  lines  and primary EBV-CTLs.  The  development  of  CN  inhibitor 
resistant  EBV-CTLs  may  represent  a  considerable  advance  in  the  management  of 
PTLD, particularly  for  high risk patients.  Reconstitution  of effective EBV-specific 
immunity  without  the  requirement  for  a  reduction  in  immunosuppressive  therapy 
should  allow  the  prevention  or  treatment  of  EBV-driven  B  cell  proliferation,  in 
conjunction  with  continued  protection  of  the  grafted  organ.  Establishment  of  a 
memory  population  of  CN  inhibitor  resistant  EBV-specific  cells  may  result  in 
effective long-term surveillance and protection from relapse along with unimpaired 
graft function. In addition, the wider application of this approach may allow more 
effective T cell immunotherapy for viral infections  and malignancy post  stem  cell 
transplantation.References
_____________________________________________________________________
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